AUTHOR INDEX

Aalders JG, *see* de Hullu JA
Aaltonen LA, *see* Salovaara R
Aamdal S, *see* Middleton MR
Aaron D, *see* Boon H
Aaronson N, *see* Middleton MR
Aaronson NK, *see* Detmar SB
—*see* Lønning PE
Abbasciano V, *see* Sartori S
Abboud CN, *see* DiPersio JF
Abbruzzese JL, *see* Hoff PM
—*see* Pisters PWT
Abdolell M, *see* Brezden CB
Abeloff M, *see* Sledge GW Jr
Abgrall JF, *see* Harousseau JL
Abhyankar SH, *see* Godder KT
Abner A, *see* Park CC
Abonour R, *see* Bhatia S
Abraksia S, Kumar PD, Kasal J. Two Unusual Lymphomas; Case 1: Primary Malignant Lymphoma (Diffuse Large B-Cell Lymphoma) of the Spleen Mimicking Splenic Abscess, 3731
Abrams J, *see* Krag D
Abrey LE, Yahalom J, DeAngelis LM. Treatment for Primary CNS Lymphoma: The Next Step, 3144
Ackermann J, *see* Königsberg R
Acute Lymphoblastic Leukemia Committee of the Tokyo Children's Cancer Study Group, *see* Toyoda Y
Adam R, *see* Giacchetti S
Adams K, *see* Apostolidis J
Adams R, *see* Grupp SA
Adamson PC, *see* Warren KE
Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, DeCamp M, Vargo JJ, Dumot JA, Zuccaro G. Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy, 2032
Adi S, *see* Idelevich E
Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid Tumors, 1748
Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C. Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity, 1116
Agarwala S, *see* Hillner BE
Agostini P, *see* Cuneo A
A'Hern R, *see* Spillane AJ
Ahrens S, *see* Cotterill SJ
Ah-See AK, *see* Smith IC
Ahtola H, *see* Salovaara R
Aida N, *see* Nishihira H
Aikin AA, *see* Warren KE
Aisenberg AC, Finkelstein DM. Second Malignancies in Hodgkin's Disease (correspondence), 2185
Aisner J, *see* Kamen BA
—*see* Kaufman D
Ajani JA. Standard Chemotherapy for Gastric Carcinoma: Is It a Myth? (correspondence), 4001
Akabani G, *see* Cokgor I
Akard L. Optimum Methods to Mobilize Stem Cells (correspondence), 3063
Akard LP, *see* Fife BL
Akasaka H, *see* Akasaka T
Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A, Yamabe H, Fukuhara S, Uchiyama T, Ohno H. Molecular and Clinical Features of Non-Burkitt's, Diffuse Large-Cell Lymphoma of B-Cell Type Associated with the c-*MYC*/immunoglobulin Heavy-Chain Fusion Gene, 510
Alba E, *see* Pérez-Manga G
Albain KS, *see* Hillner BE
Albanell J, *see* Bellmunt J
Albers P, *see* von der Maase H
Alberto P, *see* Hügli A
Alberts DS, *see* Monsky WL
—*see* Peters WA III
Alberts SR, *see* Adjei AA
Albright L, *see* Thomas PRM
Aldrighetti D, *see* Boccardo F
Aleksandrovic J, *see* Jeremic B
Aleman BMP, *see* van Leeuwen FE
Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J-P, Viens P, Faivre S, Chahine A, Spielman M, Bensmaïne A, Marty M, Mahjoubi M, Cvitkovic E. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients, 562
Alexanian R, Anderson K, Barlogie B, Berenson J, Dalton WS, Kyle RA. In Memoriam: Syndney E. Salmon, M.D., 1
Allegra CJ, *see* Takimoto CH
Allen JC, *see* Thomas PRM
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. *c-ErbB-2* Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems, 2201
Allman D, *see* Van Cutsem E
Allred DC, *see* Zellars RC
Almadrones L, *see* Barakat RR
Alquati P, *see* Berruti A
Alvarez R, *see* Muggia FM
Alvarez RD, *see* Muggia FM
Al-Zoubi A, *see* Savarese D
Amabile M, *see* Martinelli G
Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, Gambi A, Catalano G, Perroni D, Scarpi E, Giunchi DC, Tienghi A, Becciolini A, Volpi A. Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study, 3125
Amato R, *see* Stadler WM
Amdur RJ, *see* Mendenhall WM
American Society of Clinical Oncology, *see* Desch CE
American Society of Clinical Oncology Bisphosphonates Expert Panel, *see* Hillner BE
American Society of Clinical Oncology Growth Factors Expert Panel, *see* Ozer H
Ames FC, *see* Breslin TM
Amess JAL, *see* Apostolidis J
—*see* Micallef INM
Ammassari A, *see* Cingolani A

AUTHOR INDEX

Aalders JG, *see* de Hullu JA
Aaltonen LA, *see* Salovaara R
Aamdal S, *see* Middleton MR
Aaron D, *see* Boon H
Aaronson N, *see* Middleton MR
Aaronson NK, *see* Detmar SB
—*see* Lønning PE
Abbasciano V, *see* Sartori S
Abboud CN, *see* DiPersio JF
Abbruzzese JL, *see* Hoff PM
—*see* Pisters PWT
Abdolell M, *see* Brezden CB
Abeloff M, *see* Sledge GW Jr
Abgrall JF, *see* Harousseau JL
Abhyankar SH, *see* Godder KT
Abner A, *see* Park CC
Abonour R, *see* Bhatia S
Abraksia S, Kumar PD, Kasal J. Two Unusual Lymphomas; Case 1: Primary Malignant Lymphoma (Diffuse Large B-Cell Lymphoma) of the Spleen Mimicking Splenic Abscess, 3731
Abrams J, *see* Krag D
Abrey LE, Yahalom J, DeAngelis LM. Treatment for Primary CNS Lymphoma: The Next Step, 3144
Ackermann J, *see* Königsberg R
Acute Lymphoblastic Leukemia Committee of the Tokyo Children's Cancer Study Group, *see* Toyoda Y
Adam R, *see* Giacchetti S
Adams K, *see* Apostolidis J
Adams R, *see* Grupp SA
Adamson PC, *see* Warren KE
Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, DeCamp M, Vargo JJ, Dumot JA, Zuccaro G. Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy, 2032
Adi S, *see* Idelevich E
Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid Tumors, 1748
Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C. Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity, 1116
Agarwala S, *see* Hillner BE
Agostini P, *see* Cuneo A
A'Hern R, *see* Spillane AJ
Ahrens S, *see* Cotterill SJ
Ah-See AK, *see* Smith IC
Ahtola H, *see* Salovaara R
Aida N, *see* Nishihira H
Aikin AA, *see* Warren KE
Aisenberg AC, Finkelstein DM. Second Malignancies in Hodgkin's Disease (correspondence), 2185
Aisner J, *see* Kamen BA
—*see* Kaufman D
Ajani JA. Standard Chemotherapy for Gastric Carcinoma: Is It a Myth? (correspondence), 4001
Akabani G, *see* Cokgor I
Akard L. Optimum Methods to Mobilize Stem Cells (correspondence), 3063
Akard LP, *see* Fife BL
Akasaka H, *see* Akasaka T
Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A, Yamabe H, Fukuhara S, Uchiyama T, Ohno H. Molecular and Clinical Features of Non-Burkitt's, Diffuse Large-Cell Lymphoma of B-Cell Type Associated with the c-*MYC*/immunoglobulin Heavy-Chain Fusion Gene, 510
Alba E, *see* Pérez-Manga G
Albain KS, *see* Hillner BE
Albanell J, *see* Bellmunt J
Albers P, *see* von der Maase H
Alberto P, *see* Hügli A
Alberts DS, *see* Monsky WL
—*see* Peters WA III
Alberts SR, *see* Adjei AA
Albright L, *see* Thomas PRM
Aldrighetti D, *see* Boccardo F
Aleksandrovic J, *see* Jeremic B
Aleman BMP, *see* van Leeuwen FE
Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J-P, Viens P, Faivre S, Chahine A, Spielman M, Bensmaïne A, Marty M, Mahjoubi M, Cvitkovic E. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients, 562
Alexanian R, Anderson K, Barlogie B, Berenson J, Dalton WS, Kyle RA. In Memoriam: Syndney E. Salmon, M.D., 1
Allegra CJ, *see* Takimoto CH
Allen JC, *see* Thomas PRM
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. *c-ErbB-2* Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems, 2201
Allman D, *see* Van Cutsem E
Allred DC, *see* Zellars RC
Almadrones L, *see* Barakat RR
Alquati P, *see* Berruti A
Alvarez R, *see* Muggia FM
Alvarez RD, *see* Muggia FM
Al-Zoubi A, *see* Savarese D
Amabile M, *see* Martinelli G
Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, Gambi A, Catalano G, Perroni D, Scarpi E, Giunchi DC, Tienghi A, Becciolini A, Volpi A. Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study, 3125
Amato R, *see* Stadler WM
Amdur RJ, *see* Mendenhall WM
American Society of Clinical Oncology, *see* Desch CE
American Society of Clinical Oncology Bisphosphonates Expert Panel, *see* Hillner BE
American Society of Clinical Oncology Growth Factors Expert Panel, *see* Ozer H
Ames FC, *see* Breslin TM
Amess JAL, *see* Apostolidis J
—*see* Micallef INM
Ammassari A, *see* Cingolani A

Amoroso D, *see* Boccardo F
Amos CI, *see* Frazier ML
Ancelot M, *see* Le Gouill S
Anderson JR, *see* Baker KS
Anderson K, *see* Alexanian R; Crémieux P-Y
Anderson SA, *see* Smalley RV
Anderson V, *see* Baselga J
Andersson M, *see* Metayer C
Andreeff M, *see* Kantarjian HM
Andreesen R, *see* Blank C
Andre F, Grunenwald D, Pignon J-P, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le Chevalier T. Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and Implications, 2981
Andre M, *see* Wijermans P
Andrulis IL, *see* Wunder JS
Aneliunas V, *see* Wunder JS
Angelberger P, *see* Raderer M
Angiolini C, *see* Venturini M
Annunziata M, *see* Ferrara F
Ansquer Y, *see* Stoppa-Lyonnet D
Antin JH, *see* Lee SJ
Antinori A, *see* Cingolani A
Antolak JA, *see* Pollack A
Antonescu CR, *see* Lewis JJ
Apostolidis J, *see* Micallef INM
Apostolidis J, Gupta RK, Grenzelias D, Johnson PWM, Pappa VI, Summers KE, Salam A, Adams K, Norton AJ, Amess JAL, Matthews J, Bradburn M, Lister TA, Rohatiner AZS. High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up, 527
Arbuck SG, *see* Takimoto CH
Arceci RJ, *see* Dahl GV
Arcediano A, *see* Gomez-Martin C
Arcenas A, *see* von Pawel J
Arends JW, *see* van Oostenbrugge RJ
Aricò M, *see* Caselli D
Arimidex Study Group, *see* Bonneterre J
—*see* Nabholtz JM
Arkhipov A, *see* Kaufmann M
—*see* Lønning PE
Arlen P, *see* Marshall JL
Armand J-P, *see* Boige V
—*see* Couteau C
—*see* Fandi A
—*see* Fizazi K
Armitage JO. Myelodysplasia and Acute Leukemia After Autologous Bone Marrow Transplantation (editorial), 945
Armitage JO, *see* Bishop MR
—*see* Ozer H
Arndt CAS, *see* Cagnoni PJ
Aronin P, *see* Thomas PRM
Asbell S, *see* Valicenti R
Ascani S, *see* Zinzani PL
Ashley DM, *see* Friedman HS
Ashley R, *see* Potters L
Asselain B, *see* Delozier T
—*see* Stoppa-Lyonnet D
Aster JC, *see* Hecht JL
Atherton P, *see* Adjei AA
Athow A, *see* Mokbel K
Atkins M, *see* Manola J
Atkinson EN, *see* Verschraegen CF
Atkinson JB, *see* Nickerson HJ
—*see* Perez CA
Attal M, *see* Blaise D
Attar EC, Ervin T, Janicek M, Deykin A, Godleski J. Acute Interstitial Pneumonitis Related to Gemcitabine, 693
Auclerc MF, *see* Michel G
Audhuy B, *see* Harousseau JL
Auvrignon A, *see* Michel G
Au WY, *see* Liang R
Au WY, Ma SK, Ooi C, Liang R, Kwong YL. Unusual Manifestations of Acute Leukemia; Case 1: CNS Extramedullary Relapse of Acute Promyelocytic Leukemia After Arsenic Trioxide-Induced Remission, 3435
Au WY, Shek TW, Ma SK, Leung G, Ooi GC, Liang R, Kwong YL. Myeloblastoma (Chloroma) in Leukemia; Case 2: Meningeal Granulocytic Sarcoma (Chloroma) in Essential Thrombocythemia, 3996
Avet-Loiseau H, *see* Le Gouill S
Avril N, *see* Schelling M
Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M. Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations, 3495
Awada A, *see* Paridaens R
Axtell RA, *see* Henrickson KJ
Aylesworth C, *see* Rowinsky EK
Ayoub J, *see* von Pawel J
Azli N, *see* Fandi A

Babic R, *see* Allgayer H
Bacchini P, *see* Bacci G
Bacci G, Ferrari S, Bertoni F, Donati D, Bacchini P, Longhi A, del Prever AB, Forni C, Rimondini S. Neoadjuvant Chemotherapy for Peripheral Malignant Neuroectodermal Tumor of Bone: Recent Experience at the Istituto Rizzoli, 885
Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P. Prognostic Factors in Nonmetastatic Ewing's Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli, 4
Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Instituto Ortopedico Rizzoli According to the Instituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report, 4016
Bachouchi M, *see* Fandi A
Bacik J, *see* Motzer RJ
Badell I, *see* Marco F
Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB. Expression of Apoptosis-Related Proteins Is an Independent Determinant of Patient Prognosis in Advanced Ovarian Cancer, 3775
Bafaloukos D, *see* Briasoulis E
Baggen MGA, *see* Bontenbal M
Baggers J, Ratzinger G, Young JW. Dendritic Cells as Immunologic Adjuvants for the Treatment of Cancer (editorial), 3879
Bahary JP, *see* Del Rowe J

Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer, 2710
Bailes J. Managed Care Oncology: The Quality Debate (editorial), 705
Bailes JS. Presidential Address, 2s
Bailey S, *see* Mann JR
Bains M, *see* Motzer RJ
Bajetta E, *see* Kaufmann M
—*see* Lønning PE
Bajorin D, *see* Motzer RJ
Bajorin DF, *see* Dodd PM
—*see* Motzer RJ
Baker CS, *see* Earle CC
Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, Breneman JC, Wiener ES, Crist WM. Benefit of Intensified Therapy for Patients With Local or Regional Embryonal Rhabdomyosarcoma: Results From the Intergroup Rhabdomyosarcoma Study IV, 2427
Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohnecker JA, Rowinsky EK. Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil, 915
Baker SD, *see* Eckhardt SG
—*see* Gallo JM
Balcerzak SP, *see* Fisher RI
Balducci L, *see* Extermann M
Balis FM, *see* Warren KE
Baliva G, *see* Zinzani PL
Balmer A, *see* Beck MN
Band RA, *see* Takimoto CH
Bandarenko N, *see* Sood N
Bandini G, *see* Martinelli G
Banks PM, *see* Socié G
Banús JM, *see* Bellmunt J
Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, Hoskins WJ. Effect of Adjuvant Tamoxifen on the Endometrium in Women With Breast Cancer: A Prospective Study Using Office Endometrial Biopsy, 3459
Barakat RR. In Reply (correspondence), 445
Baral RN, *see* Foon KA
Barber JA, *see* Swerdlow AJ
Barbieri RL, *see* Holmes MD
Barcos M, *see* Berry DA
Barcos MP, *see* Green DM
Bardi A, *see* Cuneo A
Barista I. Intrathecal Cytarabine and Bone Marrow Suppression (correspondence), 2003
Barlogie B, *see* Alexanian R
Barnes EA, Hanson J, Neumann CM, Nekolaichuk CL, Bruera E. Communication Between Primary Care Physicians and Radiation Oncologists Regarding Patients With Cancer Treated With Palliative Radiotherapy, 2902
Baron B, *see* Vanhoefer U
—*see* Wilke H
Baron RA, *see* Boon H
Barr RD, Chalmers D, De Pauw S, Furlong W, Weitzman S, Feeny D. Health-Related Quality of Life in Survivors of Wilms' Tumor and Advanced Neuroblastoma: A Cross-Sectional Study, 3280
Barrett B, *see* Crémieux P-Y
Barrett RJ II, *see* Peters WA III
Bartlett NL, *see* Horning SJ
Barton CM, *see* Smith IE
Barton DL, *see* Loprinzi CL
—*see* Quella SK
—*see* Sloan JA
Barton M, *see* O'Brien P
Baruchel A, *see* Michel G
—*see* Morschhauser F
Baselga J, *see* Bellmunt J
Baselga J. New Therapeutic Agents Targeting the Epidermal Growth Factor Receptor, 54s
Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin, 904
Bash RO, *see* Mantadakis E
Basili LA, *see* Dorval M
Basser RL, Underhill C, Davis I, Green MD, Cebon J, Zalcberg J, MacMillan J, Cohen B, Marty J, Fox RM, Begley CG. Enhancement of Platelet Recovery After Myelosuppressive Chemotherapy by Recombinant Human Megakaryocyte Growth and Development Factor in Patients With Advanced Cancer, 2852
Bastert G, *see* Sauerbrei W
—*see* Schmoor C
Bastús R, *see* Bellmunt J
Batiste-Alentorn E, *see* Bellmunt J
Battista R, *see* Zinzani PL
Bauduer F, *see* Michel G
Bauer KA. Venous Thromboembolism in Malignancy (editorial), 3065
Baum CM, *see* DiPersio JF
Baume D, *see* Girinsky T
Beale P, *see* Briasoulis E
Bearman SI, *see* Nieto Y
Beauchamp CP, *see* Wunder JS
Beauchamp RD, *see* Talamonti MS
Beaudre A, *see* Girinsky T
Beaune P, *see* Cabelguenne A
Becciolini A, *see* Amadori D
Beck MN, Balmer A, Dessing C, Pica A, Munier F. First-Line Chemotherapy With Local Treatment Can Prevent External-Beam Irradiation and Enucleation in Low-Stage Intraocular Retinoblastoma, 2881
Beck T, *see* Mani S
Beckwith C, Butera J, Sadaniantz A, King TC, Fingleton J, Rosmarin AG. Non-Hodgkin's Lymphoma Involving the Heart; Case 1: Primary Transmural Cardiac Lymphoma, 1996
Bégin LR, *see* Chappuis PO
Begley CG, *see* Basser RL
Behm F, *see* Sandlund JT
Behn M, *see* Kersting M
Beijnen JH, *see* Malingré MM
Beitler J. Why Stop at Using High-Dose-Rate Brachytherapy as a Boost for the Prostate? (correspondence), 4003
Belani C, *see* Gandara DR
Belin TR, *see* Bower JE

Belinson J, *see* Markman M
Belkora JK, *see* Sepucha KR
Bell CM, *see* Earle CC
Bell RS, *see* Wunder JS
Bell WN, *see* Mani S
Belli M, *see* Frasci G
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, Baselga J for the Spanish Oncology Genitourinary Group. Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium, 3247
Belly RT, *see* Zujewski J
Ben-Baruch N, *see* Idelevich E
Bendandi M, *see* Zinzani PL
Benedetti-Panici P, *see* Piccart MJ
Benhamou E, *see* Girinsky T
Benjamin RS, *see* Meric F
—*see* Pisters PWT
Benner S, *see* Hoff PM
Bennett CL, *see* Ozer H
Bennett CL, Stinson TJ, Vogel V, Robertson L, Leedy D, O'Brien P, Hobbs J, Sutton T, Ruckdeschel JC, Chirikos TN, Weiner RS, Ramsey MM, Wicha MS. Evaluating the Financial Impact of Clinical Trials in Oncology: Results From a Pilot Study From the Association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project, 2805
Bennett JM, *see* Hochster HS
—*see* Horning SJ
Bennett K, *see* Norris B
Benoehr C, *see* Santoro A
Bense S, *see* Avril N
Bensmaïne A, *see* Alexandre J
Benson AB III, *see* Desch CE
—*see* Harris JE
—*see* Talamonti MS
Bentzen SM, *see* Rustin GJS
Benz CC, *see* Thor AD
Benzohra A, *see* Foran JM
Beran M, *see* Kantarjian HM
Berard CW, *see* Sandlund JT
Berd D, *see* Ejadi S
Berdel WE, *see* Koch P
Berek JS, *see* Peters WA III
Berenson J, *see* Alexanian R
Berenson JR, *see* Hillner BE
Berg C, *see* Pierce LJ
Berg WJ, *see* Motzer RJ
Berger C, *see* Frappaz D
Berger NA, *see* Takimoto CH
Berger SJ, *see* Takimoto CH
Bergman B, *see* von Pawel J
Bergstralh EJ, *see* Cheng L
Bergstrom K, *see* Swanson G
Berille J, *see* Shepherd FA
Berkey BA, *see* Coia LR
Berkowitz RS, *see* Lu KH
Berlin J, *see* Talamonti MS
Berman S, *see* Feld R
Bermúdez J, *see* Cañete A
Bernard JL, *see* Frappaz D
Bernard SA, Bruera E. Drug Interactions in Palliative Care, 1780
Bernaudin J-F, *see* Temam S
Bernhard J, *see* Coates AS
—*see* Crivellari D
Bernhardt B. Correspondence Re: 'Doc, Shouldn't We Be Getting Some tests?' (correspondence), 3739
Bernhardt BA, *see* Matloff ET
Bernini G, *see* Faulkner LB
Berns EMJJ, *see* Verhoog LC
Bernstein M, *see* Estlin EJ
Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L. Phase II Study of Vinorelbine With Protracted Fluorouracil Infusion as a Second- or Third-Line Approach for Advanced Breast Cancer Patients Previously Treated With Anthracyclines, 3370
Berry D, *see* Blackwell K
Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. HER-2/*neu* and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer, 3471
Bertelli G, *see* Venturini M
Bertheaut-Cvitkovic F, *see* Giacchetti S
Berthold F, *see* Poremba C
Berthou C, *see* Michel G
Berthou P, *see* Morschhauser F
Bertoni F, *see* Bacci G
Bertrand Y, *see* Landman-Parker J
Besenval M, *see* Gelmon KA
Bessell EM, *see* Foran JM
Bessho F, *see* Toyoda Y
Betaille R, *see* Le Gouill S
Betman L, *see* Israel O
Beudeker M, *see* Bontenbal M
Beveridge RA, Regan DH. Evaluation: Continued Need for Randomized Trials (correspondence), 3321
Beyerle C, *see* Sauerbrei W
Bezjak A, *see* Geels P
—*see* Kirkbride P
Bhatia S, *see* Porcu P
Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH. High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients With Relapsed Testicular Cancer, 3346
Bhattacharya-Chatterjee M, *see* Foon KA
Bi D-Q, *see* Grem JL
Bianco A, *see* Frasci G
Biegel JA, *see* Grotzer MA
Bienvenu J, *see* Voog E
Biermann JS, *see* Hillner BE
Biganzoli E, *see* Coradini D
Biganzoli L, *see* Paridaens R
Bigner DD, *see* Cokgor I
—*see* Friedman HS
Bigner SH, *see* Cokgor I
Bigoni R, *see* Cuneo A
Bilancia D, *see* Comella P
—*see* Frasci G

Billingham L, Cullen M. In Reply (correspondence), 1800
Birch R, *see* Weaver CH
Biron P, *see* Blay J-Y
—*see* Tilly H
Bishop MC, *see* Hughes ODM
Bishop MR, Tarantolo SR, Pavletic ZS, Lynch JC, Morris ME, Zacharias D, Armitage JO, Kessinger A. Filgrastim as an Alternative to Donor Leukocyte Infusion for Relapse After Allogeneic Atem-Cell Transplantation, 2269
Bjurstrom T, *see* Johnston E
Black JL, *see* Warren KE
Black PM, *see* Fine HA
Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-Dimer Levels in Operable Breast Cancer Patients Correlate With Clinical Stage and Axillary Lymph Node Status, 600
Blackwell S, *see* Johnston E
Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, Jouet J-P, Attal M, Bordigoni P, Cahn J-Y, Boiron J-M, Schuller M-P, Moatti J-P, Michallet M. Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Société Française de Greffe de Moelle, 537
Blanco G, *see* Holli K
Blank C, Wagner HM, Hohenleutner U, Andreesen R. Unusual Manifestations of Acute Leukemia: Case 2: Leukemia and Rash: Paraneoplastic or Drug-Induced?, 3437
Blay JY, *see* Le Cesne A
Blay J-Y, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation for Advanced Soft Tissue Sarcoma in Adults, 3643
Bleiberg H, *see* Vanhoefer U
Blessing JA, *see* McGuire WP
Bleuzen P, *see* Alexandre J
Blitzer JB, *see* Nagourney RA
Blobe GC, Mantel M, Janicek M, Demetri GD. Uterine Sarcoma, 2341
Blodd P, *see* Kirkbride P
Blons H, *see* Cabelguenne A
Bloomfield CA, *see* Harris NL
Blum RH, *see* Kirkwood JM
Blumberg D, *see* Lewis JJ
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D, Farris A, and Other Participants in the Italian Breast Cancer Adjuvant Study Group. Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial, 2718
Boccardo F (on Behalf of the Italian Prostate Cancer Project). In Reply (correspondence), 445
Boccuni P, *see* Ferrara F
Boddy AV, *see* Thomas H
Bodenstein H, *see* Vanhoefer U
Bodensteiner D, *see* Cagnoni PJ
Bodey G, *see* Elting LS
Bodrogi I, *see* von der Maase H
Boecker W, *see* Poremba C
Bogaerts J, *see* Gatzemeier U
Boige V, Raymond E, Faivre S, Gatineau M, Meely K, Mekhaldi S, Pautier P, Ducreux M, Rixe O, Armand J-P. Phase I and Pharmacokinetic Study of the Camptothecin Analog DX-8951f Administered as a 30-Minute Infusion Every 3 Weeks in Patients With Advanced Cancer, 3986
Boiron J-M, *see* Blaise D
Bojar H, *see* Sauerbrei W
Bok R, *see* Small EJ
Bol CJ, *see* Zujewski J
Bolis G, *see* Lavarino C
Bolla M, *see* Hügli A
Bollinger JW, *see* Martenson JA
Bolognesi A, *see* Boccardo F
Bolwell B, *see* Davies SM
Bonadonna G, *see* Santoro A
Bond SJ, *see* Rustin GJS
Bonetti A, *see* de Gramont A
—*see* Piccart MJ
Bonetti M, *see* Colleoni M
—*see* Crivellari D
Bonfante V, *see* Santoro A
Boni C, *see* de Gramont A
Bonithon-Kopp C, *see* Chaplain G
Bonnay M, *see* Fizazi K
Bonnefoi H, *see* Hügli A
Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, Buchsbaum DJ, Saleh MN, Stackhouse MA, LoBuglio AF, Peters GE, Carroll WR, Waksal HW. Enhanced Apoptosis With Combination C225/Radiation Treatment Serves as the Impetus for Clinical Investigation in Head and Neck Cancers, 47s
Bonneterre J, *see* Alexandre J
Bonneterre J, Thürlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M for the Arimidex Study Group. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study, 3748
Bonomi P, *see* Gandara DR
Bonomi P, Kim KM, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial, 623
Bontenbal M, van Putten WLJ, Burghouts JThM, Baggen MGA, Ras GJ, Stiegelis WF, Beudeker M, Janssen JThP, Braun JJ, van der Linden GHM, van der Velden PC, van Geel AN, Helle P, Leisink M, Foekens JA, Klijn JGM. Value of Estrogenic Recruitment Before Chemotherapy: First Randomized Trial in Primary Breast Cancer, 734
Bookman MA, *see* McGuire WP
Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T. Use of Complementary/Alternative Medicine by Breast Cancer Survivors in Ontario: Prevalence and Perceptions, 2515
Boracchi P, *see* Coradini D
Bordessoule D, *see* Tilly H

Bordigoni P, *see* Blaise D
—*see* Michel G
Borell TJ, *see* Smith JS
Borgomastro A, *see* Zampa G
Bormans G, *see* Flamen P
Bos M, *see* Baselga J
Bosl GJ, *see* Motzer RJ
Bosly A, *see* Haioun C
—*see* Tilly H
—*see* Wijermans
Bostrom BC, *see* Heerema NA
Bostwick DG, *see* Cheng L
Bot FJ, *see* Veltman JA
Botta M, *see* Berruti A
Bottini A, *see* Berruti A
Bouaouina N, *see* Girinsky T
Boucher J, *see* Savarese D
Bouffet E, *see* Frappaz D
Bouhour D, *see* Blay J-Y
Bourhis JH, *see* Blaise D
Bourhis J-H, *see* Girinsky T
Bourquelot P, *see* Mamzer-Bruneel M-F
Bourstyn E, *see* Stoppa-Lyonnet D
Bouscary M-L, *see* Macquart-Moulin G
Boussen H, *see* Fandi A
Bowden C, *see* Zujewski J
Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life, 743
Bowman L, *see* Phipps S
Bowman LC, *see* Leung W
Boyd JH, *see* Lowe VJ
Boyer M, *see* Klastersky J
—*see* von Pawel J
Boyett JM, *see* Thomas PRM
Boyle MG, *see* Dodd PM
Brabbins DS, *see* Kestin LL
Brada M, *see* Osoba D
Bradburn M, *see* Apostolidis J
Brady MF, *see* Muggia FM
Brainstem Glioma Cooperative Group, *see* Broniscer A
Braly PS, *see* Muggia FM
Brasnu D, *see* Cabelguenne A
Braun JJ, *see* Bontenbal M
Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K. Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients, 80
Bredenfeld H, *see* Santoro A
Brekelmans CTM, *see* Verhoog LC
Brendel C, *see* Schmidt M
Breneman JC, *see* Baker KS
Brennan MB, *see* Giuliano AE
Brennan MF, *see* Lewis JJ
—*see* Linehan DC
Brenner B, *see* Idelevich E
Bresciani G, *see* Coradini D
—*see* Lavarino C
Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel Lymph Node Biopsy Is Accurate After Neoadjuvant Chemotherapy for Breast Cancer, 3480
Breslow N, *see* Porteus MH
Bretscher M. Caring for Dying Patients: What Is Right?, 233
Brewer H, *see* Saleh MN
Brezden CB, Phillips K-A, Abdolell M, Bunston T, Tannock IF. Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy, 2695
Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A. Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group, 3535
Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N. Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study, 3101
Brice P, *see* Haioun C
Brichon PY, *see* Andre F
Bridges KD, *see* Godder KT
Bridier A, *see* Girinsky T
Briere J, *see* Guermazi A
Brière J, *see* Haioun C
—*see* Tilly H
Brierley K, *see* Matloff ET
Brignoli S, *see* Pestalozzi BC
Briot E, *see* Girinsky T
British Medical Research Council Lung Cancer Working Party, *see* Hopwood P
Britten CD, *see* Eckhardt SG
Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer, 3339
Broadwater G, *see* Berry DA
—*see* Blackwell K
Brock P, *see* Pritchard J
Brockstein BE. Reduction of Distant Metastases in Head and Neck Cancer With Concomitant Chemotherapy (correspondence), 3320
Brodeur GM, *see* Maris JM
—*see* Nickerson HJ
—*see* Schmidt ML
Bromberg JI, *see* Dorval M
Broniscer A, da Costa Leite C, Lanchote VL, Machado TMS, Cristófani LM, and the Brainstem Glioma Cooperative Group. Radiation Therapy and High-Dose Tamoxifen in the Treatment of Patients With Diffuse Brainstem Gliomas: Results of a Brazilian Cooperative Study, 1246
Brooks SE, *see* Zamboni WC
Brophy N, *see* Dahl GV
Brouchet L, *see* Andre F
Broun ER, *see* Fife BL
Brousse N, *see* Mamzer-Bruneel M-F
Brouwer E, *see* de Jonge MJA
Brown CM, *see* McMasters KM
Brown F, *see* Jänne PA

Brown J, *see* Pritchard J
Brown JB, *see* Boon H
Brown R, *see* Mackay HJ
Bruera E, MacDonald N. To Hydrate or Not to Hydrate: How Should It Be?, 1156
Bruera E, *see* Barnes EA
—*see* Bernard SA
Brunelli A, *see* Berruti A
Brunet J-S, *see* Chappuis PO
Brunetti C, *see* Lorusso V
Bruning P, *see* Paridaens R
Bruno R, *see* Couteau C
Bubley G, *see* Shaneyfelt T
Buchholz TA, *see* Katz A
Buchsbaum DJ, *see* Bonner JA
Buckley JD, *see* Gamis AS
Buckner CD, *see* Weaver CH
Buclon M, *see* Frappaz D
Budman D, *see* Venook AP
Budman DR, *see* Berry DA
Bueno R, *see* Sekeres M
Buesa J, *see* Verweij J
Buhl P, *see* Langer SW
Bull SB, *see* Wunder JS
Büller HR, *see* Hutten BA
Bunin GR, *see* Friedman DL
Bunin N, *see* Grupp SA
Bunnell CA, *see* Burstein HJ
Bunston T, *see* Brezden CB
Bureo E, *see* Marco F
Burger HU, *see* Van Cutsem E
Burger PC, *see* Smith JS
Burgers JMV, *see* van Leeuwen FE
Burgess MA, *see* Meric F
Burghouts JThM, *see* Bontenbal M
Burkes R, *see* Shepherd FA
Burnett CB, *see* Cheng JD
Burns P, *see* Madajewicz S
Burstein HJ. Discussing Complementary Therapies With Cancer Patients: What Should We Be Talking? (editorial), 2501
Burstein HJ. Radiation Recall Dermatitis from Gemcitabine, 693
Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer, 1212
Burtness B, *see* Baselga J
Burtness BA, *see* Heath EI
Burton G, *see* Nabholtz JM
Buter J, *see* Langer SW
Butera J, *see* Beckwith C
Butera J, Freeman NJ. Hodgkin's Disease Presenting as a Cystic Neck Mass, 1150
Butler P, *see* List MA
Butler TW, *see* von Pawel J
Butow P, *see* Meiser B
Buzdar A, *see* Nabholtz JM
Buzdar AU. Letrozole: Which Dose to Be Used? (correspondence), 1800
Buzdar AU, *see* Breslin TM
—*see* Katz A
Bydder S, *see* Elsaleh H
Byrd J, *see* Venook AP

Cabanillas F. Interferon Does Not Prolong Progression-Free Survival After ProMACE-MOPP (correspondence), 3322
Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier A-M, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P. *p53* Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series, 1465
Cabriales S, *see* Tulpule A
Cady B. Sentinel Lymph Node Procedure in Squamous Cell Carcinoma of the Vulva (editorial), 2795
Cagnoni PJ, *see* Nieto Y
Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CAS, Schuster M, Seibel N, Yeldandi V, Tong KB. Pharmacoeconomic Analysis of Liposomal Amphotericin B Versus Conventional Amphotericin B in the Empirical Treatment of Persistently Febrile Neutropenic Patients, 2476
Cagossi K, *see* Federico M
—*see* Sabbatini R
Cahn J-Y, *see* Blaise D
—*see* Davies SM
Caillot D, *see* Yakoub-Agha I
Cairo MS, *see* Gururangan S
—*see* Lones MA
Calaminus G, *see* Schneider DT
Callard P, *see* Temam S
Calzone K, *see* Dorval M
Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, Ellison R, Warrell RP Jr. Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide, 2620
Cameron D, *see* Mackay HJ
Camitta B, *see* Mahoney DH Jr
Camitta BM, *see* Davies SM
—*see* Pollock BH
Campanacci M, *see* Bacci G
Campbell E, *see* Hidalgo M
Canellos GP, *see* Loprinzi CL
Canellos GP. Introduction, 1s
Canellos GP. The Policing of Clinical Trials (editorial), 2353
Cañete A, Castel V, Navarro S. In Reply (correspondence), 2788
Cañete A, Navarro S, Bermúdez J, Pellín A, Castel V, Llombart-Bosch A. Angiogenesis in Neuroblastoma: Relationship to Survival and Other Prognostic Factors in a Cohort of Neuroblastoma Patients, 27
Cannistra SA. When Is a 'Prognostic Factor' Really Prognostic? (editorial), 3745
Canto MI, *see* Heath EI
Cantor SB, *see* Elting LS
Caplan AI, *see* Koç ON
Capuron L, Ravaud A, Dantzer R. Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy, 2143
Carbone D, *see* Gandara DR
Cardenas-Cardos R, *see* Rivera-Luna R
Carducci M, *see* Kaufman D
Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT. Autografting Followed

by Nonmyeloablative Immunosuppressive Chemotherapy and Allogeneic Peripheral-Blood Hematopoietic Stem-Cell Transplantation as Treatment of Resistant Hodgkin's Disease and Non-Hodgkin's Lymphoma, 3918
Carles J, *see* Bellmunt J
Carli P-M, *see* Chaplain G
Carlo-Stella C, *see* Siena S
Carlson DJ, *see* McMasters KM
Carlson GA, *see* Chen EA
Carlson RW, *see* Wolden SL
Carnot F, *see* Cabelguenne A
Caron D, *see* Morse MA
Carpagnano F, *see* Lorusso V
Carpenter R, *see* Mokbel K
Carr KM, Rabinowitz I. Physician Compliance With Warfarin Prophylaxis for Central Venous Catheters in Patients With Solid Tumors, 3665
Carrère M-O, *see* Mille D
Carroll PR, *see* Roach M III
Carroll PR. Prostate Biopsy: A Wealth of Information When Done and Interpreted Correctly (editorial), 1161
Carroll WR, *see* Bonner JA
Carter D, *see* Smith BD
Caruso R, *see* Madajewicz S
Caruso RC, *see* Conley B
Casadei R, *see* Bacci G
Casassus P, *see* Harousseau JL
Cascinu S, *see* Graziano F
Caselli D, Klersy C, de Martino M, Gabiano C, Galli L, Tovo PA, Aricò M for the Italian Register for HIV Infection in Children. Human Immunodeficiency Virus–Related Cancer in Children: Incidence and Treatment Outcome—Report of the Italian Register, 3854
Cassidy J, *see* de Gramont A
—*see* Van Cutsem E
Cassileth P, *see* Horning SJ
Cassileth PA, *see* Hochster HS
Cassisi NJ, *see* Mendenhall WM
Castellano D, Hitt R, Cortés-Funes H, Romero A, Rodriguez-Peralto JL. Radiation Recall Reaction Induced by Gemcitabine, 693
Castel V, *see* Cañete A
—*see* Marco F
Castiglione-Gertsch M, *see* Coates AS; Colleoni M
—*see* Colleoni M
—*see* Crivellari D
Castoldi G, *see* Cuneo A
Catalano G, *see* Amadori D
Catalano PJ, *see* Talamonti MS
Caty A, *see* Négrier S
Cavaliere M, *see* Carella AM
Cavalli F, *see* Colleoni M
—*see* Crivellari D
Cavo M, *see* Martinelli G
Cayuela JM, *see* Morschhauser F
Cazenave LA, *see* Fracasso PM
Cebon J, *see* Basser RL
—*see* Middleton MR
Cederberg D, *see* Smalley RV
Celio L, *see* Lønning PE
Cella D, *see* Bonomi P
—*see* Motzer RJ
Cellini C, *see* Zinzani PL
Cerrito PB, *see* McMasters KM
Cervantes A, *see* de Gramont A
Cervek J, *see* Kaufmann M
Chabbert I, *see* Yakoub-Agha I
Chabner BA, *see* Gutierrez M
Chahine A, *see* Alexandre J
Chalmers D, *see* Barr RD
Chamness GC, *see* Zellars RC
Champlin R, *see* van Besien K
Champlin RE, *see* Seong C-M
Chan K-Y, *see* Cheng SH
Chanel S, *see* Camacho LH
Chang A, *see* Levitan N
Chang E, *see* Khuri FR
Chang H-H, *see* Chang T-C
Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Dowsett M. In Reply (correspondence), 1601
Chang JT, *see* Chang T-C
Chang M, *see* Dahl GV
Chang P, *see* Marshall JL
Chang T-C, Lai C-H, Hong J-H, Hsueh S, Huang K-G, Chou H-H, Tseng C-J, Tsai C-S, Chang JT, Lin C-T, Chang H-H, Chao P-J, Ng K-K, Tang SG-J, Soong Y-K. Randomized Trial of Neoadjuvant Cisplatin, Vincristine, Bleomycin, and Radical Hysterectomy Versus Radiation Therapy for Bulky Stage IB and IIA Cervical Cancer, 1740
Chao P-J, *see* Chang T-C
Chaplain G, Milan C, Sgro C, Carli P-M, Bonithon-Kopp C. Increased Risk of Acute Leukemia After Adjuvant Chemotherapy for Breast Cancer: A Population-Based Study, 2836
Chapman RH, *see* Earle CC
Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet J-S, Narod SA, Slingerland J, Foulkes WD. Germline BRCA1/2 Mutations and $p27^{Kip1}$ Protein Levels Independently Predict Outcome After Breast Cancer, 4045
Chaudri HA, Trunet PF. In Reply (correspondence), 1800
Chauvin F, *see* Mille D
Chen AP, *see* Takimoto CH
Chen EA, Carlson GA, Coughlin BF, Reed WP Jr, Garb JL, Frank JL. Routine Chest Roentgenography Is Unnecessary in the Work-Up of Stage I and II Breast Cancer, 3503
Chen G, *see* Sandlund JT
Chen L, *see* Small EJ
Chen M-H, *see* D'Amico AV
Chen PY, *see* Kestin LL
—*see* Vicini FA
Cheng JC, *see* Cheng SH
Cheng JD, Hitt J, Koczwara B, Schulman KA, Burnett CB, Gaskin DJ, Rowland JH, Meropol NJ. Impact of Quality of Life on Patient Expectations Regarding Phase I Clinical Trials, 421
Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG. Preoperative Prediction of Surgical Margin Status in Patients With Prostate Cancer Treated by Radical Prostatectomy, 2862
Cheng SH, Tsai SYC, Yen KL, Jian JJ-M, Chu N-M, Chan K-Y, Tan T-D, Cheng JC, Hsieh C-Y, Huang AT. Concomitant Radiotherapy and Chemotherapy for Early-Stage Nasopharyngeal Carcinoma, 2040
Cherlow J, *see* Thomas PRM
Cheson B, *see* Kantarjian HM

Cheson BD, *see* Gutierrez M
Cheson BD. The Curious Case of the Baffling Biological (editorial), 2007
Chevlen EM, *see* Mani S
Chevret S, *see* Yakoub-Agha I
Chiang KY, *see* Godder KT
Chiao J, *see* Zujewski J
Chichino G, *see* Nasti G
Chilcott F, *see* Smith IC
Child JA, *see* Davies FE
Chim CS, Choy C, Ooi GC, Chung LP, Wong KK, Liang R. Two Unusual Lymphomas; Case 2: Pulmonary Intravascular Lymphomatosis, 3733
Chim CS, Shek TW, Ooi GC, Liang R. Meningeal Relapse in Hodgkin's Disease, 1150
Chirikos TN, *see* Bennett CL
Chiusa L, *see* Pich A
Chlebowski RT, *see* Hillner BE
Cho JH, *see* Kim GE
Chollet P, *see* Giacchetti S
Chompret A, *see* Delaloge S
Chou H-H, *see* Chang T-C
Chow C, *see* Conley B
—*see* Zujewski J
Chowdhury AD, *see* Kirkbride P
Choy C, *see* Chim CS
Choy CKW, *see* Liang R
Chrastek J, *see* Hilden JM
Christian M, *see* Eisenhauer EA
Christiansen H, *see* Poremba C
Christiansen NP, *see* Godder KT
Christodoulou C, *see* Briasoulis E
Christos P, *see* Vickers A
Chu N-M, *see* Cheng SH
Chung EJ, *see* Kim GE
Chung LP, *see* Chim CS
Ciccone F, *see* Zinzani PL
Ciezki J, *see* Adelstein DJ
Cingolani A, Gastaldi R, Fassone L, Pierconti F, Giancola ML, Martini M, De Luca A, Ammassari A, Mazzone C, Pescarmona E, Gaidano G, Larocca LM, Antinori A. Epstein-Barr Virus Infection Is Predictive of CNS Involvement in Systemic AIDS-Related Non-Hodgkin's Lymphomas, 3325
Cinieri S, *see* Lorusso V
Cioffi R, *see* Comella P
Cirera L. In Reply (correspondence), 3061
Cirkel DT, *see* Smith IE
Cisternino ML, *see* Lorusso V
Clahsen PC, *see* Elkhuizen PHM
Clark GM, *see* Eckhardt SG
—*see* Monsky WL
—*see* Zellars RC
Clark P, *see* von Pawel J
Clark T, *see* Micallef INM
Clarke A, *see* Metayer C
Clarke KD, *see* Burstein HJ
Clarke PA, *see* Waters JS
Clavien P, *see* Morse MA
Clay T, *see* Morse MA
Cleall SP, *see* von der Maase H
Cleary KR, *see* Hoff PM
Clerico M, *see* Postmus PE
Cleton FJ, *see* Weijl NI
Climent MA, *see* Bellmunt J
Clough KB, *see* Stoppa-Lyonnet D
Cnaan A, *see* Grotzer MA
Coates A, *see* Middleton MR
Coates AS, Hürny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A for the International Breast Cancer Study Group. Quality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer, 3768
Coates AS, *see* Colleoni M
—*see* Crivellari D
Cobau CD, *see* Simpson JF
Cocconi G. Chemotherapy With and Without Anthracycline (correspondence), 1392
Cohen B, *see* Basser RL
Cohen L, *see* Breslin TM
Cohen MB, *see* Dreicer R
Cohen MH, Johnson JR. Temozolomide for Advanced, Metastatic Melanoma (correspondence), 2185
Cohen MH. Thalidomide in the Treatment of High-Grade Gliomas (correspondence), 3453
Cohen R, *see* Baselga J
Cohn SL, *see* Katzenstein HM
Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber M. *MYCN* Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified *MYCN*, 3604
Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of Patients Receiving Radiation for Cancer of the Esophagus: Results of the 1992-1994 Patterns of Care Study, 455
Coiffier B, *see* Foran JM
—*see* Haioun C
—*see* Tilly H
—*see* Voog E
Cokgor I, *see* Friedman HS
Cokgor I, Akabani G, Kuan C-T, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao X-G, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE II, Provenzale JM, Zalutsky MR, Bigner DD. Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas, 3862
Colabianchi N, *see* Siminoff LA
Colangelo L, *see* List MA
Colditz GA, *see* Holmes MD
Coleman R, *see* Paridaens R
—*see* Verweij J
Coleman RE, *see* Cokgor I
Colevas AD. In Reply (correspondence), 1392
Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam C-M, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A for the International Breast Cancer Study Group. Early Start of Adjuvant Chemotherapy May Improve Treatment Outcome for Premenopausal Breast Cancer Patients With Tumors Not Expressing Estrogen Receptors, 584
Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürli-

mann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam C-M for the International (Ludwig) Breast Cancer Study Group. Identifying Breast Cancer Patients at High Risk for Bone Metastases, 3925
Collins BT, *see* Lowe VJ
Collins DM, *see* DiPersio JF
Collins J, *see* Colleoni M
—*see* Crivellari D
Colombo N, *see* Torri V
Coltman CA Jr, *see* Moinpour CM
—*see* Monsky WL
Colvin OM, *see* Friedman HS
Combaret V, *see* Frappaz D
Comella G, *see* Comella P
—*see* Frasci G
Comella P, *see* Frasci G
Comella P, Frasci G, Panza N, Manzione L, De Cataldis G, Cioffi R, Maiorino L, Micillo E, Lorusso V, Di Rienzo G, Filippelli G, Lamberti A, Natale M, Bilancia D, Nicolella G, Di Nota A, Comella G. Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group, 1451
Comis R, *see* Gandara DR
Confalonieri C, *see* Fossati R
Confalonieri C. In Reply (correspondence), 1392
Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Merino MJ, Kaiser-Kupfer MI, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, Zujewski J. Pilot Trial of the Safety, Tolerability, and Retinoid Levels of *N*-(4-Hydroxyphenyl) Retinamide in Combination with Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer, 275
Connolly J, *see* Park CC
Connors D, *see* Nemunaitis J
Conrad EU, *see* Wunder JS
Conte PF, *see* von der Maase H
Conway K, *see* Stark A
Cook B, *see* Nieto Y
Cooksley CS, *see* Khuri FR
Coombes RC, *see* Smith BM
Cooper BW, *see* Koç ON
Cooper DL. Radiation for Early-Stage Hodgkin's Disease? (correspondence), 942
Cooper MR, *see* Baselga J
Coosemans W, *see* Flamen P
Coradini D, Daidone MG, Boracchi P, Biganzoli E, Oriana S, Bresciani G, Pellizzaro C, Tomasic G, Di Fronzo G, Marubini E. Time-Dependent Relevance of Steroid Receptors in Breast Cancer, 2702
Corey A, *see* Nemunaitis J
Corey GR, *see* Gopal AK
Cormier Y, *see* Sandler AB
Cornelissen JJ, *see* Lokhorst HM
Cornes PGS, Shahidi M. Radiation Endocrine Action in Prostate Cancer (correspondence), 4004
Cornetta K, *see* Bhatia S
Cornetta KG, *see* Fife BL
Corry M, *see* Small EJ
Corsetti MT, *see* Carella AM
Cortes J, *see* Kantarjian HM
Cortés-Funes H, *see* Bellmunt J
—*see* Castellano D
—*see* Crivellari D
—*see* Gomez-Martin C
Cortes-Funes H, *see* Colleoni M
—*see* de Gramont A
Cosset JM, *see* Girinsky T
Cotter FE, *see* Waters JS
Cotterill S, *see* Estlin EJ
Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H, Craft AW. Prognostic Factors in Ewing's Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing's Sarcoma Study Group, 3108
Cottrell J, *see* Takimoto CH
Coudert B, *see* Giacchetti S
Coughlin BF, *see* Chen EA
Coughlin S, *see* Shepherd FA
Coulet F, *see* Temam S
Couteau C, Risse M-L, Ducreux M, Lefresne-Soulas F, Riva A, Lebecq A, Ruffié P, Rougier P, Lokiec F, Bruno R, Armand J-P. Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors, 3545
Couvreur M-L, *see* Vanhoefer U
Covelli A, *see* Tidefelt U
Cowan KH, *see* Conley B
—*see* Zujewski, J
Coyle J, *see* Rowinsky EK
Coze C, *see* Frappaz D
—*see* Landman-Parker J
Craffey M, *see* Levitan N
Craft AW, *see* Cotterill SJ
—*see* Lewis IJ
Cramer DW, *see* Lu KH
Crane C, *see* Hoff PM
Crane CH, *see* Pisters PWT
Crawford ED, *see* Hussain M
—*see* Small EJ
Crawford J, *see* Fossella F
—*see* Johnston E
—*see* Ozer H
Crawford JG, *see* Baidas SM
Crawford S, *see* Katzenstein HM
Crémieux P-Y, Barrett B, Anderson K, Slavin MB. Cost of Outpatient Blood Transfusion in Cancer Patients, 2755
Cristófani LM, *see* Broniscer A
Crist WM, *see* Baker KS
—*see* Sandlund JT
Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam C-M, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A for the International Breast Cancer Study Group. Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients with Breast Cancer: The International Breast Cancer Study Group trial VII, 1412
Cross NCP, *see* Smith BM
Cross P, *see* Kirkbride P

Crowther D, *see* Le Cesne A
Crump M, *see* Patnaik A
Cubells J, *see* Marco F
Cullen M, *see* Billingham L
Cumming RI, *see* Morse MA
Cummings S. The Genetic Testing Process: How Much Counseling Is Needed?, 60s
Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Milani R, Bardi A, Minotto C, Agostini P, De Angeli C, Narducci MG, Sabbioni S, Russo G, Negrini M, Castoldi G. Acquired Chromosome 11q Deletion Involving the Ataxia Teleangiectasia Locus in B-Cell Non-Hodgkin's Lymphoma: Correlation With Clinicobiologic Features, 2607
Cunningham D, *see* Foran JM
—*see* Ross PJ
—*see* Swerdlow AJ
—*see* Waters JS
Curran D, *see* Piccart MJ
—*see* Postmus PE
—*see* Van Zandwijk N
Curran WJ, *see* Del Rowe J
Curtis RE, *see* Metayer C
—*see* Socié G
Cvitkovic E, *see* Alexandre J
—*see* Fandi A
Czuczman MS, *see* Davis TA

da Costa Leite C, *see* Broniscer A
Dagovic A, *see* Jeremic B
Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ. Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia, 1867
Daidone MG, *see* Coradini D
Daigneault L, *see* Gelmon KA
Dalakas M, *see* Dimopoulos MA
Dalley D, *see* Van Cutsem E
D'Aloisio S, *see* Gelmon KA
Dalton WS, *see* Alexanian R
Damaj G, *see* Yakoub-Agha I
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen M-H, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical Utility of the Percentage of Positive Prostate Biopsies in Defining Biochemical Outcome After Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer, 1164
D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M-H, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing Predictions of Early Prostate-Specific Antigen Failure to Optimize Patient Selection for Adjuvant Systemic Therapy Trials, 3240
Dana BW, *see* Fisher RI
Dancey J, *see* Shepherd FA
Dandekar S, *see* Pauletti G
D'Andrea G, *see* Baselga J
Danforth D, *see* Conley B
Daniel C, *see* Fizazi K
Daniel CR, *see* Saleh MN
Dantzer R, *see* Capuron L
Dar AR, *see* Kirkbride P
Darling M, *see* Galsky M
Das R, *see* Foon KA
Dauriac C, *see* Yakoub-Agha I
Davidson K, *see* Hidalgo M
Davidson NE, *see* Wolff AC
Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA, Morgan GJ. High-Producer Haplotypes of Tumor Necrosis Factor Alpha and Lymphotoxin Alpha Are Associated With an Increased Risk of Myeloma and Have an Improved Progression-Free Survival After Treatment, 2843
Davies SM, Ramsay NKC, Klein JP, Weisdorf DJ, Bolwell B, Cahn J-Y, Camitta BM, Gale RP, Giralt S, Heilmann C, Henslee-Downey PJ, Herzig RH, Hutchinson R, Keating A, Lazarus HM, Milone GA, Neudorf S, Perez WS, Powles RL, Prentice HG, Schiller G, Socié G, Vowels M, Wiley J, Yeager A, Horowitz MM. Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia, 340
Daviet A, *see* Le Gouill S
Davis AM, *see* Wunder JS
Davis I, *see* Basser RL
Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment, 3135
Dawson L, *see* Pierce LJ
Dawson LA, McGinn CJ, Normolle D, Haken RKT, Walker S, Ensminger W, Lawrence TS. Escalated Focal Liver Radiation and Concurrent Hepatic Artery Fluorodeoxyuridine for Unresectable Intrahepatic Malignancies, 2210
Day A, *see* Geels P
Day RS, *see* Zamboni WC
de Alava E, Gerald WL. Molecular Biology of the Ewing's Sarcoma/Primitive Neuroectodermal Tumor Family, 204
De Angeli C, *see* Cuneo A
DeAngelis LM, *see* Abrey LE
DeBaun MR, *see* Pollock BH
De Bernardi B, *see* Faulkner LB
de Boer RH, *see* Smith IE
de Boer-Dennert MM, *see* de Jonge MJA
de Braud F, *see* de Gramont A
de Bruijn P, *see* de Jonge MJA
Debruyne C, *see* Van Zandwijk N
DeCamp M, *see* Adelstein DJ
De Cataldis G, *see* Comella P
—*see* Frasci G
Deconinck E, *see* Harousseau JL
—*see* Yakoub-Agha I
DeCorato D, *see* Schwartz LH
Deeg HJ, *see* Socié G
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and Fluorouracil With or Withut Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer, 2938
de Hae JCJM, *see* Ong LML
de Hullu JA, Hollema H, Piers DA, Verheijen RHM, van Diest PJ, Mourits MJE, Aalders JG, van der Zee AGJ. Sentinel Lymph Node Procedure Is Highly Accurate in Squamous Cell Carcinoma of the Vulva, 2811

De Jager RL, *see* Rowinsky EK
de Jonge MJA, Loos WJ, Gelderblom H, Planting ASTh, van der Burg MEL, Sparreboom A, Brouwer E, van Beurden V, Mantel MA, Doyle E, Hearn S, Ross G, Verweij J. Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects, 2104
de Jonge MJA, Sparreboom A, Planting AST, van der Burg MEL, de Boer-Dennert MM, ter Steeg J, Jacques C, Verweij J. Phase I Study of 3-Week Schedule of Irinotecan Combined With Cisplatin in Patients With Advanced Solid Tumors, 187
de Jonge MJA, Verweij J, de Bruijn P, Brouwer E, Mathijssen RHJ, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A. Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin, 195
de Kerviler E, *see* Guermazi A
de la Chapelle A, *see* Salovaara R
de la Cruz JJ, *see* Bellmunt J
Delain M, *see* Harousseau JL
Delaloge S, Morice P, Chompret A, Lhommé C. Prophylactic Surgery: Oophorectomy or Adnexectomy? (correspondence), 3454
de La Salmonière P, *see* Yakoub-Agha I
De Lena M, *see* Berruti A
—*see* Frasci G
—*see* Lorusso V
De Leyn P, *see* Flamen P
Del Favero A, *see* Roila F
Del Mastro L, *see* Venturini M
Delozier T, *see* Macquart-Moulin G
Delozier T, Spielmann M, Macé-Lesec'h J, Janvier M, Hill C, Asselain B, Julien J-P, Weber B, Mauriac L, Petit J-C, Kerbrat P, Malhaire J-P, Vennin P, Leduc B, Namer M for the Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group. Tamoxifen Adjuvant Treatment Duration in early Breast Cancer: Initial Results of a Randomized Study Comparing Short-Term Treatment With Long-Term Treatment, 3507
Delpassand ES, *see* Breslin TM
del Prever AB, *see* Bacci G
Del Rowe J, Scott C, Werner-Wasik M, Bahary JP, Curran WJ, Urtasun RC, Fisher B. Single-Arm, Open-Label Phase II Study of Intravenously Administered Tirapazamine and Radiation Therapy for Glioblastoma Multiforme, 1254
De Luca A, *see* Cingolani A
Del Vecchio L, *see* Ferrara F
DeMarinis F, *see* Gatzemeier U
de Martino M, *see* Caselli D
Demeocq F, *see* Michel G
Demetri GD, *see* Blobe GC
—*see* Ozer H
Deng Y, *see* Morse MA
Denham C, *see* Sandler AB
Denley H, *see* Hughes ODM
Denton G, *see* Hughes ODM
de Paula Guedes E, *see* Verschraegen CF
DePauw B, *see* Feld R
De Pauw S, *see* Barr RD
Depenni R, *see* Federico M
—*see* Sabbatini R
De Renzo A, *see* Zinzani PL
Desablens B, *see* Harousseau JL
Desch CE, *see* Hillner BE
Desch CE, Benson AB III, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Smith TJ, Somerfield MR for the American Society of Clinical Oncology. 2000 Update of American Society of Clinical Oncology Colorectal Cancer Surveillance Guidelines, 3586
De Simone M, *see* Ferrara F
Desmond KA, *see* Bower JE
Dessing C, *see* Beck MN
De Stefano F, *see* Carella AM
de Swart CAM, *see* Neijt JP
DeSwarte-Wallace J, *see* Gamis AS
Detmar SB, Aaronson NK, Wever LDV, Muller M, Schornagel JH. How Are You Feeling? Who Wants to Know? Patients' and Oncologists' Preferences for Discussing Health-Related Quality-of-Life Issues, 3295
Deutsch M, *see* Thomas PRM
de Vivo A, *see* Martinelli G
Devizzi L, *see* Santoro A
Devore R, *see* Gandara DR
DeVore R, *see* Fossella F
—*see* Levitan N
de Vries EG, *see* Mourits MJ
de Vries EGE, *see* Meinardi MT
de Vries MJ, *see* van Groeningen CJ
de Waal J, *see* Braun S
de Waziers I, *see* Cabelguenne A
De Wever W, *see* Flamen P
Dewhirst M, *see* Blackwell K
Deykin A, *see* Attar EC
Dhermain F, *see* Girinsky T
Diab SG, *see* Hidalgo M
Diamandis EP, *see* Nam RK
Diasio RB, *see* Baker SD
Díaz MA, *see* Marco F
Diaz-Rubio E, *see* Bellmunt J
Dicks-Mireaux C, *see* Pritchard J
Diebold J, *see* Harris NL
Diehl V, *see* Josting A
—*see* Santoro A
Diel IJ, *see* Pfeilschifter J
Di Fronzo G, *see* Coradini D
DiGianni L, *see* Dorval M
DiGiovanna MP, *see* Thor AD
Diller L, *see* Grupp SA
—*see* Porteus MH
Dilliogluğil O, *see* Thaller C
Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's Macroglobulinemia: Clinical Features, Complications, and Management, 214
Di Nota A, *see* Comella P
Di Noto R, *see* Ferrara F
di Paola ED, *see* Verweij J
DiPersio JF, Schuster MW, Abboud CN, Winter JN, Santos VR, Collins DM, Sherman JW, Baum CM. Mobilization of Peripheral-Blood Stem Cells by Concurrent Administration of Daniplestim and Granulocyte Colony-Stimulating Factor in Patients With Breast Cancer or Lymphoma, 2762
Di Rienzo G, *see* Comella P
—*see* Lorusso V
Dirix L, *see* Van Cutsem E

Dirix LY, *see* Kaufmann M
di Salle E, *see* Kaufmann M
—*see* Lønning PE
Distante V, *see* Boccardo F
di Stefano F, *see* Waters JS
Dixon JM, *see* Love CDB
Dixon JM. In Reply (correspondence), 445
Dobson JM, *see* Zamboni WC
Dockhorn-Dworniczak B, *see* Poremba C
Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, Icasiano E, Boyle MG, Bajorin DF. Phase I Evaluation of Sequential Doxorubicin + Gemcitabine Then Ifosfamide + Paclitaxel + Cisplatin for Patients With Unresectable Metastatic Transitional-Cell Carcinoma of the Urothelial Tract, 840
Doerksen L, *see* Nemunaitis J
Dogliotti L, *see* Berruti A
—*see* von der Maase H
Dolan ME, *see* Friedman HS
—*see* Vokes EE
Donadieu J, *see* Landman-Parker J
Donadio M, *see* Berruti A
Donaldson GW, *see* Moinpour CM
Donati D, *see* Bacci G
Donavan S, *see* Grem JL
Donehower RC, *see* Baker SD
Donohue JP, *see* Sweeney CJ
Dorr RT, *see* Monsky WL
Dorval M, Patenaude AF, Schneider KA, Kieffer SA, DiGianni L, Kalkbrenner KJ, Bromberg JI, Basili LA, Calzone K, Stopfer J, Weber BL, Garber JE. Anticipated Versus Actual Emotional Reactions to Disclosure of Results of Genetic Tests for Cancer Susceptibility: Findings from *p53* and *BRCA1* Testing programs, 2135
Dose J, *see* Avril N
—*see* Schelling M
Dos Santos JG, *see* Vanhoefer U
Douglass EC, *see* Ortega JA
Douglass HO Jr. Results From National Surgical Adjuvant Breast and Bowel Project Colon Cancer Trials (correspondence), 235
Douillard J-Y, *see* Négrier S
Dowlati A, *see* Levitan N
Doyle E, *see* de Jonge MJA
Doyle JJ, *see* Klaassen RJ
Doyle LA, *see* Zamboni WC
Drach J, *see* Königsberg R
Drayson M, *see* Davies FE
Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II Study of Cisplatin and Paclitaxel in Advanced Carcinoma of the Urothelium: An Eastern Cooperative Oncology Group Study, 1058
Drengler R, *see* Eckhardt SG
—*see* Rowinsky EK
Drengler RL, *see* Hidalgo M
—*see* Patnaik A
Dreno B, *see* Middleton MR
Dressler L, *see* Berry DA
Dressler LG, *see* Simpson JF
Dreyfus F, *see* Yakoub-Agha I
Dreyfus H, *see* Stoppa-Lyonnet D
Dubuc-Lissoir J, *see* Hoskins P
Duchin K, *see* Malingré MM
Ducreux M, *see* Boige V
—*see* Couteau C
—*see* Fizazi K
—*see* Pignon J-P
Ducreux MP, *see* Vanhoefer U
Duelge J. Is Tamoxifen Cost-Effective for Prevention of Breast Cancer? (correspondence), 1800
Duffner P, *see* Thomas PRM
Dugardyn J-L, *see* Kaufmann M
Dujon A, *see* Andre F
Dumas MC, *see* Rini BI
Dumontet C, *see* Blay J-Y
—*see* Voog E
Dumot JA, *see* Adelstein DJ
Dunavant M, *see* Phipps S
Dundas G, *see* Kirkbride P
Dunleavy T, *see* Lowe VJ
Dunlop D, *see* von Pawel J
Dunphy F, *see* Fossella F
Dunphy FR, *see* Lowe VJ
Dunton CJ, *see* McGuire WP
Dunussi-Joannopoulos K, *see* Dahl GV
Dupont P, *see* Flamen P
Dupriez B, *see* Tilly H
Duyn JH, *see* Warren KE
Dyhouse SM, *see* Koç ON
Dzik S, *see* Partridge A

Eager R, *see* Nemunaitis J
Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ. Systematic Overview of Cost-Utility Assessments in Oncology, 3302
Eastern Cooperative Oncology Group, *see* Sledge GW Jr
Eastham JA, *see* Small EJ
Eckhardt SG, *see* Hidalgo M
—*see* Patnaik A
—*see* Rowinsky EK
Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies, 4086
Eckhardt SG, Rowinsky EK. In Reply (correspondence), 1800
Economic/Quality-Of-Life/Intensive Therapy Group of the French National Federation of Anticancer Centers, *see* Macquart-Moulin G
Ectors N, *see* Flamen P
Edgerton S, *see* Thor AD
Edmundson GK, *see* Kestin LL
Edwards MJ, *see* McMasters KM
Eeles RA, Powles TJ. Chemoprevention Options for *BRCA1* and *BRCA2* Mutation Carriers, 93s
Egorin MJ, *see* Fracasso PM
—*see* Patnaik A
—*see* Venook AP
—*see* Zamboni WC
Ehninger G, *see* Schmidt M

Eichele G, *see* Thaller C
Einhorn LH, *see* Bhatia S
—*see* Porcu P
—*see* Sandler AB
—*see* Sweeney CJ
Einstein S, *see* Schwartz LH
Eisen A, *see* Pierce LJ
Eisen A, Rebbeck TR, Wood WC, Weber BL. In Reply (correspondence), 3455
Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic Surgery in Women With a Hereditary Predisposition to Breast and Ovarian Cancer, 1980
Eisenberg PD, *see* Lønning PE
—*see* Schapira L
Eisenberger M, *see* Small EJ
Eisenberger MA, *see* Hussain M
Eisenhauer E, *see* Geels P
—*see* Gelmon KA
—*see* Hoskins P
Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I Clinical Trial Design in Cancer Drug Development, 684
Ejadi S, Rosenblum J, Berd D, McCue P, Mastrangelo M. Diagnostic Dilemmas in Oncology; Case 1: Melanoma Metastatic to the Testis, 3187
Elisson LO, *see* von Pawel J
Elkhuizen PHM, Van Slooten H-J, Clahsen PC, Hermans J, Van De Velde CJH, Van Den Broek LCJM, Van De Vijver MJ, and Cooperating Investigators. High Local Recurrence Risk After Breast-Conserving Therapy in Node-Negative Premenopausal Breast Cancer Patients Is Greatly Reduced by One Course of Perioperative Chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study, 1075
Elledge RM, *see* Zellars RC
Ellison R, *see* Camacho LH
Elmhorn-Rosenborg A, *see* Tidefelt U
Elsaleh H, Joseph D, Bydder S. Radiation Dose Escalation for Prostate Cancer (correspondence), 4003
Elting L, *see* Klastersky J
Elting LS, Rubenstein EB, Rolston K, Cantor SB, Martin CG, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey G. Time to Clinical Response: An Outcome of Antibiotic Therapy of Febrile Neutropenia With Implications for Quality and Cost of Care, 3699
Empen K, Otto C, Müller-Höcker J, Zapf J, Schwandt P. Small Round-Cell Tumors; Case 1: Hypoglycemic Syncope Due to a Peripheral Neuroectodermal Tumor, 1594
End DW, *see* Zujewski J
Engelholm SA, *see* Neijt JP
Engert A, *see* Josting A
English J, *see* Smith BM
English MW, *see* Thomas H
Ensminger W, *see* Dawson LA
Epstein SA, *see* Green BL
Eremin O, *see* Smith IC
Erlichman C, *see* Adjei AA
Erlichman C. In Reply (correspondence), 235
Ernstoff MS, *see* Kirkwood JM
—*see* Spitler LE
Ernst T, *see* Kisor DF
Errante D, *see* Nasti G
Ervin T, *see* Attar EC
Eschwege F, *see* Brizel DM
—*see* Fandi A
Escudier B, *see* Négrier S
Eskelinen M, *see* Salovaara R
Esper P, *see* Trask PC
Espina BM, *see* Tulpule A
Esposito M, *see* Venturini M
Esserman LJ, *see* Sepucha KR
Estlin EJ, Cotterill S, Pratt CB, Pearson ADJ, Bernstein M. Phase I Trials in Pediatric Oncology: Perceptions of Pediatricians From the United Kingdom Children's Cancer Study Group and the Pediatric Oncology Group, 1900
European Organization for Research and Treatment of Cancer-Investigational Drug Branch for Breast Cancer/Early Clinical Studies Group, *see* Paridaens R
European Osteosarcoma Intergroup, *see* Lewis IJ
Evans DB, *see* Pisters PWT
Evans MT, *see* Steele JPC
Evans SS, *see* Nagourney RA
Evans WE, *see* Leung W
—*see* Woo MH
Ewesuedo RB, *see* Friedman HS
Exemestane Study Group, *see* Kaufmann M
Extermann M, Balducci L, Lyman GH. What Threshold for Adjuvant Therapy in Older Breast Cancer Patients?, 1709

Fabbri N, *see* Bacci G
Fabbro M, *see* Macquart-Moulin G
Faggiuolo R, *see* Giacchetti S
Fagotti A, *see* Lavarino C
Fairclough D, *see* Bonomi P
Fairclough DL, *see* Motzer RJ
Faivre S, *see* Alexandre J
—*see* Boige V
Falcey J, *see* Baselga J
Falkson CI, *see* Simpson JF
—*see* Sparano JA
Falkson G, *see* Sledge GW Jr
Fan S-T, *see* Poon RT-P
Fandi A, *see* Fizazi K
Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand J-P, Simon J, Cvitkovic E. Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type, 1324
Faraguna K, *see* Marshall JL
Farris A, *see* Boccardo F
Fasan M, *see* Nasti G
Fassone L, *see* Cingolani A
Faulkner LB, Garaventa A, Paoli A, Tintori V, Tamburini A, Lacitignola L, Veltroni M, Lo Piccolo MS, Viscardi E, Milanaccio C, Tondo A, Spinelli S, Bernini G, De Bernardi B. In Vivo Cytoreduction Studies and Cell Sorting–Enhanced Tumor-Cell Detection in High-Risk Neuroblastoma Patients: Implications for Leukapheresis Strategies, 3829
Fears CL, *see* Fracasso PM
Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group, *see* Delozier T
Federico M, *see* Sabbatini R
Federico M, Sabbatini R, Morselli M, Depenni R, Cagossi K, Luppi M, Torelli G, Silingardi V. In Reply (correspondence), 3197

Feeny D, *see* Barr RD
Feig BW, *see* Breslin TM
—*see* Meric F
Feigal E, *see* Little RF
Feigelson HS, *see* McKean-Cowdin R
Fein LE, *see* Kaufmann M
Feld R, *see* Klastersky J
Feld R, DePauw B, Berman S, Keating A, Ho W. Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial, 3690
Felton S, *see* Eckhardt SG
Felton SA, *see* Patnaik A
Fenaux P, *see* Morschhauser F
Feng L, *see* Khuri FR
Fenig E, *see* Idelevich E
Ferdjaoui N, *see* Mille D
Fernandez CM, *see* Piccart MJ
Fernandez-Casal M, *see* Morse MA
Ferrandina G, *see* Lavarino C
Ferrant A, *see* Wijermans P
Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L, Lo Coco F. CD56 Expression Is an Indicator of Poor Clinical Outcome in Patients With Acute Promyelocytic Leukemia Treated With Simultaneous All-*trans*-Retinoic Acid and Chemotherapy, 1295
Ferrara R, *see* Carella AM
Ferrari S, *see* Bacci G
Festen J, *see* Van Zandwijk N
Feusner JH, *see* Gamis AS
—*see* Ortega JA
Fey M, *see* Colleoni M
—*see* Crivellari D
Fibbe W, *see* Lokhorst HM
Fiedler F, *see* Santoro A
Fierlbeck G, *see* Middleton MR
Fife BL, Huster GA, Cornetta KG, Kennedy VN, Akard LP, Broun ER. Longitudinal Study of Adaptation to the Stress of Bone Marrow Transplantation, 1539
Figer A, *see* de Gramont A
Figg WD, *see* Fine HA
—*see* Little RF
Filipovich AH, *see* Socié G
Filippelli G, *see* Comella P
Findlay B, *see* Norris B
Findlay M, *see* Van Cutsem E
Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WKA. Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas, 708
Finegold MJ, *see* Ortega JA
Fingleton B, *see* Nelson AR
Fingleton J, *see* Beckwith C
Finkelstein DM, *see* Aisenberg AC
Finlay JL, *see* Gururangan S
—*see* Thomas PRM
Finn L, *see* Pettaway CA
Finnish Breast Cancer Group, *see* Holli K
Fiore J, *see* Madajewicz S
Fischer DB, *see* Obedian E
Fisher B, *see* Del Rowe J
—*see* Gelmon KA
—*see* Hoskins P
Fisher C, *see* Spillane AJ
Fisher E, *see* Morse MA
Fisher EI, *see* Hussain M
Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin's Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809, 2010
Fisher RI, LeBlanc M, Miller T. In Reply (correspondence), 3322
Fizazi K, Ducreux M, Ruffié P, Bonnay M, Daniel C, Soria J-C, Hill C, Fandi A, Poterre M, Smith M, Armand J-P. Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer, 2293
Flahault A, *see* Temam S
Flaherty LE, *see* Kirkwood JM
Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L. Utility of Positron Emission Tomography for the Staging of Patients With Potentially Operable Esophageal Carcinoma, 3202
Flander M, *see* Holli K
Fleming GF, *see* Baidas SM
Fleming JB, *see* Breslin TM
Flemming D, *see* Takimoto CH
Fletcher JW, *see* Lowe VJ
Flockhart D, *see* Baidas SM
Flombaum C, *see* Motzer RJ
Flynn PJ, *see* Desch CE
Focan C, *see* Giacchetti S
Foekens JA, *see* Bontenbal M
Fojo A, *see* Gutierrez M
Fondurulia J, *see* D'Amico AV
Font A, *see* Bellmunt J
Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M. Clinical and Immune Responses in Advanced Melanoma Patients Immunized With an Anti-Idiotype Antibody Mimicking Disialoganglioside GD2, 376
Foran JM, *see* Micallef INM
Foran JM, Rohatiner AZS, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson PWM, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA. European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma, 317
Forand D, *see* Gelmon KA
Forastiere AA, *see* Heath EI
Forbes J, *see* Colleoni M
—*see* Crivellari D
Forman JD, *see* Fisher RI
Formenti SC, Preston-Martin S. BRCA1/2 Germline Mutations: A Marker for Radioresistance or Radiosensitivity? (correspondence), 1159

Forni C, *see* Bacci G
Forsthoff C, *see* Nagourney RA
Fortanier C, *see* Blaise D
Fosså, SD. Interim Analyses in Clinical Trials: Why Do We Plan Them? (editorial), 4007
Fossati R. In Reply (correspondence), 1392
Fossella F, *see* Nemunaitis J
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L, and the TAX 320 Non–Small-Cell Lung Cancer Study Group. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens, 2354
Foster RS, *see* Sweeney CJ
Fouladi M, Langston J, Mulhern R, Jones D, Xiong X, Yang J, Thompson S, Walter A, Heideman R, Kun L, Gajjar A. Silent Lacunar Lesions Detected by Magnetic Resonance Imaging of Children With Brain Tumors: A Late Sequela of Therapy, 824
Foulkes WD, *see* Chappuis PO
Fountzilas G, *see* Briasoulis E
Fouret P, *see* Temam S
Fourquet A, *see* Frappaz D
—*see* Stoppa-Lyonnet D
Fowler JM, *see* Rose PG
Fowler VG Jr, *see* Gopal AK
Fowst C, *see* Kaufmann M
—*see* Lønning PE
Fox RM, *see* Basser RL
—*see* Koç ON
Fraass U, *see* Middleton MR
Fracasso PM, *see* Patnaik A
Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ. Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies, 1124
François S, *see* Yakoub-Agha I
Frangiadaki C, *see* Koukourakis MI
Frank JA, *see* Warren KE
Frank JL, *see* Chen EA
Frappaz D, Michon J, Coze C, Berger C, Plouvier E, Lasset C, Bernard JL, Stephan JL, Bouffet E, Buclon M, Combaret V, Fourquet A, Philip T, Zucker JM. LMCE3 Treatment Strategy: Results in 99 Consecutively Diagnosed Stage 4 Neuroblastomas in Children Older Than 1 Year at Diagnosis, 468
Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De Cataldis G, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De Lena M for the Southern Italy Cooperative Oncology Group and Interregional Association for the Study of Lung Carcinoma–Italy. Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer, 2529
Frasci G, *see* Comella P
—*see* Lorusso V
Fratesi P, *see* Small EJ
Frazier ML, Su L-K, Amos CI, Lynch PM. Current Applications of Genetic Technology in Predisposition Testing and Microsatellite Instability Assays, 70s
Frazier RC, *see* Vicini FA
Freedman AS, *see* Friedberg JW
Freeman NJ, *see* Butera J
Freireich EJ, *see* Kantarjian HM
The French Epirubicin Study Group. Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment, 3115
Frenkel A, *see* Israel O
Freyer G, *see* de Gramont A
Fried M, *see* Madajewicz S
Friedberg JW, Neuberg D, Freedman AS. In Reply (correspondence), 3446
Friedl C, *see* Kersting M
Friedlander M, *see* Meiser B
Friedman AH, *see* Cokgor I
—*see* Friedman HS
Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D, Bunin GR, Meadows AT. Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma, 12
Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE II, Bigner DD, Dolan ME. Phase I Trial of Carmustine Plus O^6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma, 3522
Friedman HS, *see* Cokgor I
—*see* Thomas PRM
Frier M, *see* Hughes ODM
Friese K, *see* Gerber B
Frija J, *see* Guermazi A
Frisch J, *see* Le Cesne A
Fritz E, *see* Königsberg R
Frohlich MW, *see* Small EJ
Frolov A, *see* Thaller C
Front D, *see* Israel O
Fujii A, *see* Gohji K
Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K. Gene Expression for Dihydropyrimidine Dehydrogenase and Thymidine Phosphorylase Influences Outcome in Epithelial Ovarian Cancer, 3946
Fujiwara K, *see* Kurata T
Fuks Z, *see* Kattan MW
—*see* Zelefsky MJ
Fukuhara S, *see* Akasaka T
Fukumoto M, *see* Fujiwaki R
Fukuoka M, *see* Masuda N
Fung K-M, *see* Grotzer MA
Fuqua AW, *see* Osborne CK
Furlong W, *see* Barr RD
Furman WL, *see* Sandlund JT
Fuss H, *see* Sezer O

Gabiano C, *see* Caselli D
Gadner H, *see* Cotterill SJ
Gaffney D, *see* Pierce LJ
Gaidano G, *see* Cingolani A
Gajewski J, *see* Kantarjian HM
Gajjar A, *see* Fouladi M

Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-Type Intestinal T-Cell Lymphoma: Clinical Features and Treatment of 31 Patients in a Single Center, 795
Gale RP, *see* Davies SM
Gall H, *see* van Groeningen CJ
Gallagher J, *see* Klastersky J
Gallant G, *see* Gatzemeier U
Gallardo E, *see* Bellmunt J
Gallego R, *see* Seeger RC
Galli L, *see* Caselli D
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials, 2459
Galsky M, Darling M, Hecht J, Salgia R. Small Bowel Obstruction Due to Metastatic Lung Cancer, 227
Gambi A, *see* Amadori D
Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG. Alpha Hemolytic Streptococcal Infection During Intensive Treatment for Acute Myeloid Leukemia: A Report From the Children's Cancer Group Study CCG-2891, 1845
Gamucci T, *see* Paridaens R
Gamza F, *see* Fossella F
Gan J, *see* Ozkaynak MF
Ganansia V, *see* Girinsky T
Gandara D, *see* Fossella F
Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C. Activity of Docetaxel in Platinum-Treated Non–Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial, 131
Gandhi V, *see* Kisor DF
Ganguly PK, *see* Kirkbride P
Gans S, *see* Van Zandwijk N
Ganz PA, *see* Bower JE
—*see* Moinpour CM
Ganzenko N, *see* List MA
Garaventa A, *see* Faulkner LB
Garb JL, *see* Chen EA
Garber J, *see* Pierce LJ
Garber JE, *see* Burstein HJ
—*see* Dorval M
—*see* Lu KH
García-Conde J, *see* Pérez-Manga G
Garcia-Turner AM, *see* Cokgor I
—*see* Friedman HS
Gardner S, *see* Johnston E
Garner A, *see* Rowinsky EK
Garner AM, *see* Hidalgo M
—*see* Patnaik A
Garrison J, *see* Foon KA
Garst J, *see* Johnston E
Gaskin DJ, *see* Cheng JD
Gastaldi R, *see* Cingolani A
Gatineau M, *see* Boige V
Gattas M, *see* Meiser B
Gatti L, *see* Lavarino C
Gatzemeier U, *see* Sandler AB
—*see* von Pawel J
Gatzemeier U, von Pawel J, Gottfried M, ten Velde GPM, Mattson K, DeMarinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer, 3390
Gaulard P, *see* Haioun C
Gauthier-Villars M, *see* Stoppa-Lyonnet D
Gautier C, *see* Stoppa-Lyonnet D
Gavin A, *see* Boon H
Gaynon PS, *see* Heerema NA
Gaynor ER, *see* Fisher RI
Gee AP, *see* Godder KT
Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative Effect of Chemotherapy: Objective Tumor Response Is Associated With Symptom Improvement in Patients With Metastatic Breast Cancer, 2395
Gehan E, *see* Marshall JL
Geier SS, *see* Godder KT
Gelber RD, *see* Coates AS
—*see* Colleoni M
—*see* Crivellari D
Gelderblom H, *see* de Jonge MJA
Gelman R, *see* Park CC
Gelmon KA, Latreille J, Tolcher A, Génier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E. Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With advanced Solid Tumors, 4098
Génier L, *see* Gelmon KA
Gent M, *see* Hutten BA
Genta F, *see* Boccardo F
Gentilini P, *see* Zinzani PL
Georgoulias V, *see* Koukourakis MI
Georgoulias V. In Reply (correspondence), 445
Gerald WL, *see* de Alava E
Gerber B, Krause A, Müller H, Reimer T, Külz T, Makovitzky J, Kundt G, Friese K. Effects of Adjuvant Tamoxifen on the Endometrium in Postmenopausal Women With Breast Cancer: A Prospective Long-Term Study Using Transvaginal Ultrasound, 3464
Gerbing RB, *see* Maris JM
—*see* Nickerson HJ
—*see* Perez CA
—*see* Schmidt ML
—*see* Seeger RC
German Breast Cancer Study Group, *see* Sauerbrei W
—*see* Schmoor C
German Cooperative Group on Liver Metastases, *see* Lorenz M
Gerson SL, *see* Koç ON
Gessain A, *see* Mamzer-Bruneel M-F
Gesty-Palmer D, *see* Gopal AK
Gewirtz AM. Oligonucleotide Therapeutics: A Step Forward (editorial), 1809
Geyer CE Jr, *see* Rowinsky EK
Gherlinzoni F, *see* Zinzani PL
Ghielmini M, *see* Foran JM
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Flu-

orouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer, 136
Giaccone G, *see* Huisman C
—*see* Langer SW
—*see* Postmus PE
—*see* van Groeningen CJ
—*see* Van Zandwijk N
Giai M, *see* Boccardo F
Giancola ML, *see* Cingolani A
Giardina S, *see* Kreitman RJ
Giatromanolaki A, *see* Koukourakis MI
Gietema JA, *see* Meinardi MT
Gilbert FJ, *see* Smith IC
Gilchrist J, *see* Tai PTH
Gilchrist KW, *see* Simpson JF
Giles FJ, *see* Kantarjian HM
Gilewski TA, *see* Barakat RR
Gill PS, *see* Tulpule A
Ginsberg J, *see* Hutten BA
Ginsberg MS, *see* Schwartz LH
Giralt S, *see* Davies SM
—*see* Seong C-M
Girinsky T, Benhamou E, Bourhis J-H, Dhermain F, Guillot-Valls D, Ganansia V, Luboinski M, Perez A, Cosset JM, Socie G, Baume D, Bouaouina N, Briot E, Beaudre A, Bridier A, Pico JL. Prospective Randomized Comparison of Single-Dose Versus Hyperfractionated Total-Body Irradiation in Patients With Hematologic Malignancies, 981
Girinsky T, Benhamou E. In Reply (correspondence), 3062
Girling DJ, *see* Thatcher N
Gisselbrecht C, *see* Foran JM
—*see* Haioun C
—*see* Mounier N
Gisslinger H, *see* Königsberg R
Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR. Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node–Negative Breast Cancer, 2553
Giuliano AE. In Reply (correspondence), 3873
Giunchi DC, *see* Amadori D
Glaser RL, *see* McMasters KM
Glass EC, *see* Giuliano AE
Glassman AB, *see* Seong C-M
Glatstein E, *see* Kamen BA
Glimelius B, *see* Metayer C
Glisson B, Scott C, Komaki R, Movsas B, Wagner H. Cisplatin, Ifosfamide, Oral Etoposide, and Concurrent Accelerated Hyperfractionated Thoracic Radiation for Patients With Limited Small-Cell Lung Carcinoma: Results of Radiation Therapy Oncology Group Trial 93-12, 2990
Glisson BS, *see* Nemunaitis J
Gluckman E, *see* Yakoub-Agha I
Gobbi M, *see* Zinzani PL
Göbel U, *see* Schneider DT
Godder KT, Hazlett LJ, Abhyankar SH, Chiang KY, Christiansen NP, Bridges KD, Lee CG, Geier SS, Goon-Johnson KS, Gee AP, Pati AR, Parrish RS, Henslee-Downey PJ. Partially Mismatched Related-Donor Bone Marrow Transplantation for Pediatric Patients With Acute Leukemia: Younger Donors and Absence of Peripheral Blasts Improve Outcome, 1856
Godleski J, *see* Attar EC
Goedert JJ, *see* Little RF
Goeminne J-C, Guillaume T. Detection of Circulating Tumor by Reverse Transcriptase Polymerase Chain Reaction (correspondence), 3196
Goffinet DR, *see* Wolden SL
Gohji K, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y, Nakajima M. Independent Prognostic Value of Serum Hepatocyte Growth Factor in Bladder Cancer, 2963
Goldberg RM, *see* Adjei AA
Goldhirsch A, *see* Coates AS
—*see* Colleoni M
—*see* Crivellari D
Goldspiel B, *see* Conley B
Goldstein J, *see* Conley B
Goldstein NS, *see* Vicini FA
Gomez F, *see* Négrier S
Gomez-Martin C, Solá C, Hornedo J, Perea S, Lumbreras C, Valentí V, Arcediano A, Rodriguez M, Salazar R, Cortés-Funes H, Hidalgo M. Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical Trial, 2126
González-Larriba JL, *see* Bellmunt J
Goodman TR, *see* Klaassen RJ
Goodwin W, *see* List MA
Goon-Johnson KS, *see* Godder KT
Gopal AK, Fowler VG Jr, Shah M, Gesty-Palmer D, Marr KA, McClelland RS, Kong LK, Gottlieb GS, Lanclos K, Li J, Sexton DJ, Corey GR. Prospective Analysis of *staphylococcus Aureus* Bacteremia in Nonneutropenic Adults With Malignancy, 1110
Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer, 3093
Gordon LI, *see* Hochster HS
Gordon MS. Vascular Endothelial Growth Factor as a Target for Antiangiogenic Therapy, 45s
Gordon W Jr, *see* Peters WA III
Gore M, *see* Middleton MR
Gorlin JB, *see* Grupp SA
Gornall P, *see* Mann JR
Gorzegno G, *see* Berruti A
Gosky DM, *see* Takimoto CH
Gospodarowicz M, *see* Metayer C
Goss KH, Groden J. Biology of the Adenomatous Polyposis Coli Tumor Suppressor, 1967
Goss P, *see* Norris B
—*see* Patnaik A
Gottfried M, *see* Gatzemeier U
Gottlieb GS, *see* Gopal AK
Gower NH, *see* Steele JPC
Gozzetti A, *see* Martinelli G
Graeff H, *see* Avril N
—*see* Schelling M
Graham H, *see* Smith BM
Gralla R, *see* Shepherd FA
Granai CO, *see* Gordon AN
Grankvist K, *see* Linderholm B
Gratecos N, *see* Yakoub-Agha I
Gray E, *see* Mann JR

Gray R, *see* Boon H
—*see* Simpson JF
Graziano F, Cascinu S and Italian Group for the Study of Gastrointestinal Tract Carcinomas. Docetaxel Chemotherapy for Pancreatic Cancer: Do Results Support Certainty? (correspondence), 445
Greco FA, *see* Hainsworth JD
Greco FA, Hainsworth JD. Paclitaxel for Limited-Stage Small-Cell Lung Cancer (correspondence), 3453
Green BL, Krupnick JL, Rowland JH, Epstein SA, Stockton P, Spertus I, Stern N. Trauma History as a Predictor of Psychologic Symptoms in Women With Breast Cancer, 1084
Green DM, *see* Porteus MH
Green DM, Hyland A, Barcos MP, Reynolds JA, Lee RJ, Hall BC, Zevon MA. Second Malignant Neoplasms After Treatment for Hodgkin's Disease in Childhood or Adolescence, 1492
Green JA, *see* Piccart MJ
Green M, *see* Gandara DR
Green MD, *see* Basser RL
Greenberg C, *see* Blackwell K
Greenberg RN, *see* Cagnoni PJ
Greenwald C, *see* Sandlund JT
Greer BE, *see* Rose PG
Gregor A, *see* Postmus PE
—*see* Sandler AB
Greisinger A, *see* Richardson MA
Grem JL, *see* Takimoto CH
Grem JL, Harold N, Shapiro J, Bi D-Q, Quinn MG, Zentko S, Keith B, Hamilton JM, Monahan BP, Donavan S, Grollman F, Morrison G, Takimoto CH. Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors, 3952
Grenzelias D, *see* Apostolidis J
Gress RE, *see* Zujewski J
Gressot L, *see* Shepherd FA
Grier HE, *see* Baker KS
—*see* Grupp SA
Grignon D, *see* Valicenti R
Grigsby P, *see* Peters WA III
Grillo-López AJ, *see* Davis TA
Grimer RJ, *see* Wunder JS
Grimshaw R, *see* Hoskins P
Grob JJ, *see* Middleton MR
Grochow LB, *see* Baker SD
—*see* Gallo JM
Groden J, *see* Goss KH
Groen HJM, *see* Postmus PE
Grollman F, *see* Grem JL
Groot Y, *see* Briasoulis E
Gross HM, *see* Small EJ
Grossbard ML, *see* Spitler LE
Grossfeld G, *see* Small EJ
Grotzer MA, Janss AJ, Fung K-M, Biegel JA, Sutton LN, Rorke LB, Zhao H, Cnaan A, Phillips PC, Lee VM-Y, Trojanowski JQ. TrkC Expression Predicts Good Clinical Outcome in Primitive Neuroectodermal Brain Tumors, 1027
Groupe d'Etudes des Lymphomes de L'Adulte, *see* Tilly H
Groupe d'Oncologie Thoracique des Régions Alpines, *see* Hügli A
Groupe Français d'Immunothérapie, Federation Nationale des Centres de Lutte Contre le Cancer, *see* Négrier S
Gruber A, *see* Tidefelt U
Gruetzner KU, *see* Allgayer H
Grunberg SM. Stage Shift and Complementary/Alternative Medicine (correspondence), 3455
Grunenwald D, *see* Andre F
Grupo Español de Trasplante de Médula Ósea en Niña, *see* Marco F
Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M, Adams R, Grier HE, Gorlin JB, Shamberger R, Marcus K, Neuberg D, Weinstein HJ, Diller L. Tandem High-Dose Therapy in Rapid Sequence for Children With High-Risk Neuroblastoma, 2567
Guardigni L, *see* Zinzani PL
Guaspari A, *see* Smalley RV
Guastalla J-P, *see* Alexandre J
Gudgeon A, *see* Colleoni M
—*see* Crivellari D
Guemei A, *see* Takimoto CH
Guermazi A, Quoc SN, Socie G, Briere J, de Kerviler E, Solal-Celigny P, Frija J, Rousselot P. Myeloblastoma (Chloroma) in Leukemia; Case 1: Granulocytic Sarcoma (Chloroma) of the Breast, 3993
Guglielmi C, *see* Ferrara F
Guilhot F, *see* Harousseau JL
Guillaume T, *see* Goeminne J-C
Guillem V, *see* Bellmunt J
Guillot-Valls D, *see* Girinsky T
Guitart J, *see* Pandolfino TL
—*see* Siegel RS
Gulavita S, *see* Kirkbride P
Gunnett K, *see* Baselga J
Guo C, *see* Maris JM
Gupta RK, *see* Apostolidis J
—*see* Swerdlow AJ
Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL. Outcome of CNS Disease at Diagnosis in Disseminated Small Noncleaved-Cell Lymphoma and B-Cell Leukemia: A Children's Cancer Group Study, 2017
Gustafson GS, *see* Kestin LL
Gustavsson B, *see* Tidefelt U
Guthrie K, *see* Porteus MH
Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH. Role of Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8-Year Follow-Up Study of EPOCH, 3633
Gutjahr P, *see* Schneider DT
Gutowski M-C, *see* Voog E
Guyotat D, *see* Harousseau JL

Ha CS, *see* Kantarjian HM
Haan E, *see* Meiser B
Haas JE, *see* Ortega JA
Haase GM, *see* Perez CA
—*see* Schmidt ML
Haase-Statz S, *see* Smalley RV
Haaxma-Reiche H, *see* Postmus PE
Haber M, *see* Cohn SL
Habrand JL, *see* Landman-Parker J
Haffty B, *see* Pierce LJ
Haffty BG, *see* Obedian E
—*see* Smith BD
Haffty BG. In Reply (correspondence), 1159, 4001
Hagenbeek A, *see* van Leeuwen FE

Haglund MM, *see* Friedman HS
Hahn JS, *see* Kim GE
Haigh PI, *see* Giuliano AE
Haines-Kamka T, *see* Boon H
Hainsworth J, *see* Gordon AN
Hainsworth JD, *see* Greco FA
Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in Patients With Poorly Differentiated Carcinoma or Poorly Differentiated Adenocarcinoma of Unknown Primary Site, 632
Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Brière J, Gaulard P, Reyes F. Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin's Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d'Etude des Lymphomes de l'Adulte Study, 3025
Hak LJ, *see* Woo MH
Haken RKT, *see* Dawson LA
Hakim FT, *see* Zujewski J
Hale J, *see* Mann JR
Hall BC, *see* Green DM
Haller D, *see* Coia LR
Haller DG, *see* Harris JE
Haller DG. Waiting for the Definitive Trial of Hepatic Arterial Chemotherapy for Colorectal Cancer (editorial), 239
Hamilton JM, *see* Grem JL
—*see* Takimoto CH
Hammershaimb L, *see* Fossella F
—*see* Shepherd FA
Hammond A, *see* Tai PTH
Hammond LA, *see* Eckhardt SG
—*see* Hidalgo M
—*see* Patnaik A
—*see* Rowinsky EK
Hammond N, *see* Small EJ
Hanada R, *see* Toyoda Y
Hanauske A, *see* Briasoulis E
Hanauske AR, *see* van Groeningen CJ
Hancock BW, *see* Swerdlow AJ
Hancock SL, *see* Wolden SL
Hanfelt J, *see* Baidas SM
Hankinson SE, *see* Holmes MD
Hanks GE, *see* Coia LR
Hanna MG Jr, *see* Harris JE
Hansen M, *see* Neijt JP
Hansen NM, *see* Giuliano AE
Hansen SW, *see* von der Maase H
Hanson J, *see* Barnes EA
Hanson LJ, *see* Adjei AA
Haraf D, *see* List MA
Haraf DJ, *see* Vokes EE
Härkönen N, *see* Salovaara R
Harms D, *see* Schneider DT
Harold N, *see* Grem JL
—*see* Takimoto CH
Haroon Z, *see* Blackwell K
Harousseau J-L, *see* Le Gouill S
Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M, Guilhot F, Le Prise PY, Abgrall JF, Deconinck E, Guyotat D, Vilque JP, Casassus P, Tournilhac O, Audhuy B, Solary E. Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques, 780
Harper P, *see* Gatzemeier U
Harper PG, *see* Torri V
Harris CC, *see* Shields PG
Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB III, Mansour E, Haller DG, Manola J, Hanna MG Jr. Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer With an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283, 148
Harris JR, *see* Hayman JA
—*see* Park CC
Harris JR. Notes on the Ontario Trial in the Context of Breast-Conserving Therapy for Early-Stage Breast Cancer, 43s
Harris L, *see* Baidas SM
—*see* Blackwell K
Harris NL, Jaffe ES, Mueller-Hermelink HK, Diebold J, Lister AK, Bloomfield CA, Isaacson P. In Reply (correspondence), 2788
Harrison PL, *see* Woo MH
Harwin W, *see* Nabholtz JM
Hata K, *see* Fujiwaki R
Hatfield AK, *see* Dreicer R
Haustermans K, *see* Flamen P
Hawkins M, *see* Venook AP
Hawkins MJ, *see* Baidas SM
Hayes D, Loprinzi CL, Smith TJ. In Reply (correspondence), 3740
Hayes D, *see* Berry DA
—*see* Loprinzi CL
Hayes DF, *see* Baidas SM
Hayes FA, *see* Spitler LE
Hayes K, *see* Seong C-M
Hayman JA, Hillner BE, Harris JR, Pierce LJ, Weeks JC. Cost-Effectiveness of Adding an Electron-Beam Boost to Tangential Radiation Therapy in Patients With Negative Margins After Conservative Surgery for Early-Stage Breast Cancer, 287
Haynesworth SE, *see* Koç ON
Hazlett LJ, *see* Godder KT
Head D. In Reply (correspondence), 3451
Healey D, *see* Saleh MN
Healey JH, *see* Lewis JJ
—*see* Wunder JS
Hearn S, *see* de Jonge MJA
Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JPS, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu T-T, Olukayode K, Forastiere AA. Phase II Evaluation of Preoperative Chemoradiation and Postoperative Adjuvant Chemotherapy for Squamous Cell and Adenocarcinoma of the Esophagus, 868
Hecht J, *see* Galsky M
Hecht JL, Aster JC. Molecular Biology of Burkitt's Lymphoma, 3707
Heddens DK, *see* Monsky WL
Heelan RT, *see* Miller VA
Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon PS, Uckun FM. Abnormalities of Chromosome Bands 13q12 to 13q14 in Childhood Acute Lymphoblastic Leukemia, 3837
Heerema NA, Sather HN, Sensel MG, Zhang T, Hutchinson RJ, Nachman JB, Lange BJ, Steinherz PG, Bostrom BC, Reaman

GH, Gaynon PS, Uckun FM. Prognostic Impact of Trisomies of Chromosomes 10, 17, and 5 Among Children With Acute Lymphoblastic Leukemia and High Hyperdiploidy (50 Chromosomes), 1876
Hehlmann R, *see* Schmidt M
Hehman H, *see* Takimoto CH
Heideman R, *see* Fouladi M
Heilman DK, *see* Sweeney CJ
Heilmann C, *see* Davies SM
Heimann R, *see* Pierce LJ
Heimann R, Hellman S. Clinical Progression of Breast Cancer Malignant Behavior: What to Expect and When to Expect It, 591
Heinz R, *see* Königsberg R
Heiss MM, *see* Allgayer H
Heit W, *see* Sezer O
Heitmiller RF, *see* Heath EI
Hejna MHL, *see* Raderer M
Helle P, *see* Bontenbal M
Heller G, *see* Camacho LH
Hellman S, *see* Heimann R
Hellmann K. Dexrazoxane and the ASCO Guidelines for the Use of Chemotherapy and Radiotherapy Protectants: A Critique (correspondence), 2003
Henderson BE, *see* McKean-Cowdin R
Henderson IC, *see* Berry DA
Hendler D, *see* de Gramont A
Henke M, *see* Brizel DM
Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, Klein JP. Prevention of Central Venous Catheter-Related Infections and Thrombotic Events in Immunocompromised Children by the Use of Vancomycin/ciprofloxacin/heparin Flush Solution: A Randomized, Multicenter, Double-Blind Trial, 1269
Henriksson R, *see* Linderholm B
Henslee-Downey PJ, *see* Davies SM
—*see* Godder KT
Hensley ML, Peterson B, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013, 1301
Hensley ML, Schuchter LM, Winer EP, Meropol NJ, Pfister D. In Reply (correspondence), 2003
Hentschel P, *see* Madajewicz S
Henz M, *see* Middleton MR
Hepp F, *see* Braun S
Herbrecht R, *see* Tilly H
Herfindal ET, *see* Swanson G
Herman TS, *see* Zellars RC
Hermans BP, *see* Sweeney CJ
Hermans C, *see* Le Cesne A
Hermans J, *see* Elkhuizen PHM
—*see* Nagtegaal ID
Hermine O, *see* Mamzer-Bruneel M-F
Herndon JE II, *see* Cokgor I
—*see* Friedman HS
Hero B, *see* Poremba C
Herr H, *see* Dodd PM
Herrera L, *see* Mantadakis E
Herrstedt J, *see* Klastersky J
Herzig RH, *see* Davies SM
Hesketh PJ, *see* Ioannidis JPA
Hess KR, *see* Meric F
—*see* Meyers CA
Hetelekidis S, *see* Park CC
Heys SD, *see* Smith IC
Hickish TF, *see* Smith IE
Hidalgo M, *see* Eckhardt SG
—*see* Gomez-Martin C
—*see* Patnaik A
—*see* Rowinsky EK
Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil JD, Von Borstel R, Von Hoff DD, Rowinsky EK. Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies, 167
Hiele M, *see* Flamen P
Hiemenz S, *see* Cagnoni PJ
Hietanen P, *see* Holli K
Hildebrandt G, *see* Meric F
Hilden JM, Watterson J, Chrastek J. Tell the Children, 3193
Hilgers J, *see* von Mensdorff-Pouilly S
Hill C, *see* Delozier T
—*see* Fizazi K
Hill ME, *see* Ross PJ
Hill RS, *see* Warren KE
Hillner BE, *see* Hayman JA
—*see* Smith TJ
Hillner BE, Agarwala S, Middleton MR. Post Hoc Economic Analysis of Temozolomide Versus Dacarbazine in the Treatment of Advanced Metastatic Melanoma, 1474
Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG for the American Society of Clinical Oncology Bisphosphonates Expert Panel. ASCO Guidelines on the Role of Bisphosphonates in Breast Cancer, 1378
Hillner BE. In Reply (correspondence), 3318
Hillner BE, Smith TJ, Desch CE. Hospital and Physician Volume or Specialization and Outcomes in Cancer Treatment: Importance in Quality of Cancer Care, 2327
Hillner BE, Weeks JC, Desch CE, Smith TJ. Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis, 72
Hilsenbeck SG, *see* Zellars RC
Hilton S, *see* Dodd PM
Himelstein B, *see* Friedman DL
Hinerman RW, *see* Mendenhall WM
Hinkle A, *see* Hobbie WL
Hirota H, *see* Takimoto CH
Hirsch FR, *see* Neijt JP
Hirsh V, *see* von Pawel J
Hitt J, *see* Cheng JD
Hitt R, *see* Castellano D
Hmissi A, *see* de Gramont A
Ho R, *see* Camacho LH
Ho W, *see* Feld R
Hobbie WL, Stuber M, Meeske K, Wissler K, Rourke MT, Ruccione K, Hinkle A, Kazak AE. Symptoms of Posttraumatic Stress in Young Adult Survivors of Childhood Cancer, 4060
Hobbs J, *see* Bennett CL
Hobeika A, *see* Morse MA

Hobson R, *see* Thomas H
Hochhaus A, *see* Schmidt M
Hochster H, *see* Mani S
Hochster HS, Oken MM, Winter JN, Gordon LI, Raphael BG, Bennett JM, Cassileth PA. Phase I Study of Fludarabine Plus Cyclophosphamide in Patients With Previously Untreated Low-Grade Lymphoma: Results and Long-Term Follow-Up–A Report From the Eastern Cooperative Oncology Group, 987
Hodge JP, *see* Kisor DF
Hoekstra HJ, *see* Plaat BEC
Hoff PM, *see* Nemunaitis J
Hoff PM, Janjan N, Saad ED, Skibber J, Crane C, Lassere Y, Cleary KR, Benner S, Randolph J, Abbruzzese JL, Pazdur R. Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer, 3529
Hoffman JP, *see* Coia LR
Hogarty MD, *see* Maris JM
Hohenleutner U, *see* Blank C
Hohl R, *see* Venook AP
Hohnecker JA, *see* Baker SD
Hohneker J, *see* Mani S
Hohneker JA, *see* Smalley RV
Holden L, *see* Newlands ES
Hollema H, *see* de Hullu JA
—*see* Plaat BEC
Hollenbeak C, *see* Lowe VJ
Holli K, Valavaara R, Blanco G, Kataja V, Hietanen P, Flander M, Pukkala E, Joensuu H for the Finnish Breast Cancer Group. Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer, 3487
Hollis D, *see* Venook AP
Holm R, *see* Baekelandt M
Holmberg S, *see* Colleoni M
Holmes MD, Spiegelman D, Willett WC, Manson JE, Hunter DJ, Barbieri RL, Colditz GA, Hankinson SE. Dietary Fat Intake and Endogenous Sex Steroid Hormone Levels in Postmenopausal Women, 3668
Holowaty EJ, *see* Metayer C
Homerin M, *see* de Gramont A
Hong J-H, *see* Chang T-C
Hong WK, *see* Khuri FR
—*see* Nemunaitis J
Hong WK, Spitz MR, Lippman SM. Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets, 9s
Hong WP, *see* Kim GE
Hoover HC Jr, *see* Harris JE
Hoover SM, *see* Henrickson KJ
Hopman AHN, *see* van Oostenbrugge RJ
—*see* Veltman JA
Hoppe GJ, *see* Schmidt M
Hoppe RT, *see* Horning SJ
—*see* Wolden SL
Hopwood P, *see* Thatcher N
Hopwood P, Stephens RJ (for the British Medical Research Council Lung Cancer Working Party). Depression in Patients With Lung Cancer: Prevalence and Risk Factors Derived From Quality-Of-Life Data, 893
Horak ID, *see* Zujewski J
Hornedo J, *see* Gomez-Martin C
Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P. Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492, 972
Horowitz IR, *see* Rose PG
Horowitz MM, *see* Davies SM
—*see* Socié G
Hortobagyi G, *see* Katz A
Hortobagyi GN, *see* Breslin TM
Horwich A, *see* Swerdlow AJ
Hosek SM, *see* Smith JS
Hoshi Y, *see* Toyoda Y
Hoskins P, Eisenhauer E, Vergote I, Dubuc-Lissoir J, Fisher B, Grimshaw R, Oza A, Plante M, Stuart G, Vermorken J. Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study, 4038
Hoskins WJ, *see* Barakat RR
Hosoya R, *see* Toyoda Y
Houllier A-M, *see* Cabelguenne A
House R, *see* Breslin TM
Houston S, *see* Paridaens R
Hoverman JR. The Logic of Evidence (correspondence), 942
Howard W, *see* Tulpule A
Howell A. Clarification of Anastrozole/Megestrol Acetate Trial Program Design (correspondence), 4109
Howell SB. In Reply (correspondence), 2003
Howells WB, *see* Gamis AS
Hoyer RJ, *see* Marshall JL
Hsieh C-Y, *see* Cheng SH
Hsieh Y-C, *see* Vokes EE
Hsueh S, *see* Chang T-C
Hu P, *see* Sledge GW Jr
Huang AT, *see* Cheng SH
Huang D, *see* Cohn SL
Huang K-G, *see* Chang T-C
Huber H, *see* Königsberg R
Hudec WA, *see* Pisters PWT
Hudis C, *see* Barakat RR
Hudson GV, *see* Swerdlow AJ
Hudson MM, *see* Leung W
Hughes ODM, Bishop MC, Perkins AC, Wastie ML, Denton G, Price MR, Frier M, Denley H, Rutherford R, Schubiger PA. Targeting Superficial Bladder Cancer by the Intravesical Administration of Copper-67-Labeled Anti-MUC1 Mucin Monoclonal Antibody C595, 363
Hughes-Davies L. Quality of Life in Non–Small-Cell Lung Cancer (correspondence), 1800
Hügli A, Moro D, Mermillod B, Bolla M, Alberto P, Bonnefoi H, Miralbell R for the Groupe D'Oncologie Thoracique Des Régions Alpines. Phase II Trial of Up-Front Accelerated Thoracic Radiotherapy Combined With Chemotherapy and Optional Up-Front Prophylactic Cranial Irradiation in Limited Small-Cell Lung Cancer, 1662
Huh Y, *see* Kantarjian HM
Huinink WWTB, *see* Malingré MM

Huisman C, Smit EF, Giaccone G, Postmus PE. Second-Line Chemotherapy in Relapsing or Refractory Non–Small-cell Lung Cancer: A Review, 3722
Hulka BS, *see* Stark A
Humerickhouse R, *see* Vokes EE
Humphrey JS, *see* Eisenhauer EA
Humphrey R, *see* Rowinsky EK
Hunault-Berger M, *see* Harousseau JL
Hunt KK, *see* Breslin TM
—*see* Meric F
Hunter DJ, *see* Holmes MD
Hürny C, *see* Coates AS
—*see* Crivellari D
Hurwitz M, *see* D'Amico AV
Husar M, *see* Idelevich E
Husein R, *see* Shaneyfelt T
Hussain M, Fisher EI, Petrylak DP, O'Connor J, Wood DP, Small EJ, Eisenberger MA, Crawford ED. Androgen Deprivation and Four Courses of Fixed-Schedule Suramin Treatment in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Southwest Oncology Group Study, 1043
Huster GA, *see* Fife BL
Hutcheon AW, *see* Smith IC
Hutchins L, *see* Foon KA
Hutchinson R, *see* Davies SM
Hutchinson RJ, *see* Heerema NA
Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Büller HR. Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis, 3078
Huynen FC, *see* Veltman JA
Hyland A, *see* Green DM
Hyodo I, *see* Kurata T

Iannelli A, *see* Frasci G
Ibrahim J, *see* Manola J
Ibrahim JG, *see* Kirkwood JM
Icasiano E, *see* Dodd PM
Idelevich E, Husar M, Fenig E, Brenner B, Ben-Baruch N, Adi S. Diagnostic Dilemmas in Oncology; Case 2: Umbilical Metastasis as the Presenting Symptom of Non–Small-Cell Lung Cancer, 3188
Iglehart JD, *see* Blackwell K
Ijiri R, *see* Nishihira H
Ikuta K, *see* Toyoda Y
Illiger H-J, *see* Sezer O
Imeson J, *see* Mann JR
—*see* Thomas H
Ingle JN, *see* Hillner BE
Institut Curie Breast Cancer Group, *see* Stoppa-Lyonnet D
International Breast Cancer Study Group, *see* Coates AS
—*see* Colleoni M
—*see* Crivellari D
International (Ludwig) Breast Cancer Study Group, *see* Colleoni M
International MDS Study Group. Problematic WHO Reclassification of Myelodysplatic Syndromes (correspondence), 3451
Ioannidis JPA, Hesketh PJ, Lau J. Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence, 3409
Iosilevski G, *see* Israel O

Isaacs C, *see* Baidas SM
—*see* Pierce LJ
Isaacson P, *see* Harris NL
Ishimaru F. Expression of Ikaros Isoforms in Acute Lymphoblastic Leukemia Cell Lines (correspondence), 1392
Ishimoto K, *see* Toyoda Y
Ismail AS, *see* Takimoto CH
Israel O, Keidar Z, Rubinov R, Iosilevski G, Frenkel A, Kuten A, Betman L, Kolodny GM, Yarnitsky D, Front D. Quantitative Bone Single-Photon Emission Computed Tomography for Prediction of Pain Relief in Metastatic Bone Disease Treated With Rhenium-186 Etidronate, 2747
Italian Breast Cancer Adjuvant Study Group, *see* Boccardo F
Italian Group for the Study of Gastrointestinal Tract Carcinomas, *see* Graziano F
Italian Prostate Cancer Project, *see* Boccardo F
Italian Register for HIV Infection in Children, *see* Caselli D

Jackson J, *see* Lohrisch C
Jacobs F, *see* Mamzer-Bruneel M-F
Jacobs M, *see* Spitler LE
Jacobson JS, Workman SB, Kronenberg F. Research on Complementary/alternative Medicine for Patients With Breast Cancer: A Review of the Biomedical Literature, 668
Jacques C, *see* de Jonge MJA
Jadad AR, *see* Whelan TJ
Jaeckle K, *see* Fine HA
Jaffe ES, *see* Gutierrez M
—*see* Harris NL
—*see* Kreitman RJ
—*see* Socié G
Jäger U, *see* Königsberg R
James K, *see* Norris B
Janicek M, *see* Attar EC
—*see* Blobe GC
Janicek MJ, *see* Jänne PA
Jänicke F, *see* Schelling M
Janinis J, Panagos G. Docetaxel, Cisplatin, Fluorouracil, and Leucovorin in Locally Advanced Head and Neck Cancer (correspondence), 1392
Janjan N, *see* Hoff PM
—*see* Hillner BE
—*see* Pisters PWT
Jänne PA, Janicek MJ, Brown F. Meningeal Carcinomatosis in Lung Cancer; Case 2: Carcinomatous Meningitis, 2927
Janni W, *see* Braun S
Janss AJ, *see* Grotzer MA
Janssen JThP, *see* Bontenbal M
Janvier M, *see* Delozier T
—*see* Macquart-Moulin G
Järvinen H, *see* Salovaara R
Jatoi A, Kumar S, Sloan JA, Nguyen PL. On Appetite and Its Loss, 2930
Javorsky B, *see* Ozkaynak MF
Jeffrey SS, *see* Wolden SL
Jenkins RB, *see* Smith JS
Jensen, *see* Langer SW
Jeremic B. In Reply (correspondence), 3320
Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cis-

platin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial, 1458
Jett J, *see* Adjei AA
—*see* Levitan N
Jewett MAS, *see* Nam RK
Jhingran A, *see* Katz A
Jian JJ-M, *see* Cheng SH
Jiroutek M, *see* Bonomi P
Joens S, *see* Stark A
Joensuu H, *see* Holli K
Joensuu T, *see* Metayer C
Johansson M, *see* Linderholm B
John MJ, *see* Coia LR
Johnson D, *see* Bonomi P
—*see* Levitan N
Johnson JR, *see* Cohen MH
Johnson MD, *see* Baidas SM
Johnson ME, *see* Loprinzi CL
Johnson PWM, *see* Apostolidis J
—*see* Foran JM
Johnson TR, *see* Rowinsky EK
Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang B-B, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G. Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy, 2522
Johnston SRD, *see* Smith IE
Jones A, *see* Lohrisch C
Jones D, *see* Fouladi M
—*see* Saleh MN
—*see* Sandlund JT
Jones E, *see* Conley B
Jones RB, *see* Nieto Y
Jones SE, *see* Kaufmann M
Joseph D, *see* Elsaleh H
Joseph JT, *see* Wong ET
Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of Primary Progressive Hodgkin's and Aggressive Non-Hodgkin's Lymphoma: Is There a Chance for Cure?, 332
Jouet J-P, *see* Blaise D
Jouet JP, *see* Morschhauser F
—*see* Yakoub-Agha I
Judson I, *see* Briasoulis E
—*see* Le Cesne A
Judson IR, *see* Spillane AJ
—*see* Verweij J
Juergens H, *see* Poremba C
Julian J, *see* Whelan TJ
Julien J-P, *see* Delozier T
Juliusson G, *see* Tidefelt U
Julkunen R, *see* Salovaara R
Jürgens HF, *see* Cotterill SJ

Kääriäinen H, *see* Salovaara R
Kadin ME, *see* Lones MA
Kadmon D, *see* Lotan Y
—*see* Thaller C
Kaiser-Kupfer MI, *see* Conley B
Kakolyris S, *see* Koukourakis MI
Kalkbrenner KJ, *see* Dorval M
Kalman L, *see* Fossella F
Kalofonos H, *see* Briasoulis E
Kamen BA, *see* Mantadakis E
Kamen BA, Rubin E, Aisner J, Glatstein E. High-Time Chemotherapy or High Time for Low Dose (editorial), 2935
Kaminski MS, *see* Vose JM
Kamiya Y, *see* Yamamoto N
Kamoi K, *see* Pettaway CA
Kaneko T, *see* Toyoda Y
Kanesan K, *see* Elting LS
Kangas E, *see* Salovaara R
Kantarjian H, *see* Seong C-M
Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia, 547
Kantarjian HM, Talpaz M, Smith TL, Cortes J, Giles FJ, Rios MB, Mallard S, Gajewski J, Murgo A, Cheson B, O'Brien S. Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia, 3513
Kantoff PW, *see* D'Amico AV
Kaplan R, *see* Fine HA
Kapp A, *see* Middleton MR
Kapusta L, *see* Chappuis PO
Karnicka H, *see* Postmus PE
Karp D, *see* Fossella F
—*see* Gandara DR
Kasal J, *see* Abraksia S
Kashala OL, *see* Foon KA
Kashimura M, *see* Kurata T
Kasowitz KM, *see* Thor AD
Kastrissios H, *see* Adjei AA
Kataja V, *see* Holli K
Kato K, *see* Nishihira H
Katsuoka Y, *see* Gohji K
Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment Nomogram for Predicting the Outcome of Three-Dimensional Conformal Radiotherapy in Prostate Cancer, 3352
Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, Hortobagyi G, Buzdar AU, Theriault R, Singletary SE, McNeese MD. Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation, 2817
Katzenstein HM, *see* Cohn SL
Katzenstein HM, Cohn SL, Crawford S, Meitar D. Angiogenesis in Neuroblastoma (correspondence), 2788
Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer, 1921
Kaufman HS, *see* Heath EI
Kaufmann H, *see* Königsberg R
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn J-L, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, Di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G for the Exemestane Study Group. Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in

Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial, 1399
Kaufmann M. In Reply (correspondence), 4109
Kavanagh JJ, *see* Verschraegen CF
Kaye SB, *see* Mackay HJ
Kazak AE, *see* Hobbie WL
Keating A, *see* Davies SM
—*see* Feld R
—*see* Patnaik A
Keating MJ, *see* Kantarjian HM
—*see* Kisor DF
Keeling J, *see* Pritchard J
Kehl SC, *see* Henrickson KJ
Keidar Z, *see* Israel O
Keith B, *see* Grem JL
Keizer HJ, *see* Le Cesne A
—*see* Weijl NI
Kelley MC, *see* Giuliano AE
Kelly WK, *see* Dodd PM
—*see* Small EJ
—*see* Zelefsky MJ
Kelsen DP. Postoperative Adjuvant Chemoradiation Therapy for Patients With Resected Gastric Cancer: Intergroup 116, 32s
Kemp BL, *see* Khuri FR
—*see* Nemunaitis J
Kenemans P, *see* von Mensdorff-Pouilly S
Kennard MA, *see* Boon H
Kennedy A, *see* Markman M
Kennedy VN, *see* Fife BL
Kentenich C, *see* Braun S
Kepner JL, *see* Thomas PRM
Kerbrat P, *see* Delozier T
—*see* von der Maase H
Kerr DJ, Midgley RJ, McArdle CS. Hepatic Arterial Chemotherapy: Still on Trial (correspondence), 1800
Kerr I, *see* Patnaik A
Kerr RN, *see* Fossella F
Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M. Differential Frequencies of $p16^{INK4a}$ Promoter Hypermethylation, *p53* Mutation, and K-*ras* Mutation in Exfoliative Material Mark the Development of Lung Cancer in Symptomatic Chronic Smokers, 3221
Kessinger A, *see* Bishop MR
Kestin LL, *see* Vicini FA
Kestin LL, Martinez AA. In Reply (correspondence), 4004
Kestin LL, Martinez AA, Stromberg JS, Edmundson GK, Gustafson GS, Brabbins DS, Chen PY, Vicini FA. Matched-Pair Analysis of Conformal High-Dose-Rate Brachytherapy Boost Versus External-Beam Radiation Therapy Alone for Locally Advanced Prostate Cancer, 2869
Khayat D, *see* Pérez-Manga G
Khor SP, *see* Baker SD
Khouri I, *see* Seong C-M
—*see* van Besien K
Khuri FR, *see* Nemunaitis J
Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu H, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, Walsh GL, Lee JS, Hong WK, Xu X-C. Retinoic Acid Receptor-Beta as a Prognostic Indicator in Stage I Non–Small-Cell Lung Cancer, 2798
Kieffer SA, *see* Dorval M
Kies M, *see* List MA
Kies MS, *see* Vokes EE
Kigasawa H, *see* Nishihira H
Kijewski P, *see* Schwartz LH
Kim BS, *see* Kim GE
Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK, Kim BS. Angiocentric Lymphoma of the Head and Neck: Patterns of Systemic Failure After Radiation Treatment, 54
Kim H, *see* Lowe VJ
Kim KM, *see* Bonomi P
Kim Y, *see* Fossella F
—*see* Shepherd FA
Kim YS, *see* Shepherd FA
Kimmel D, *see* Smith JS
King DR, *see* Ortega JA
King TC, *see* Beckwith C
Kingma DW, *see* Socié G
Kirk J, *see* Meiser B
Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, Cross P, Gulavita S, Blodd P, Sun A, Dundas G, Ganguly PK, Lim J, Chowdhury AD, Kumar SE, Dar AR. Dexamethasone for the Prophylaxis of Radiation-Induced Emesis: A National Cancer Institute of Canada Clinical Trials Group Phase III Study, 1960
Kirkpatrick A, *see* Postmus PE
Kirkwood J, *see* Manola J
Kirkwood JM, *see* Lawson D
Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190, 2444
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of Nelarabine and 9-Beta-D-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies, 995
Kitazawa S, *see* Gohji K
Kittler H, *see* Königsberg R
Kivelä T. In Reply (correspondence), 235
Kjeldsberg C, *see* Fisher RI
Kjeldsberg CR, *see* Lones MA
Klaassen RJ, Goodman TR, Pham B, Doyle JJ. 'Low-Risk' Prediction Rule for Pediatric Oncology Patients Presenting With Fever and Neutropenia, 1012
Klar N, *see* Lee SJ
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J for the Study Section on Infections of Mulitnational Association for Supportive Care in Cancer: The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients, 3038
Klein CE, *see* Adjei AA
Klein JP, *see* Davies SM
—*see* Henrickson KJ
Kleinberg L, *see* Heath EI
Klersy C, *see* Caselli D
Klijn JGM, *see* Bontenbal M
—*see* Paridaens R
—*see* Verhoog LC
Klokman WJ, *see* van Leeuwen FE

Knisely JPS, *see* Heath EI
Knost JA, *see* Quella SK
Knox SJ, *see* Vose JM
Knuth A, *see* von der Maase H
Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM. Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy, 307
Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM. Randomized Cross-Over Trial of Progenitor-Cell Mobilization: High-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor (G-CSF) Versus Granulocyte-Macrophage Colony-Stimulating Factor Plus G-CSF, 1824
Koch P, Berdel WE, Willich N, Tieman M, Parwaresch R. Grading in Marginal-Zone Lymphomas (correspondence), 2788
Kocha W, *see* Van Cutsem E
Koczwara B, *see* Cheng JD
Kohler DR, *see* Zujewski J
Koike K-I, *see* Toyoda Y
Kok A, *see* von Mensdorff-Pouilly S
Koller C, *see* Kantarjian HM
Kolodny GM, *see* Israel O
Komaki R, *see* Glisson B
Kong LK, *see* Gopal AK
König-Merediz SA, *see* Schmidt M
Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L, Gisslinger H, Jäger U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma, 804
Koopman FJ, *see* Malingré MM
Koops HS, *see* Meinardi MT
Kopp WC, *see* Zujewski J
Koralewski P, *see* Bonneterre J
Korbling M, *see* Seong C-M
Kosmidis P, *see* Briasoulis E
Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, Georgoulias V. Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study, 2226
Kouriefs C, *see* Mokbel K
Kouroussis C, *see* Koukourakis MI
Krag D, Abrams J. Sentinel Nodes: Clinical Trial Data Needed (correspondence), 3873
Krailo MD, *see* Ortega JA; Ozkaynak MF
Kramer GWP, *see* Van Zandwijk N
Kranenbarg EK, *see* Nagtegaal ID
Kraus A, *see* Kersting M
Krause A, *see* Gerber B
Krause C, *see* Desch CE
Kreis H, *see* Mamzer-Bruneel M-F
Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I. Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies, 1622
Kremens B, *see* Schneider DT
Kremer AB, *see* Zujewski J
Kris M, *see* Fossella F
Kris MG, *see* Miller VA
Krischer J, *see* Thomas PRM
Kristeller-Tome V, *see* Piccart MJ
Kristensen GB, *see* Baekelandt M
Kristo P, *see* Salovaara R
Krol ADG, *see* van Leeuwen FE
Krömer E, *see* Königsberg R
Kronenberg F, *see* Jacobson JS
Krop IE, Wieczorek TJ, Mayer RJ. Diagnostic Dilemmas in Oncology; Case 3: Metastatic Ovarian Cancer Simulating Colon Cancer, 3189
Krug LM, *see* Miller VA
Krupnick JL, *see* Green BL
Krupp KR, *see* Quella SK
Krzakowski M, *see* Bonneterre J
Kuan C-T, *see* Cokgor I
Kucera PR, *see* Muggia FM
Kudelka AP, *see* Verschraegen CF
Kudoh S, *see* Masuda N
Kuenen BC, *see* Ong LML
Kuentz M, *see* Blaise D
—*see* Yakoub-Agha I
Kuerer HM, *see* Breslin TM
Kugler J, *see* Bonomi P
Kuhn JG, *see* Eckhardt SG
Kuhn SM, *see* Henrickson KJ
Kuhn W, *see* Avril N
—*see* Schelling M
Kulke MH. The Treatment of Advanced Gastric Cancer: In Search of the Right Combination (editorial), 2645
Kulp B, *see* Markman M
Külz T, *see* Gerber B
Kumar PD, *see* Abraksia S
Kumar S, *see* Jatoi A
Kumar SE, *see* Kirkbride P
Kundt G, *see* Gerber B
Kunitoh H, *see* Yamamoto N
Kun L, *see* Fouladi M
—*see* Thomas PRM
Kun LE, *see* Leung W
Kuntz KM, *see* Ng AK
Kuntz KM. In Reply (correspondence), 942
Kupelian PA, *see* Kattan MW
Kurata T, Shimada Y, Tamura T, Yamamoto N, Hyodo I, Saeki T, Takashima S, Fujiwara K, Wakasugi H, Kashimura M. Phase I and Pharmacokinetic Study of a New Taxoid, RPR 109881A, Given as a 1-Hour Intravenous Infusion in Patients With Advanced Solid Tumors, 3164
Kurie JM, *see* Nemunaitis J
Kurtaran A, *see* Penz M
—*see* Raderer M
Kurtin D, *see* Elting LS
Kurtzberg J, *see* Kisor DF
Kuten A, *see* Israel O
Kutteh L, *see* Koç ON
Kuzel T, *see* Kaufman D
Kuzel TM, *see* Pandolfino TL
—*see* Siegel RS
Kwong YL, *see* Au WY
—*see* Liang R
Kyle RA, *see* Alexanian R

Kyrias G, *see* Koukourakis MI
Kyritsis AP, *see* Fine HA

Lacave AJ, *see* Piccart MJ
—*see* Vanhoefer U
Lacayo NJ, *see* Dahl GV
Laccourreye O, *see* Cabelguenne A
Lacitignola L, *see* Faulkner LB
Lacombe D, *see* Piccart MJ
Lahoti S, *see* Pisters PWT
Lai C-H, *see* Chang T-C
Lam T, *see* Elting LS
Lamagnere JP, *see* Michel G
Lambelet P, *see* Carella AM
Lamberti A, *see* Comella P
Lammes FB, *see* Ong LML
Lanchote VL, *see* Broniscer A
Lanclos K, *see* Gopal AK
Land VJ, *see* Pollock BH
Landman-Parker J, *see* Michel G
Landman-Parker J, Pacquement H, Leblanc T, Habrand JL, Terrier-Lacombe MJ, Bertrand Y, Perel Y, Robert A, Coze C, Thuret I, Donadieu J, Schaison G, Leverger G, Lemerle J, Oberlin O. Localized Childhood Hodgkin's Disease: Response-Adapted Chemotherapy With Etoposide, Bleomycin, Vinblastine, and Prednisone Before Low-Dose Radiation Therapy – Results of the French Society of Pediatric Oncology Study MDH90, 1500
Landonio G, *see* Nasti G
Landry J, *see* Coia LR
Lange BJ, *see* Heerema NA
Langer SW, Sehested M, Buhl P, Jensen, Buter J, Giaccone G. Dexrazoxane in Anthracycline Extravasation (correspondence), 3064
Langston J, *see* Fouladi M
—*see* Thomas PRM
Larkin G, *see* Zujewski J
Larocca LM, *see* Cingolani A
Larregain-Fournier D, *see* Giacchetti S
Larson RA, *see* Hensley ML
Larto MA, *see* Adelstein DJ
Lassere Y, *see* Hoff PM
Lasset C, *see* Frappaz D
Latreille J, *see* Gelmon KA
—*see* Norris B
Lau J, *see* Ioannidis JPA
Laub PB, *see* Gallo JM
Lauer S, *see* Mahoney DH Jr
Lauer SJ, *see* Pollock BH
Laughlin M, *see* Koç ON
Laurent-Puig P, *see* Cabelguenne A
Laus R, *see* Small EJ
Lauta VM, *see* Zinzani PL
Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F. *p53* Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma, 3936
LaVasseur BI, *see* Quella SK
Lawrence DD, *see* Nemunaitis J
Lawrence J, *see* Conley B
Lawrence TS, *see* Dawson LA
Lawson D, Kirkwood JM. Granulocyte-Macrophage Colony-Stimulating Factor: Another Cytokine With Adjuvant Therapeutic Benefit in Melanoma? (editorial), 1603
Lazarus HM, *see* Davies SM
—*see* Koç ON
Leal-Leal C, *see* Rivera-Luna R
Leavey PJ, *see* Mantadakis E
Le Bail N, *see* de Gramont A
—*see* Giacchetti S
Lebecq A, *see* Couteau C
—*see* Gelmon KA
LeBherz D, *see* Saleh MN
LeBlanc M, *see* Fisher RI
—*see* Fisher RI
Leblanc T, *see* Landman-Parker J
—*see* Michel G
Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group, 2676
Le Chevalier T, *see* Andre F
Lederlin P, *see* Haioun C
—*see* Tilly H
Leduc B, *see* Delozier T
Lee BH, *see* Oh WK
Lee CG, *see* Godder KT
Lee H, *see* Zelefsky MJ
Lee HK, *see* Smith JS
Lee JE, *see* Pisters PWT
Lee JJ, *see* Khuri FR
—*see* Nemunaitis J
—*see* Pollack A
Lee JS, *see* Fossella F
—*see* Khuri FR
—*see* Nemunaitis J
Lee MK, *see* Heerema NA
Lee PD, *see* Wunder JS
Lee RJ, *see* Green DM
Lee SJ, Klar N, Weeks JC, Antin JH. Predicting Costs of Stem-Cell Transplantation, 64
Lee SM, *see* Verweij J
Lee VM-Y, *see* Grotzer MA
Leedy D, *see* Bennett CL
Lefresne-Soulas F, *see* Couteau C
Legall E, *see* Michel G
Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P, Harousseau J-L, Betaille R, Avet-Loiseau H. Fluorescence in Situ Hybridization on Peripheral-Blood Specimens Is a Reliable Method to Evaluate Cytogenetic Response in Chronic Myeloid Leukemia, 1533
Lehman S, *see* Tidefelt U
Leibel S, *see* Potters L
Leibel SA, *see* Kattan MW
—*see* Zelefsky MJ
Leimer M, *see* Raderer M

Leisink M, *see* Bontenbal M
Lemerle J, *see* Landman-Parker J
Lemoli RM, *see* Martinelli G
Lenehan PF, *see* Small EJ
Lennington WJ, *see* Hainsworth JD
Lentz SL, *see* Muggia FM
Lentz SS, *see* McGuire WP
Lenzi R, *see* Pisters PWT
Lepage E, *see* Haioun C
Leporrier M, *see* Yakoub-Agha I
Le Prise PY, *see* Harousseau JL
Leris ACA, *see* Mokbel K
Leris C, *see* Mokbel K
Lerma E, *see* Carella AM
Le Rol A, *see* Giacchetti S
Lerut A, *see* Flamen P
Lesimple T, *see* Négrier S
Letourneau Y, *see* Giacchetti S
Leung D, *see* Linehan DC
Leung DHY, *see* Lewis JJ
Leung G, *see* Au WY
Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, Razzouk BI, Mathew P, Shearer P, Evans WE, Pui C-H. Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia, 3273
Leverger G, *see* Landman-Parker J
—*see* Michel G
Lévi F, *see* Giacchetti S
Levine EG, *see* Kaufman D
Levine ML, *see* Whelan TJ
Levin J, *see* Mani S
Levin VA, *see* Fine HA
—*see* Meyers CA
Levitan N, *see* Shepherd FA
Levitan N, Dowlati A. In Reply (correspondence), 3454
Levitan N, Dowlati A, Shina D, Craffey M, Mackay W, DeVore R, Jett J, Remick SC, Chang A, Johnson D. Multi-Institutional Phase I/II Trial of Paclitaxel, Cisplatin, and Etoposide With Concurrent Radiation for Limited-Stage Small-Cell Lung Carcinoma, 1102
Levitt R, *see* Martenson JA
Levy R, *see* Davis TA
Levy V, *see* Mamzer-Bruneel M-F
Lew D, *see* Small EJ
Lewinski T, *see* Postmus PE
Lewis BK, *see* Warren KE
Lewis I, *see* Thomas H
Lewis IJ, Weeden S, Machin D, Stark D, Craft AW for the European Osteosarcoma Intergroup. Received Dose and Dose-Intensity of Chemotherapy and Outcome in Nonmetastatic Extremity Osteosarcoma, 4028
Lewis JJ, *see* Linehan DC
Lewis JJ, Antonescu CR, Leung DHY, Blumberg D, Healey JH, Woodruff JM, Brennan MF. Synovial Sarcoma: A Multivariate Analysis of Prognostic Factors in 112 Patients With Primary Localized Tumors of the Extremity, 2087
Lhommé C, *see* Delaloge S
Li J, *see* Gopal AK
Liang R, *see* Au WY
—*see* Chim CS
Liang R, Yu CM, Au WY, Choy CKW, Kwong YL. Non-Hodgkin's Lymphoma Involving The Heart; Case 2: Secondary Lymphoma of the Heart Manifesting as Intracavitary Masses, 1998
Liebowitz D, *see* Stadler WM
Lieverst J, *see* Malingré MM
Liew K, *see* O'Brien P
Lightdale CJ. Positron Emission Tomography: Another Useful Test for Staging Esophageal Cancer (editorial), 3199
Liliemark E, *see* Tidefelt U
Liliemark J, *see* Tidefelt U
Liljegren G (for the Uppsala Örebro Breast Cancer Study Group). In Reply (correspondence), 942
Lillington DM, *see* Micallef INM
Lim J, *see* Kirkbride P
Lin C-T, *see* Chang T-C
Linch DC, *see* Swerdlow AJ
Lincoff N, *see* Wetzler M
Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment, 1423
Lindsey KR, Rosenberg SA, Sherry RM. Impact of the Number of Treatment Courses on the Clinical Response of Patients Who Receive High-Dose Bolus Interleukin-2, 1954
Lindtner J, *see* Colleoni M
—*see* Crivellari D
Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence of Biologic Factors and Anatomic Site in Completely Resected Liposarcoma, 1637
Linggood R, *see* Thomas PRM
Link BK, *see* Davis TA
Link JS, *see* Nagourney RA
Link MP, *see* Baker KS
Lioure B, *see* Harousseau JL
Lippert CM, *see* von der Maase H
Lippman ME, *see* Baidas SM
Lippman SM, *see* Hong WK
—*see* Khuri FR
Lipton A, *see* Hillner BE
Liso V, *see* Ferrara F
List M, *see* Vokes EE
List MA, Stracks J, Colangelo L, Butler P, Ganzenko N, Lundy D, Sullivan P, Haraf D, Kies M, Goodwin W, Vokes EE. How Do Head and Neck Cancer Patients Prioritize Treatment Outcomes Before Initiating Treatment?, 877
Lister AK, *see* Harris NL
Lister TA, *see* Apostolidis J
—*see* Foran JM
—*see* Micallef INM
—*see* Swerdlow AJ
Litchman M, *see* Fracasso PM
—*see* Patnaik A
Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R. Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma, 2593
Liu C-L, *see* Poon RT-P
Liu ET, *see* Berry DA; Stark A
Liu PY, *see* Peters WA III

Liu S, *see* Thor AD
Liu-Mares W, *see* Ortega JA
Llombart-Bosch A, *see* Cañete A
Llorens V, *see* Takimoto CH
Llory JF, *see* Giacchetti S
Lloyd RV, *see* Oliveira AM
Lluch A, *see* Pérez-Manga G
Lo C-M, *see* Poon RT-P
LoBuglio AF, *see* Bonner JA
—*see* Saleh MN
Lockbaum P, *see* Johnston E
Lo Coco F, *see* Ferrara F
Loeffler JS, *see* Fine HA
Loehrer P, *see* Motzer RJ
Lofters W, *see* Norris B
Logothetis CJ, *see* Pettaway CA
Lohrisch C, Jackson J, Jones A, Mates D, Olivotto IA. Relationship Between Tumor Location and Relapse in 6,781 Women With Early Invasive Breast Cancer, 2828
Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MHJ, Fibbe W, Russell I, vd Donk NWCJ, Verdonck LF. Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome, 3031
Lokich J, *see* Mani S
Lokiec F, *see* Couteau C
Lomé C, *see* Mamzer-Bruneel M-F
London WB, *see* Cohn SL
Lones MA, Perkins SL, Sposto R, Kadin ME, Kjeldsberg CR, Wilson JF, Cairo MS. Large-Cell Lymphoma Arising in the Mediastinum in Children and Adolescents Is Associated With an Excellent Outcome: A Children's Cancer Group Report, 3845
Long L, *see* Friedman HS
Longhi A, *see* Bacci G
Loni C, *see* Carella AM
Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, Di Salle E, Polli A, Massimini G. Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial, 2234
Loos WJ, *see* de Jonge MJA
Lopez A, *see* Gordon AN
López-Brea M, *see* Bellmunt J
Lo Piccolo MS, *see* Faulkner LB
Loprinzi C, *see* Schapira L
Loprinzi CL, *see* Desch CE
—*see* Hayes D
—*see* Quella SK
—*see* Sloan JA
Loprinzi CL, Canellos GP. A New Addition to the *Journal of Clinical Oncology:* The Art of Oncology–When the Tumor Is Not the Target (editorial), 3
Loprinzi CL, Hayes D, Smith T. Doc, Shouldn't We Be Getting Some Tests?, 2345
Loprinzi CL, Johnson ME, Steer G. Doc, How Much Time Do I Have?, 699
Loprinzi CL, Quella SK, Barton DL. In Reply (correspondence), 2788
Lorenz M, Müller H-H for the German Cooperative Group on Liver Metastases. Randomized, Multicenter Trial of Fluorouracil Plus Leucovorin Administered Either Via Hepatic Arterial or Intravenous Infusion Versus Fluorodeoxyuridine Administered Via Hepatic Arterial Infusion in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma, 243
Lorusso V, *see* Berruti A
—*see* Comella P
—*see* Frasci G
Lorusso V, Carpagnano F, Frasci G, Panza N, Di Rienzo G, Cisternino ML, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S, De Lena M. Phase I/II Study of Gemcitabine Plus Vinorelbine as First-Line Chemotherapy of Non–Small-Cell Lung Cancer, 405
Lotan R, *see* Khuri FR
—*see* Lotan Y
Lotan Y, Xu XC, Shalev M, Lotan R, Williams R, Wheeler TM, Thompson TC, Kadmon D. Differential Expression of Nuclear Retinoid Receptors in Normal and Malignant Prostates, 116
Louie A, *see* Hidalgo M
Loukola A, *see* Salovaara R
Louvet C, *see* de Gramont A
Lovato LC, *see* Moinpour CM
Love CDB. In Reply (correspondence), 445
Lowe VJ, Boyd JH, Dunphy FR, Kim H, Dunleavy T, Collins BT, Martin D, Stack BC Jr, Hollenbeak C, Fletcher JW. Surveillance for Recurrent Head and Neck Cancer Using Positron Emission Tomography, 651
Lu J, *see* Valicenti R
Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult Ovarian Tumors in Women With *BRCA1* or *BRCA2* Mutations Undergoing Prophylactic Oophorectomy, 2728
Lübbert M, *see* Wijermans P
Luboinski M, *see* Girinsky T
Lucas VS, *see* Baker SD
Lucchini V, *see* Lavarino C
Lucenti A, *see* Gatzemeier U
Lüchtenborg M, *see* Smith BM
Ludwig H, *see* Königsberg R
Lukens J, *see* Nickerson HJ
Lukens JN, *see* Maris JM
—*see* Perez CA
—*see* Schmidt ML
Lumbreras C, *see* Gomez-Martin C
Lunardi G, *see* Venturini M
Lund B, *see* Neijt JP
Lundy D, *see* List MA
Luppi M, *see* Federico M
—*see* Sabbatini R
Lutzky J, *see* Foon KA
Lyerly HK, *see* Morse MA
Lyman GH, *see* Extermann M
Lynch CF, *see* Metayer C
Lynch HT, Lynch J. Lynch Syndrome: Genetics, Natural History, Genetic Counseling, and Prevention, 19s
Lynch J, *see* Lynch HT
Lynch JC, *see* Bishop MR
Lynch PM, *see* Frazier ML

Ma SK, *see* Au WY
Macapinlac HA, *see* Motzer RJ
MacDonald JR, *see* Eckhardt SG

MacDonald N, *see* Bruera E
—*see* Schapira L
Macé-Lesec'h J, *see* Delozier T
Machado TMS, *see* Broniscer A
Machin D, *see* Lewis IJ
Mac Intyre E, *see* Mamzer-Bruneel M-F
Mack M, *see* Nemunaitis J
Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, Brown R. Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival, 87
Mackay W, *see* Levitan N
Mackean MJ, *see* Mackay HJ
MacKinnon J, *see* Patnaik A
Macklis R, *see* Unnithian J
MacMillan J, *see* Basser RL
Macquart-Moulin G, Viens P, Palangié T, Bouscary M-L, Delozier T, Roché H, Janvier M, Fabbro M, Moatti J-P for the Economic/Quality-Of-Life/Intensive Therapy Group of the French National Federation of Anticancer Centers. High-Dose Sequential Chemotherapy With Recombinant Granulocyte Colony-Stimulating Factor and Repeated Stem-Cell Support for Inflammatory Breast Cancer Patients: Does Impact on Quality of Life Jeopardize Feasibility and Acceptability of Treatment?, 754
Madafiglio J, *see* Cohn SL
Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, Malhotra H, Ostrow S, Sugarman S, Viola M. Phase I Chemotherapy Study of Biochemical Modulation of Folinic Acid and Fluorouracil by Gemcitabine in Patients With Solid Tumor Malignancies, 3553
Madero L, *see* Marco F
Maeda M, *see* Toyoda Y
Maesako Y, *see* Akasaka T
Magagnoli M, *see* Zinzani PL
—*see* Zinzani PL
Magdelanat H, *see* This P
Magdelénat H, *see* Stoppa-Lyonnet D
Magklara A, *see* Nam RK
Magnolfi E, *see* Zampa G
Mahjoubi M, *see* Alexandre J
Mahoney DH Jr, *see* Pollock BH
Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer S, Steuber CP, Camitta B. Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Actue Lymphoblastic Leukemia: A Pediatric Oncology Group Study, 1285
Mailliard JA, *see* Martenson JA
Maiorino L, *see* Comella P
Makovitzky J, *see* Gerber B
Maldonado MS, *see* Marco F
Malhaire J-P, *see* Delozier T
Malhotra H, *see* Madajewicz S
Malingré MM, Terwogt JMM, Beijnen JH, Rosing H, Koopman FJ, Van Tellingen O, Duchin K, Huinink WWTB, Swart M, Lieverst J, Schellens JHM. Phase I and Pharmacokinetic Study of Oral Paclitaxel, 2468
Malkowicz SB, *see* D'Amico AV
—*see* D'Amico AV
Mallard S, *see* Kantarjian HM
Mallikaarjun S, *see* Patnaik A
Malogolowkin MH, Stanley P, Steele DA, Ortega JA. Feasibility and Toxicity of Chemoembolization for Children With Liver Tumors, 1279
Maloney DG, *see* Davis TA
Mamzer-Bruneel M-F, Lomé C, Morelon E, Levy V, Bourquelot P, Jacobs F, Gessain A, Mac Intyre E, Brousse N, Kreis H, Hermine O. Durable Remission After Aggressive Chemotherapy for Very Late Post–Kidney Transplant Lymphoproliferation: A Report of 16 Cases Observed in a Single Center, 3622
Manabe A, *see* Toyoda Y
Mancarella S, *see* Berruti A
Manegold C, *see* Sandler AB
Manfrini M, *see* Bacci G
Mangalik A, *see* Nabholtz JM
Mangioni C, *see* Lavarino C
Mani S, *see* Venook AP
Mani S, Hochster H, Beck T, Chevlen EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohneker J, Schilsky RL, Lokich J. Multicenter Phase II Study to Evaluate a 28-Day Regimen of Oral Fluorouracil Plus Eniluracil in the Treatment of Patients With Previously Untreated Metastatic Colorectal Cancer, 2894
Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, Gray E, McKeever P, Hale J, Bailey S, Oakhill A. The United Kingdom Children's Cancer Study Group's Second Germ Cell Tumor Study: Carboplatin, Etoposide, and Bleomycin Are Effective Treatment for Children With Malignant Extracranial Germ Cell Tumors, With Acceptable Toxicity, 3809
Manni JJ, *see* Veltman JA
Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials, 3782
Manola J, *see* Burstein HJ
—*see* Dreicer R
—*see* Harris JE
Manson JE, *see* Holmes MD
Mansour E, *see* Harris JE
Mantadakis E, Herrera L, Leavey PJ, Bash RO, Winick NJ, Kamen BA. Fractionated Cyclophosphamide and Etoposide for Children With Advanced or Refractory Solid Tumors: A Phase II Window Study, 2576
Mantel M, *see* Blobe GC
Mantel MA, *see* de Jonge MJA
Mantzoros CS, *see* Shaneyfelt T
Manzione L, *see* Comella P
Marangolo M, *see* Amadori D
Marco F, Bureo E, Ortega JJ, Badell I, Verdaguer A, Martínez A, Muñoz A, Madero L, Olivé T, Cubells J, Castel V, Sastre A, Maldonado MS, Díaz MA from the Grupo Español de Trasplante de Médula Ósea en Niños: High Survival Rate in Infant Acute Leukemia Treated With Early High-Dose Chemotherapy and Stem-Cell Support, 3256
Marcus K, *see* Grupp SA
Margaria E, *see* Pich A
Mariani L, Marubini E. Content and Quality of Currently Published Phase II Cancer Trials, 429
Mariani T, *see* Motzer RJ
Marini G, *see* Colleoni M
Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS,

Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression but Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children's Cancer Group Study, 1888
Marit G, *see* Yakoub-Agha I
Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center, 102
Markowitz S. DNA Repair Defects Inactivate Tumor Suppressor Genes and Induce Hereditary and Sporadic Colon Cancers, 75s
Marlin S, *see* Norris B
Marr KA, *see* Gopal AK
Marra R, *see* Zinzani PL
Marshall GM, *see* Cohn SL
Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses, 3964
Marshall ME, *see* Small EJ
Marshall V, *see* Little RF
Martenson JA, Bollinger JW, Sloan JA, Novotny PJ, Urias RE, Michalak JC, Shanahan TG, Mailliard JA, Levitt R. Sucralfate in the Prevention of Treatment-Induced Diarrhea in Patients Receivig Pelvic Radiation Therapy: A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial, 1239
Martin CG, *see* Elting LS
Martin D, *see* Lowe VJ
Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, Bandini G, Motta MR, Testoni N, Amabile M, Ottaviani E, Vianelli N, De Vivo A, Gozzetti A, Tura S, Cavo M. Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma, 2273
Martínez A, *see* Marco F
Martinez AA, *see* Kestin LL
—*see* Vicini FA
Martini M, *see* Cingolani A
Martini S, *see* Morschhauser F
Martino B, *see* Ferrara F
Marty J, *see* Basser RL
Marty M, *see* Alexandre J
Marubini E, *see* Coradini D
—*see* Mariani L
Massidda B, *see* Frasci G
Massimini G, *see* Kaufmann M
—*see* Lønning PE
Mastik MF, *see* Plaat BEC
Mastrangelo M, *see* Ejadi S
Masuda N, Negoro S, Kudoh S, Sugiura T, Nakagawa K, Saka H, Takada M, Niitani H, Fukuoka M. Phase I and Pharmacologic Study of Docetaxel and Irinotecan in Advanced Non–Small-Cell Lung Cancer, 2996
Mates D, *see* Lohrisch C
Mathew P, *see* Leung W
Mathey C, *see* Michel G
Mathijssen RHJ, *see* de Jonge MJA
Matloff ET, Shappell H, Brierley K, Bernhardt BA, McKinnon W, Peshkin BN. What Would You Do? Specialists' Perspectives on Cancer Genetic Testing, Prophylactic Surgery, and Insurance Discrimination, 2484
Matrisian LM, *see* Nelson AR
Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a Complication of Treating Acute Lymphoblastic Leukemia in Children: A Report From the Children's Cancer Group, 3262
Matthay KK, *see* Maris JM
—*see* Nickerson HJ
—*see* Ozkaynak MF
—*see* Perez CA
—*see* Schmidt ML
—*see* Seeger RC
Matthay KK. *MYCN* Expression in Neuroblastoma: A Mixed Message? (editorial), 3591
Matthews J, *see* Apostolidis J
—*see* Micallef INM
Mattson K, *see* Gatzemeier U
—*see* Sandler AB
—*see* Shepherd FA
Matulonis UA, *see* Burstein HJ
Mauch PM, *see* Ng AK
Mauch PM. In Reply (correspondence), 942
Maurer HM, *see* Baker KS
Mauriac L, *see* Bonneterre J
—*see* Delozier T
Mayer RJ, *see* Krop IE
Mazumdar M, *see* Dodd PM
—*see* Motzer RJ
Mazza P, *see* Zinzani PL
Mazzone C, *see* Cingolani A
McArdle CS, *see* Kerr DJ
McCaffrey JA, *see* Dodd PM
McCarthy P, *see* van Besien K
McClean P, *see* Rustin GJS
McClelland RS, *see* Gopal AK
McCue P, *see* Ejadi S
McDermit J, *see* Nieto Y
McGinn CJ, *see* Dawson LA
McGuire WP, *see* Rose PG
McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study, 1062
McGuirt C, *see* Mani S
McKean-Cowdin R, Feigelson HS, Ross RK, Pike MC, Henderson BE. Declining Cancer Rates in the 1990s, 2258
McKeever P, *see* Mann JR
McKinnon W, *see* Matloff ET
McLaughlin P, *see* Davis TA
McLendon RE, *see* Cokgor I
—*see* Friedman HS
McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, Vennekotter DJ, Turk PS, Tate PS, Sardi A, Cerrito PB, Edwards MJ. Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique is Used, 2560

Mcmenamin M, *see* Partridge A
—*see* Sekeres M
McNeese MD, *see* Katz A
McWilliam C, *see* Boon H
Mead GM, *see* Gale J
Meadows AT, *see* Friedman DL
—*see* Gururangan S
—*see* Shields CL
Mecklin J-P, *see* Salovaara R
Medical Research Council Lung Cancer Working Party, *see* Thatcher N
Meely K, *see* Boige V
Meeske K, *see* Hobbie WL
Meijer S, *see* von Mensdorff-Pouilly S
Meijers-Heijboer EJ, *see* Verhoog LC
Meinardi MT, Gietema JA, Van Der Graaf WTA, Van Veldhuisen DJ, Runne MA, Sluiter WJ, De Vries EGE, Willemse PBH, Mulder NH, Van Den Berg MP, Koops HS, Sleijfer DTh. Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer, 1725
Meisenberg BR, *see* Zamboni WC
Meiser B, Butow P, Friedlander M, Schnieden V, Gattas M, Kirk J, Suthers G, Haan E, Tucker K. Intention to Undergo Prophylactic Bilateral Mastectomy in Women at Increased Risk of Developing Hereditary Breast Cancer, 2250
Meitar D, *see* Katzenstein HM
Mekhaldi S, *see* Boige V
Melton LJ III, *see* Stark A
Mendelsohn J, *see* Baselga J
Mendenhall WM, Amdur RJ, Stringer SP. In Reply (correspondence), 3452
Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, Cassisi NJ. Radiation Therapy for Squamous Cell Carcinoma of the Tonsillar Region: A Preferred Alternative to Surgery?, 2219
Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Moore-Higgs GJ, Cassisi NJ. Is Radiation Therapy a Preferred Alternative to Surgery for Squamous Cell Carcinoma of the Base of Tongue?, 35
Mennel RG, *see* Kaufmann M
Meredith RF, *see* Bonner JA
Meric F, Milas M, Hunt KK, Hess KR, Pisters PWT, Hildebrandt G, Patel SR, Benjamin RS, Plager C, Papadopolous NEJ, Burgess MA, Pollock RE, Feig BW. Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity in Soft Tissue Sarcomas, 3378
Merino MJ, *see* Conley B
Mermillod B, *see* Hügli A
Meropol NJ, *see* Cheng JD
—*see* Hensley ML
—*see* Venook AP
Merritt J, *see* Nemunaitis J
Mesiti M, *see* Boccardo F
Messori A, *see* Trippoli S
Metayer C, Lynch CF, Clarke A, Glimelius B, Storm H, Pukkala E, Joensuu T, Van Leeuwen FE, Van't Veer MB, Curtis RE, Holowaty EJ, Andersson M, Wiklund T, Gospodarowicz M, Travis LB. Second Cancers Among Long-Term Survivors of Hodgkin's Disease Diagnosed in Childhood and Adolescence, 2435
Metz E, *see* Zelefsky MJ
Metz EM, *see* Motzer RJ
Metzner B, *see* Sezer O
Meyer M, *see* Small EJ
Meyer WH, *see* Wexler LH
Meyerowitz BE, *see* Bower JE
Meyers CA, Hess KR, Yung WKA, Levin VA. Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma, 646
Meyers FJ, *see* Small EJ
Meyerson H, *see* Koç ON
Meyerson M. Role of Telomerase in Normal and Cancer Cells, 2626
Meza-Coria C, *see* Rivera-Luna R
Micallef INM, Lillington DM, Apostolidis J, Amess JAL, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA, Rohatiner AZS. Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies, 947
Michael M, *see* Patnaik A
Michalak JC, *see* Martenson JA
Michallet M, *see* Blaise D
Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, Bordigoni P, Lamagnere JP, Demeocq F, Perel Y, Auvrignon A, Berthou C, Bauduer F, Pautard B, Schneider P, Schaison G, Leverger G, Baruchel A. Use of Recombinant Human Granulocyte Colony-Stimulating Factor to Increase Chemotherapy Dose-Intensity: A Randomized Trial in Very High-Risk Childhood Acute Lymphoblastic Leukemia, 1517
Michon J, *see* Frappaz D
Micillo E, *see* Comella P
Mickiewicz E, *see* Lønning PE
Middleton MR, *see* Hillner BE
Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma, 158
Middleton MR. In Reply (correspondence), 2185
Midgley RJ, *see* Kerr DJ
Milan C, *see* Chaplain G
Milanaccio C, *see* Faulkner LB
Milani R, *see* Cuneo A
Milas M, *see* Meric F
Milicic B, *see* Jeremic B
Mille D, Roy T, Carrère M-O, Ray I, Ferdjaoui N, Späth H-M, Chauvin F, Philip T. Economic Impact of Harmonizing Medical Practices: Compliance With Clinical Practice Guidelines in the Follow-Up of Breast Cancer in a French Comprehensive Cancer Center, 1718
Miller D, *see* Friedman DL
Miller ID, *see* Smith IC
Miller KD, *see* Quella SK
Miller LL, *see* Kaufmann M
Miller T, *see* Fisher RI
Miller V, *see* Fossella F
Miller VA, Krug LM, Ng KK, Pizzo B, Perez W, Heelan RT, Kris MG. Phase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non–Small-Cell Lung Cancer, 1346
Miller-Messana MA, *see* Johnston E
Milone GA, *see* Davies SM
Milpied N, *see* Blaise D

—*see* Le Gouill S
—*see* Yakoub-Agha I
Minotto C, *see* Cuneo A
Minsky BD, *see* Coia LR
—*see* Desch CE
Miralbell R, *see* Hügli A
Misset JL, *see* Alexandre J
—*see* Giacchetti S
Mita M, *see* Lønning PE
Mitchell B, *see* Kisor DF
Mitchell PLR. Quality of Life and Cisplatin-Gemcitabine Chemotherapy (correspondence), 2788
Mitsumori M, *see* Park CC
Mittal BB, *see* Vokes EE
Miyahara T, *see* Swanson G
Miyazaki K, *see* Fujiwaki R
Moatti J-P, *see* Blaise D
—*see* Macquart-Moulin G
Moczygemba J, *see* Eckhardt SG
Modugno G, *see* Zinzani PL
Mogul M, *see* Grupp SA
Moinpour CM, Lovato LC, Thompson IM Jr, Ware JE Jr, Ganz PA, Patrick DL, Shumaker SA, Donaldson GW, Ryan A, Coltman CA Jr. Profile of Men Randomized to the Prostate Cancer Prevention Trial: Baseline Health-Related Quality of Life, Urinary and Sexual Functioning, and Health Behaviors, 1942
Mokbel K, Athow A, Kouriefs C, Leris C, Williams N, Carpenter R. Sector Resection for Stage I Breast Cancer (correspondence), 942
Mokbel K, Leris ACA. Predictors of Response to Chemotherapy (correspondence), 1601
Molenaar WM, *see* Plaat BEC
Molina L, *see* Yakoub-Agha I
Möllgård L, *see* Tidefelt U
Monahan BP, *see* Grem JL
—*see* Takimoto CH
Monceaux G, *see* Temam S
Monk BJ, *see* Peters WA III
Monneret G, *see* Voog E
Monnier A, *see* Brizel DM
Monsky WL, Heddens DK, Clark GM, Von Hoff DD, Coltman CA Jr, Dorr RT, Alberts DS. Comparison of Young Clinical Investigators' Accuracy and Reproducibility When Measuring Pulmonary and Skin Surface Nodules Using a Circumferential Measurement Versus a Standard Caliper Measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop, 437
Moore D II, *see* Thor AD
Moore M, *see* Fossella F
Moore MJ, *see* Patnaik A
—*see* von der Maase H
Moore-Higgs GJ, *see* Mendenhall WM
Morabito F, *see* Ferrara F
Moreau P, *see* Le Gouill S
Morel P, *see* Haioun C
Morelon E, *see* Mamzer-Bruneel M-F
Moreno-Nogueira JA, *see* Pérez-Manga G
Moretti L, *see* Zinzani PL
Morgan GJ, *see* Davies FE
Mori T, *see* Toyoda Y
Morice P, *see* Delaloge S
Morland B, *see* Thomas H
Moro D, *see* Hügli A
Morris ME, *see* Bishop MR
Morrison G, *see* Grem JL
—*see* Takimoto CH
Morrow M, *see* Rowinsky EK
Morschhauser F, Cayuela JM, Martini S, Baruchel A, Rousselot P, Socié G, Berthou P, Jouet JP, Straetmans N, Sigaux F, Fenaux P, Preudhomme C. Evaluation of Minimal Residual Disease Using Reverse-Transcription Polymerase Chain Reaction in T(8;21) Acute Myeloid Leukemia: A Multicenter Study of 51 Patients, 788
Morse MA, Nair S, Fernandez-Casal M, Deng Y, St Peter M, Williams R, Hobeika A, Mosca P, Clay T, Cumming RI, Fisher E, Clavien P, Proia AD, Niedzwiecki D, Caron D, Lyerly HK. Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer, 3883
Morselli M, *see* Federico M
—*see* Sabbatini R
Mortelmans L, *see* Flamen P
Morvan F, *see* de Gramont A
Mosca P, *see* Morse MA
Moschel RC, *see* Friedman HS
Motta MR, *see* Martinelli G
Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell Carcinoma, 1928
Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ. Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin and Etoposide Salvage Therapy for Germ Cell Tumor Patients, 1173
Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M. Phase III Trial of Interferon Alfa-2a With or Without 13-*cis*-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma, 2972
Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ. Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer, 2413
Moullet I, *see* Voog E
Moulopoulos LA, *see* Dimopoulos MA
Mounier N, *see* Tilly H
Mounier N, Gisselbrecht C. Myelodysplasia After Autotransplantation (correspondence), 3446
Mourits MJ, Willemse PH, De Vries EG, Van Der Zee AG. Tamoxifen and Endometrial Screening (correspondence), 445
Mourits MJE, *see* de Hullu JA
Movsas B, *see* Glisson B
Mueller-Hermelink HK, *see* Harris NL
Muggia FM, Brady MF, Alvarez R. In Reply (correspondence), 1800
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study, 106
Mulder NH, *see* Meinardi MT

Mulhern R, *see* Fouladi M
—*see* Thomas PRM
Mulhern RK, *see* Phipps S
Mulholland PJ, *see* Newlands ES
Müller H, *see* Gerber B
Müller H-H, *see* Lorenz M
Muller M, *see* Detmar SB
—*see* Middleton MR
Müller-Höcker J, *see* Empen K
Mumber MP, *see* Schapira L
Munier F, *see* Beck MN
Muñoz A, *see* Marco F
Murgo A, *see* Kantarjian HM
Murphy B, *see* Kaufman D
Murphy BA, *see* Motzer RJ
Murphy J, *see* Nieto Y
Murphy S, *see* Kantarjian HM
Murphy SB, *see* Pollock BH
—*see* Sandlund JT
Murray J, *see* Saleh MN
Murray R, *see* Lønning PE
Muss HB, *see* Berry DA
Muto MG, *see* Lu KH
Myers RP, *see* Cheng L
Myles J, *see* Norris B

Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M for the Arimidex Study Group. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial, 3758
Nachman JB, *see* Heerema NA
—*see* Mattano LA Jr
Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients, 2245
Nagtegaal ID, Kranenbarg EK, Hermans J, Van De Velde CJH, Van Krieken JHJM and the Pathology Review Committee. Pathology Data in the Central Databases of Mulitcenter Randomized Trials Need to Be Based on Pathology Reports and Controlled by Trained Quality Managers, 1771
Nagy T, *see* Patnaik A
Nährig J, *see* Schelling M
Nair S, *see* Morse MA
—*see* Sloan JA
Nakagawa K, *see* Masuda N
Nakajima M, *see* Gohji K
Nakayama J-i, *see* Poremba C
Nakayama K, *see* Fujiwaki R
Nakazawa S, *see* Toyoda Y
Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MAS, Narod SA. Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen, 1036
Namer M, *see* Delozier T
Nancarrow C, *see* Grupp SA
Nanni O, *see* Amadori D
Nanus DM, *see* Motzer RJ
Napoli G, *see* Lorusso V
Narducci MG, *see* Cuneo A
Narkool P, *see* Porteus MH
Narod SA, *see* Chappuis PO
—*see* Nam RK
—*see* Pierce LJ
Nascimento AG, *see* Oliveira AM
Nasser S, *see* Partridge A
Nasti G, Errante D, Talamini R, Rizzardini G, Fasan M, Landonio G, Zeroli C, Chichino G, Nigra E, Vaccher E, Tirelli U. Vinorelbine Is an Effective and Safe Drug for AIDS-Related Kaposi's Sarcoma: Results of a Phase II Study, 1550
Nasurdi C, *see* Kaufmann M
Natale M, *see* Comella P
Natale RB, *see* Small EJ
Natale RR, *see* Fossella F
Navarro S, *see* Cañete A
—*see* Cañete A
Nawaz S, *see* Nieto Y
Neat M, *see* Micallef INM
Needle M, *see* Friedman DL
Negoro S, *see* Masuda N
Négrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F for the Groupe Français d'Immunothérapie, Federation Nationale des Centres de Lutte Contre le Cancer. Treatment of Patients With Metastatic Renal Carcinoma With a Combination of Subcutaneous Interleukin-2 and Interferon Alfa With or Without Fluorouracil, 4009
Negrini M, *see* Cuneo A
Neijt JP, Engelholm SA, Tuxen MK, Sørensen PG, Hansen M, Sessa C, de Swart CAM, Hirsch FR, Lund B, van Houwelingen HC. Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer, 3084
Nekolaichuk CL, *see* Barnes EA
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix Metalloproteinases: Biologic Activity and Clinical Implications, 1135
Nelson-Taylor T, *see* Verschraegen CF
Nelstrop AE, *see* Rustin GJS
Nemieboka NN, *see* Zamboni WC
Nemunaitis J, *see* Sandler AB
Nemunaitis J, Eager R, Twaddell T, Corey A, Sekar K, Tkaczuk K, Thompson J, Hoff PM, Pazdur R. Phase I Assessment of the Pharmacokinetics, Metabolism, and Safety of Emitefur in Patients With Refractory Solid Tumors, 3423
Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KMW, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-Mediated *p53* Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Cancer, 609
Nesbitt JC, *see* Nemunaitis J
Nesland JM, *see* Baekelandt M
Neubauer A, *see* Schmidt M
Neuberg D, *see* Friedberg JW
—*see* Grupp SA
—*see* Horning SJ
—*see* Porteus MH

Neudorf S, *see* Davies SM
Neumann CM, *see* Barnes EA
Neumann PJ, *see* Earle CC
Neumann RLA, *see* Sauerbrei W
Newcomb FM, *see* Little RF
Newell DR, *see* Thomas H
Newlands ES. In Reply (correspondence), 2185
Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJS. Etoposide and Cisplatin/etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors, 854
Newman LA, *see* Breslin TM
Ng AK. In Reply (correspondence), 942
Ng IO-L, *see* Poon RT-P
Ng KK, *see* Miller VA
Ng K-K, *see* Chang T-C
Nguyen B, *see* Sandler AB
Nguyen DM, *see* Nemunaitis J
Nguyen PL, *see* Jatoi A
Nichols CR, *see* Bhatia S
Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children's Cancer Group Study, 477
Nicol S, *see* Kaufman D
Nicolella G, *see* Comella P
—*see* Frasci G
Niebch G, *see* Briasoulis E
Niederle B, *see* Raderer M
Niedzwiecki D, *see* Morse MA
Nielsen I, *see* Sartori S
Niemann TH, *see* Muggia FM
Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB. Evaluation of the Predictive Value of Her-2/*neu* Overexpression and *p53* Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation, 2070
Nigra E, *see* Nasti G
Niitani H, *see* Masuda N
Niitani Y, *see* Gohji K
Nikolic N, *see* Jeremic B
Niloff J, *see* Lu KH
Nishi T, *see* Nishihira H
Nishihira H, Toyoda Y, Tanaka Y, Ijiri R, Aida N, Takeuchi M, Ohnuma K, Kigasawa H, Kato K, Nishi T. Natural Course of Neurobalstoma Detected by Mass Screening: A 5-Year Prospective Study at a Single Institution, 3012
Nitschke R, *see* Mahoney DH Jr
Nixon A, *see* Park CC
—*see* Pierce LJ
Niyikiza C, *see* Sandler AB
Nobile F, *see* Ferrara F
Nogué M, *see* Bellmunt J
Nomi M, *see* Gohji K
Noone M, *see* Conley B
—*see* Zujewski J
Noordhuis P, *see* van Groeningen CJ
Nooy MA, *see* Weijl NI
Nordlinger B, *see* Vanhoefer U
—*see* Wilke H
Norman A, *see* Ross PJ
Normolle D, *see* Dawson LA
Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A. Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8, 2385
Norris MD, *see* Cohn SL
Norton A, *see* Smith IE
Norton AJ, *see* Apostolidis J
Norton L, *see* Baselga J
—*see* Berry DA
Nösslinger T, *see* Königsberg R
Nouvel C, *see* Haioun C
—*see* Tilly H
Novotny D, *see* Stark A
Novotny PJ, *see* Martenson JA
—*see* Quella SK
—*see* Sloan JA
Noyes RD, *see* McMasters KM
Numico G, *see* Venturini M
Nussenblatt RB, *see* Zujewski J

Oakhill A, *see* Mann JR
Obedian E, Fischer DB, Haffty BG. Second Malignancies After Treatment of Early-Stage Breast Cancer: Lumpectomy and Radiation Therapy Versus Mastectomy, 2406
Oberhuber G, *see* Penz M
Oberlin O, *see* Landman-Parker J
O'Brien MER, *see* Smith IE
O'Brien P, *see* Bennett CL
O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G. Phase II Multicenter Study of Brief Single-Agent Methotrexate Followed by Irradiation in Primary CNS Lymphoma, 519
O'Brien S, *see* Kantarjian HM
O'Connor J, *see* Hussain M
O'Dwyer PJ, *see* Eisenhauer EA
O'Fallon J, *see* Smith JS
Offit K. Are *BRCA1*- and *BRCA2*-Associated Breast Cancers Different?, 104s
Oggionni M, *see* Lavarino C
Oh W, *see* Kaufman D
Oh WK, Lee BH, Sweitzer NK. Nonmalignant Diagnoses in Patients; Case 3: Right Atrial Thrombus Associated With a Central Venous Catheter in a Patient With Metastatic Adrenocortical Carcinoma, 2638
Ohara A, *see* Toyoda Y
Ohkawa Y, *see* Toyoda Y
Ohno H, *see* Akasaka T
Ohnuma K, *see* Nishihira H
Ojala S, *see* Salovaara R
Oken MM, *see* Harris JE
—*see* Hochster HS
Okimoto Y, *see* Toyoda Y

Okuno S, *see* Sloan JA
Okuno SH, *see* Oliveira AM
Oliveira AM, Nascimento AG, Okuno SH, Lloyd RV. $p27^{kip1}$ Protein Expression Correlates With Survival in Myxoid and Round-Cell Liposarcoma, 2888
Olivé T, *see* Marco F
Oliver T, *see* von der Maase H
Oliviotto I, *see* Pierce LJ
Olivotto IA, *see* Lohrisch C
Olopade OI, *see* Pierce LJ
Olukayode K, *see* Heath EI
Olver I, *see* O'Brien P
—*see* von Pawel J
Omura GA. Chemotherapy of Gestational Trophoblastic Disease (correspondence), 2185
O'Neil JD, *see* Hidalgo M
O'Neill A, *see* Colleoni M; Sparano JA
Onetto N, *see* Saleh MN
Ong LML, Visser MRM, Lammes FB, van der Velden J, Kuenen BC, de Hae JCJM. Effect of Providing Cancer Patients With the Audiotaped Initial Consultation on Satisfaction, Recall, and Quality of Life: A Randomized, Double-Blind Study, 3052
Ooi C, *see* Au WY
Ooi GC, *see* Au WY
—*see* Chim CS
Orcioni GF, *see* Zinzani PL
O'Reilly S, *see* Baker SD
Oriana S, *see* Coradini D
Orlando S, *see* Lorusso V
O'Rourke M, *see* Shepherd FA
O'Rourke MA, *see* Mani S
Ortega JA, *see* Malogolowkin MH
Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD. Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report From the Children's Cancer Group and the Pediatric Oncology Group, 2665
Ortega JJ, *see* Marco F
Osanto S, *see* Weijl NI
Osborne CK, Zhao H, Fuqua AW. Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use, 3172
O'Shaughnessy J, *see* Conley B
Osoba D, *see* Norris B
Osoba D, Brada M, Yung WKA, Prados M. Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme, 1481
Oster W, *see* Brizel DM
Osterwalder B, *see* Van Cutsem E
Ostroff JB, *see* Saleh MN
Ostrow S, *see* Madajewicz S
Ottaviani E, *see* Martinelli G
Otto C, *see* Empen K
Owen JB, *see* Coia LR
Oza A, *see* Hoskins P
Oza AM, *see* Patnaik A
Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL III, Winn RJ, Wozniak AJ, Somerfield MR for the American Society of Clinical Oncology Growth Factors Expert Panel. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines, 3558
Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. Phase I Study of Chimeric Human/Murine Anti-Ganglioside G_{D2} Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children's Cancer Group Study, 4077
Ozsahin M. Does Total-Body Irradiation Technique Influence Veno-Occlusive Disease Incidence? (correspondence), 3062
Ozsahin M. Radiation Therapy or Surgery for Base-of-Tongue Tumors? (correspondence), 3452

Pacini M, *see* Santoro A
Pacini P, *see* Amadori D
—*see* Boccardo F
Packer RJ, *see* Thomas PRM
Pacquement H, *see* Landman-Parker J
Paesmans M, *see* Klastersky J
Page DL, *see* Simpson JF
Paillot B, *see* Vanhoefer U
Palangié T, *see* Macquart-Moulin G
Palazzo S, *see* Lorusso V
Palmer JL, *see* Richardson MA
Palmer MC, *see* Sandler AB
Palmer MJ, *see* Kirkbride P
Palomero M, *see* Pérez-Manga G
Panagos G, *see* Janinis J
Panayiotidis P, *see* Dimopoulos MA
Pandolfino T, *see* Siegel RS
Pandolfino TL, Siegel RS, Kuzel TM, Rosen ST, Guitart J. Primary Cutaneous B-Cell Lymphoma: Review and Current Concepts, 2152
Pandya KJ, *see* Simpson JF
Pane F, *see* Ferrara F
Panicek DM, *see* Schwartz LH
Pankow W, *see* Kersting M
Pantel K, *see* Braun S
Panza N, *see* Comella P
—*see* Frasci G
—*see* Lorusso V
Panzini I, *see* Sartori S
Paoli A, *see* Faulkner LB
Papadopolous NEJ, *see* Meric F
Papamichael D, *see* de Gramont A
Papnastasiou PA, *see* Nam RK
Pappa VI, *see* Apostolidis J
Pappo AS, *see* Spunt SL
Paradowski LJ, *see* Sood N
Paraschou P, *see* Roukos DH
Parham DM, *see* Wexler LH
Paridaens R, Biganzoli L, Bruning P, Klijn JGM, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M on Behalf of the European Organization for Research and Treatment of Cancer-Investigational Drug Branch for Breast Cancer/Early Clinical Studies Group. Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Can-

cer Randomized Study With Cross-Over, 724
Park CC, Mitsumori M, Nixon A, Recht A, Connolly J, Gelman R, Silver B, Hetelekidis S, Abner A, Harris JR, Schnitt SJ. Outcome at 8 Years After Breast-Conserving Surgery and Radiation Therapy for Invasive Breast Cancer: Influence of Margin Status and Systemic Therapy on Local Recurrence, 1668
Park IY, *see* Kim GE
Park KR, *see* Kim GE
Parker LM, *see* Burstein HJ
Parmar MKB, *see* Torri V
Parr B, *see* Khuri FR
Parra HS, *see* Santoro A
Parrish RS, *see* Godder KT
Partridge A, Mcmenamin M, Sugarbaker D. Nonmalignant Diagnoses in Patients; Case 2: Lung Cancer With Mediastinal Lymphadenopathy Due to Amyloidosis, 2636
Partridge A, Nasser S, Dzik S. Nonmalignant Diagnoses in Patients; Case 1: Mediastinal Lymphadenopathy Associated With Congestive Heart Failure, 2635
Parwaresch R, *see* Koch P
Pastan I, *see* Kreitman RJ
Pastrone I, *see* Venturini M
Patel SR, *see* Meric F
—*see* Pisters PWT
Patenaude AF, *see* Dorval M
Pater J, *see* Kirkbride P
Pathology Review Committee, *see* Nagtegaal ID
Pati AR, *see* Godder KT
Patnaik A, MacKinnon J, Goss P, Nagy T, Stewart K, Keating A, Crump M. Phase I/II Trial of Cyclophosphamide, Mitoxantrone, and Escalated Doses of Carboplatin Supported by Peripheral-Blood Stem Cells in Women With Metastatic Breast Cancer, 2363
Patnaik A, Rowinsky EK, Tammara BK, Hidalgo M, Drengler RL, Garner AM, Siu LL, Hammond LA, Felton SA, Mallikaarjun S, Von Hoff DD, Eckhardt SG. Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer, 3974
Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM. Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors, 3677
Patrick DL, *see* Moinpour CM
Paul C, *see* Tidefelt U
Paul J, *see* Mackay HJ
Paul MA, *see* von Mensdorff-Pouilly S
Pauletti G, Dandekar S, Rong HM, Ramos L, Peng HJ, Seshadri R, Slamon DJ. Assessment of Methods for Tissue-Based Detection of the HER-2/*neu* Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry, 3651
Paulussen M, *see* Cotterill SJ
Pautard B, *see* Michel G
Pautier P, *see* Boige V
Pavletic ZS, *see* Bishop MR
Pavlidis N, *see* Briasoulis E
Payne S, *see* Smith IC
Paz-Ares L, *see* Bellmunt J
Pazdur R, *see* Hoff PM; Nemunaitis J; Van Cutsem E
Pearson ADJ, *see* Estlin EJ; Thomas H
Pearson D, *see* Gutierrez M
Peck RA, *see* Marshall JL
Pecorelli S, *see* Piccart MJ
Pedicano JE, *see* Marshall JL
Pedrazzoli P, *see* Siena S
Peeters M, *see* Flamen P
Peethambaram P, *see* Adjei AA
Pegg AE, *see* Friedman HS
Pegram CN, *see* Cokgor I
Pellín A, *see* Cañete A
Pellizzaro C, *see* Coradini D
Pelzer H, *see* Vokes EE
Peng HJ, *see* Pauletti G
Penninga J, *see* Vicini FA
Penz M, Kurtaran A, Vorbeck F, Oberhuber G, Raderer M. Small Round-Cell Tumors; Case 2: Myocardial Metastases From a Carcinoid Tumor, 1596
Perea S, *see* Gomez-Martin C
Perego P, *see* Lavarino C
Perel Y, *see* Landman-Parker J
—*see* Michel G
Perez A, *see* Girinsky T
Perez C, *see* Nickerson HJ
—*see* Schmidt ML
Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children's Cancer Group Study, 18
Perez W, *see* Miller VA
Perez WS, *see* Davies SM
Pérez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, García-Conde J, Khayat D, Rivelles N. Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial, 2545
Perez-Soler R, *see* Nemunaitis J
Périé S, *see* Temam S
Perilongo G, *see* Pritchard J
Perkins AC, *see* Hughes ODM
Perkins SL, *see* Lones MA
Perpoint B, *see* Giacchetti S
Perroni D, *see* Amadori D
Perry A, *see* Smith JS
Pescarmona E, *see* Cingolani A
Peshkin B, *see* Matloff ET
Peshwa MV, *see* Small EJ
Pestalozzi BC, Brignoli S. Trastuzumab in CSF (correspondence), 2349
Peters GE, *see* Bonner JA
Peters GJ, *see* van Groeningen CJ
Peters WA III, Liu PY, Barrett RJ II, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix, 1606
Peterson B, *see* Hensley ML
Peterson G, *see* Markman M
Peterson HF, *see* Coates AS
Petit J-C, *see* Delozier T

Petrelli NJ, *see* Desch CE
Petrylak DP, *see* Hussain M
—*see* Small EJ
Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant Chemotherapy and Hormonal Therapy Followed by Radical Prostatectomy: Feasibility and Preliminary Results, 1050
Pfeilschifter J, Diel IJ. Osteoporosis Due to Cancer Treatment: Pathogenesis and Management, 1570
Pfister D, *see* Baselga J
—*see* Desch CE
—*see* Hensley ML
—*see* Hillner BE
Pham B, *see* Klaassen RJ
Philip T, *see* Blay J-Y
—*see* Frappaz D
—*see* Mille D
Phillips A, *see* Pritchard J
Phillips K-A, *see* Brezden CB
Phillips K-A. Immunophenotypic and Pathologic Differences Between *BRCA1* and *BRCA2* Hereditary Breast Cancers, 107s
Phillips PC, *see* Grotzer MA
Phipps S, *see* Leung W
Phipps S, Dunavant M, Srivastava DK, Bowman L, Mulhern RK. Cognitive and Academic Functioning in Survivors of Pediatric Bone Marrow Transplantation, 1004
Piantedosi F, *see* Frasci G
Pica A, *see* Beck MN
Piccaluga PP, *see* Zinzani PL
Piccart M, *see* Paridaens R
Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D, Van Glabbeke M, Lacombe D, Pinel M-C, Pecorelli S. Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology, 1193
Picci P, *see* Bacci G
Pich A, Margaria E, Chiusa L. Oncogenes and Male Breast Carcinoma: *c-erbB-2* and *p53* Coexpression Predicts a Poor Survival, 2948
Pichert G, Stahel RA for the Swiss Institute for Applied Cancer Research Network for Cancer Predisposition Testing and Counseling. Organizing Cancer Genetics Programs: The Swiss Model, 65s
Pico JL, *see* Girinsky T
Pidlich J, *see* Raderer M
Piedbois P, *see* Vanhoefer U
Pierce LJ, *see* Hayman JA
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, Gaffney D, Solin LJ, Nixon A, Garber J, Berg C, Isaacs C, Heimann R, Olopade OI, Haffty B, Weber BL. Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations, 3360
Pierce S, *see* Kantarjian HM
Pierconti F, *see* Cingolani A
Pierotti MA, *see* Lavarino C
Piers DA, *see* de Hullu JA
Pignon J-P, *see* Andre F
Pignon J-P, Ducreux M, Rougier P. More Patients Needed in Stage II Colon Cancer Trials (correspondence), 235
Pijpe J, *see* Plaat BEC
Pike MC, *see* McKean-Cowdin R
Pilepich M, *see* Valicenti R
Pileri S, *see* Zinzani PL
Pileri SA, *see* Zinzani PL
Pilotti S, *see* Lavarino C
Pinedo HM, *see* van Groeningen CJ
Pinel M-C, *see* Piccart MJ
Pinkerton R, *see* Thomas H
Pinotti G, *see* Carella AM
Piotrovsky VK, *see* Zujewski J
Pisansky TM, *see* Coia LR
Piscitelli G, *see* Kaufmann M
Pisters KMW, *see* Nemunaitis J
Pisters LL, *see* Pettaway CA
Pisters PWT, *see* Meric F
Pisters PWT, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB. Preoperative Chemoradiation for Patients With Pancreatic Cancer: Toxicity of Endobiliary Stents, 860
Pisters PWT, Pollock RE, Patel SR, Benjamin RS. In Reply (correspondence), 1800
Pitot HC, *see* Adjei AA
Pitt P, *see* Lønning PE
Piver MS. Maintenance Chemotherapy in Advanced Ovarian Cancer (correspondence), 1800
Pizzo B, *see* Miller VA
Pizzo PA, *see* Ozer H
Plaat BEC, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, Hoekstra HJ, van den Berg E, Scheper RJ, van der Graaf WTA. Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins, 3211
Plager C, *see* Meric F
Planker M, *see* Vanhoefer U
Plante M, *see* Hoskins P
Planting AST, *see* de Jonge MJA
Planting ASTh, *see* de Jonge MJA
Plaschkes J, *see* Pritchard J
Plouvier E, *see* Frappaz D
Pluda J, *see* Friedman HS
Pluda JM, *see* Baidas SM
—*see* Fine HA
—*see* Little RF
Plunkett W, *see* Kisor DF
Podgor M, *see* Conley B
Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I. Preliminary Results of a Randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy With 78 Gy for Prostate Cancer, 3904
Pollak M, *see* Nabholtz JM
Polli A, *see* Kaufmann M
—*see* Lønning PE
Pollock BH, DeBaun MR, Camitta BM, Shuster JJ, Ravindranath Y, Pullen DJ, Land VJ, Mahoney DH Jr, Lauer SJ, Murphy SB. Racial Differences in the Survival of Childhood B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study, 813
Pollock RE, *see* Meric F
—*see* Pisters PWT

Poon RT-P, Fan S-T, Lo C-M, Liu C-L, Ng IO-L, Wong J. Long-Term Prognosis After Resection of Hepatocellular Carcinoma Associated With Hepatitis B-Related Cirrhosis, 1094
Popescu RA, *see* Foran JM
Porcu P, *see* Bhatia S
Porcu P, Bhatia S, Sharma M, Einhorn LH. Results of Treatment After Relapse From High-Dose Chemotherapy in Germ Cell Tumors, 1181
Poremba C, Scheel C, Hero B, Christiansen H, Schaefer K-L, Nakayama J-i, Berthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B. Telomerase Activity and Telomerase Subunits Gene Expression Patterns in Neuroblastoma: A Molecular and Immunohistochemical Study Establishing Prognostic Tools for Fresh-Frozen and Paraffin-Embedded Tissues, 2582
Porteus MH, Narkool P, Neuberg D, Guthrie K, Breslow N, Green DM, Diller L. Characteristics and Outcome of Children With Beckwith-Wiedemann Syndrome and Wilms' Tumor: A Report From the National Wilms Tumor Study Group, 2026
Possinger K, *see* Sezer O
Postmus PE, *see* Huisman C
Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJM, Karnicka H, Lewinski T, van Meerbeeck J, Clerico M, Gregor A, Curran D, Sahmoud T, Kirkpatrick A, Giaccone G. Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group, 3400
Poterre M, *see* Fizazi K
Potters L, Torre T, Ashley R, Leibel S. Examining the Role of Neoadjuvant Androgen Deprivation in Patients Undergoing Prostate Brachytherapy, 1187
Pouillart P, *see* Stoppa-Lyonnet D
Poulsen M, *see* O'Brien P
Powles RL, *see* Davies SM
Powles TJ, *see* Eeles RA
Prados M, *see* Osoba D
Pratt CB, *see* Estlin EJ
Pratt G, *see* O'Brien P
Prendergast MM, *see* Cagnoni PJ
Prentice HG, *see* Davies SM
Presant CA, Wolf W, Waluch V, Wiseman CL, Weitz I, Shani J. Enhancement of Fluorouracil Uptake in Human Colorectal and Gastric Cancers by Interferon or by High-Dose Methotrexate: An in Vivo Human Study Using Noninvasive ^{19}F-Magnetic Resonance Spectroscopy, 255
Preston-Martin S, *see* Formenti SC
Preudhomme C, *see* Morschhauser F
Price K, *see* Colleoni M
Price KN, *see* Colleoni M
—*see* Crivellari D
Price L, *see* Thomas H
Price MR, *see* Hughes ODM
Prindiville S, *see* Conley B
Prins MH, *see* Hutten BA
Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, Doxorubicin, and Delayed Surgery for Childhood Hepatoblastoma: A Successful Approach–Results of the First Prospective Study of the International Society of Pediatric Oncology, 3819
Pritchard KI, *see* Norris B
Pritchett J, *see* Henrickson KJ
Proba J, *see* Schmidt M
Proia AD, *see* Morse MA
Provenzale JM, *see* Cokgor I
—*see* Friedman HS
Pui C-H, *see* Leung W
—*see* Sandlund JT
—*see* Woo MH
Pujol JL, *see* Andre F
Pukkala E, *see* Holli K
—*see* Metayer C
Pullen DJ, *see* Pollock BH
Putnam JB, *see* Nemunaitis J

Qian W, *see* Thatcher N
Qualman SJ, *see* Baker KS
Quella SK, *see* Loprinzi CL
Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ. Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial, 1068
Quinn JA, *see* Friedman HS
Quinn JJ, *see* Ortega JA
Quinn M, *see* Takimoto CH
Quinn MG, *see* Grem JL
Quoc SN, *see* Guermazi A
Quoix E, *see* Andre F

Raafat F, *see* Mann JR
Rabinowitz I, *see* Carr KM
Raderer M, *see* Penz M
Raderer M, Kurtaran A, Leimer M, Angelberger P, Niederle B, Vierhapper H, Vorbeck F, Hejna MHL, Scheithauer W, Pidlich J, Virgolini I. Value of Peptide Receptor Scintigraphy Using ^{123}I-Vasoactive Intestinal Peptide and ^{111}In-DTPA-D-Phe^{1}-Octreotide in 194 Carcinoid Patients: Vienna University Experience, 1993 to 1998, 1331
Radford JA, *see* Foran JM
—*see* Vose JM
Raghavan D, *see* Kaufman D
Rahilly M, *see* Mackay HJ
Raijman I, *see* Pisters PWT
Raisch KP, *see* Bonner JA
Ramaekers FCS, *see* van Oostenbrugge RJ
—*see* Veltman JA
Ramlau R, *see* Shepherd FA
Rammou D, *see* Briasoulis E
Ramos L, *see* Pauletti G
Ramsay NKC, *see* Davies SM
Ramsey MM, *see* Bennett CL
Randolph J, *see* Hoff PM
Rao U, *see* Kirkwood JM
Raphael BG, *see* Hochster HS
Rapoport B, *see* Klastersky J
Ras GJ, *see* Bontenbal M
Ratain MJ, *see* Venook AP
Ratzinger G, *see* Baggers J
Ravaioli A, *see* Amadori D

Ravaud A, *see* Capuron L
Ravindranath Y, *see* Pollock BH
Ravoet C, *see* Wijermans P
Rawstron AC, *see* Davies FE
Ray I, *see* Mille D
Ray-Coquard I, *see* Blay J-Y
Raymond E, *see* Boige V
Raynaud F, *see* Waters JS
Razzouk BI, *see* Leung W
Reaman GH, *see* Heerema NA
—*see* Ozkaynak MF
Rebbeck TR, *see* Eisen A
Rebbeck TR. Prophylactic Oophorectomy in *BRCA1* and *BRCA2* Mutation Carriers, 100s
Recht A, *see* Park CC
Redman B, *see* Trask PC
Redman BG, *see* Small EJ
Reed N, *see* Piccart MJ
Reed WP Jr, *see* Chen EA
Reese D, *see* Roach M III
Reese DM, *see* Small EJ
Regan DH, *see* Beveridge RA
Reich L, *see* Motzer RJ
Reid JM, *see* Adjei AA
Reimer T, *see* Gerber B
Reinhard H, *see* Schneider DT
Reinhart T, *see* Cohn SL
Reiser M, *see* Josting A
Reisfeld RA, *see* Foon KA
—*see* Ozkaynak MF
Relling MV, *see* Woo MH
Remick SC, *see* Levitan N
Renshaw AA, *see* D'Amico AV
Retalis G, *see* Koukourakis MI
Rey A, *see* von Pawel J
Reyes F, *see* Foran JM
—*see* Haioun C
Reyno LM, *see* Small EJ
Reynolds CP, *see* Seeger RC
Reynolds JA, *see* Green DM
Reynolds M, *see* Ortega JA
Riba M, *see* Trask PC
Ribaud P, *see* Yakoub-Agha I
Ribeiro R, *see* Sandlund JT
Ribeiro RC, *see* Leung W
—*see* Woo MH
Ricciuti F, *see* Zinzani PL
Rice TW, *see* Adelstein DJ
Rich JN, *see* Friedman HS
Rich TA, *see* Pisters PWT
Richards J, *see* Kirkwood JM
Richards S, *see* Davies FE
Richardson G, *see* von Pawel J
Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology, 2505
Richie JP, *see* D'Amico AV
Richli WR, *see* Nemunaitis J
Richmond E, *see* Marshall JL
Riedl L, *see* Königsberg R
Rigolin GM, *see* Cuneo A
Rimondini S, *see* Bacci G
Rini BI. Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II Trial of Weekly Intravenous Gemcitabine With Continuous Infusion Fluorouracil in Patients With Metastatic Renal Cell Cancer, 2419
Rios MB, *see* Kantarjian HM
Risse M-L, *see* Couteau C
Riva A, *see* Couteau C
Rivelles N, *see* Pérez-Manga G
Rivera GK, *see* Woo MH
Rivera-Luna R, Cardenas-Cardos R, Leal-Leal C, Meza-Coria C. Leukemia in Mexican Versus Mexican-American Children (correspondence), 2349
Rivkin S, *see* Patnaik A
Rixe O, *see* Boige V
Rizzardini G, *see* Nasti G
Rizzo J, *see* Rowinsky EK
Roach M III, Reese D, Weinberg V, Small EJ, Carroll PR. Is the Use of Anti-Androgen Monotherapy Appropriate in Patients With Advanced Prostate Cancer? (correspondence), 445
Robert A, *see* Landman-Parker J
Robert F, *see* Bonner JA
Robert NJ, *see* Simpson JF
Roberti MG, *see* Cuneo A
Roberts JT, *see* von der Maase H
Robertson JFR, *see* Bonneterre J
Robertson L, *see* Bennett CL
Robinet G, *see* Gatzemeier U
Robinson K, *see* Mann JR
Robson M. Are *BRCA1*- and *BRCA2*-Associated Breast Cancers Different? Prognosis of *BRCA1*-Associated Breast Cancer, 113s
Roché H, *see* Macquart-Moulin G
Rock MJ, *see* Wunder JS
Rodenhuis S, *see* Le Cesne A
Rodgers A, *see* Norris B
Rodriguez G, *see* Hidalgo M
Rodriguez M, *see* Gomez-Martin C
—*see* Rose PG
Rodriguez S, *see* Elting LS
Rodriguez-Peralto JL, *see* Castellano D
Rogers R, *see* Verschraegen CF
Roh JK, *see* Kim GE
Rohatiner AZ, *see* Vose JM
Rohatiner AZS, *see* Apostolidis J
—*see* Foran JM
—*see* Micallef INM
Roila F, Del Favero A, Ballatori E. Docetaxel as Second-Line Chemotherapy for Non–Small-Cell Lung Cancer (correspondence), 3738
Rollinson SJ, *see* Davies FE
Rolston K, *see* Elting LS
—*see* Klastersky J
Roman E, *see* Davies FE
Romanelli A, *see* Carella AM
Romeo D, *see* Boccardo F
Römer W, *see* Schelling M
Romero A, *see* Castellano D
Ronconi F, *see* Zinzani PL
Ronconi S, *see* Martinelli G
Rong HM, *see* Pauletti G

Roos D, *see* O'Brien P
Rorke L, *see* Thomas PRM
Rorke LB, *see* Grotzer MA
Rosales R, *see* Gordon AN
Rose PG, *see* Gordon AN
Rose PG, Rodriguez M, Waggoner S, Greer BE, Horowitz IR, Fowler JM, McGuire WP. Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study, 2957
Rosé CA, *see* Avril N
Rosen DM, *see* Fracasso PM
Rosen I, *see* Pollack A
Rosen S, *see* Siegel RS
Rosen ST, *see* Pandolfino TL
Rosenberg J, *see* Davis TA
Rosenberg SA, *see* Lindsey KR
Rosenblum J, *see* Ejadi S
Rosendaal FR, *see* Weijl NI
Rosenfeld-Darling M, *see* Sekeres M
Rosing H, *see* Malingré MM
Roskos L, *see* Johnston E
Rosmarin AG, *see* Beckwith C
Rosner GL, *see* Venook AP
Ross AA, *see* Grupp SA
Ross G, *see* de Jonge MJA
Ross MI, *see* Breslin TM
Ross PJ, Hill ME, Norman A, Cunningham D. ECF in Gastric Cancer (correspondence), 3874
Ross RK, *see* McKean-Cowdin R
Rossi A, *see* Amadori D
Rossi J-F, *see* Négrier S
Rosso R, *see* Venturini M
Roth BJ, *see* Dreicer R
Roth J, *see* Nemunaitis J
Rothenberg LN, *see* Schwartz LH
Rothenberg ML, *see* Nelson AR
Rougier P, *see* Couteau C
—*see* Pignon J-P
—*see* Vanhoefer U
—*see* Wilke H
Roukos DH, Paraschou P. Adjuvant Chemotherapy in Gastric Cancer (correspondence), 3061
Rourke MT, *see* Hobbie WL
Rousseau P. Death Denial, 3998
Rousseau P. Spirituality and the Dying Patient, 2000
Rousselot P, *see* Guermazi A
—*see* Morschhauser F
Rowinsky E, *see* Bonomi P
Rowinsky EK, *see* Baker SD
—*see* Eckhardt SG
—*see* Gallo JM
—*see* Hidalgo M
—*see* Patnaik A
Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG. Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies, 178
Rowinsky EK, Johnson TR, Geyer CE Jr, Hammond LA, Eckhardt SG, Drengler R, Smetzer L, Coyle J, Rizzo J, Schwartz G, Tolcher A, Von Hoff DD, De Jager RL. DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies, 3151
Rowland JH, *see* Bower JE
—*see* Cheng JD
—*see* Green BL
Rowlings PA, *see* Socié G
Roy T, *see* Mille D
Roy V, *see* Fisher RI
Roychowdhury DF, *see* von der Maase H
Rozenblat Z, *see* Small EJ
Rubagotti A, *see* Boccardo F
Rubenstein EB, *see* Elting LS
—*see* Klastersky J
Rubin E, *see* Kamen BA
Rubin J, *see* Adjei AA
Rubinov R, *see* Israel O
Rubnitz JE, *see* Leung W
—*see* Woo MH
Ruccione K, *see* Hobbie WL
Ruckdeschel JC, *see* Bennett CL
Rudat V, *see* Brizel DM
Rudd RM, *see* Steele JPC
Rudenstam C-M, *see* Colleoni M
—*see* Crivellari D
Rudinskas L, *see* Norris B
Rueffer U, *see* Josting A
Ruffié P, *see* Couteau C
—*see* Fizazi K
Ruggieri P, *see* Bacci G
Ruka W, *see* Verweij J
Runne MA, *see* Meinardi MT
Runowicz CD. Gynecologic Surveillance of Women on Tamoxifen: First Do No Harm (editorial), 3457
Russell I, *see* Lokhorst HM
Russell L, *see* Brizel DM
Russell P, *see* Nieto Y
Russo G, *see* Cuneo A
Russo P, *see* Motzer RJ
Rustin GJS, *see* Newlands ES
Rustin GJS, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials, 1733
Rutherford R, *see* Hughes ODM
Rutten MFJ, *see* Weijl NI
Ryan A, *see* Moinpour CM
Ryan L, *see* Harris JE
Rybicki LA, *see* Adelstein DJ

Saad ED, *see* Hoff PM
Sabbatini R, *see* Federico M
Sabbatini R, Federico M, Morselli M, Depenni R, Cagossi K, Luppi M, Torelli G, Silingardi V. Detection of Circulating Tumor Cells by Reverse Transcriptase Polymerase Chain Reaction of Maspin in Patients With Breast Cancer Undergoing Conventional-Dose Chemotherapy, 1914
Sabbioni S, *see* Cuneo A
Sadaniantz A, *see* Beckwith C
Saeki T, *see* Kurata T

Sáenz A, *see* Bellmunt J
Sahin A, *see* Breslin TM
Sahmoud T, *see* Postmus PE
Saigo PE, *see* Barakat RR
Saijo N, *see* Yamamoto N
Saito T, *see* Toyoda Y
Saka H, *see* Masuda N
Salam A, *see* Apostolidis J
—*see* Micallef INM
Salazar R, *see* Gomez-Martin C
Saleh M, *see* Vose JM
Saleh MN, *see* Bonner JA
Saleh MN. In Reply (correspondence), 4000
Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, LoBuglio AF. Phase I Trial of the Anti-Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y-Expressing Epithelial Tumors, 2282
Salem R, *see* Heath EI
Salgia RJ, *see* Galsky M
Salles G, *see* Haioun C
—*see* Voog E
Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H, Eskelinen M, Härkönen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Järvinen H, Mecklin J-P, Aaltonen LA, De La Chapelle A. Population-Based Molecular Detection of Hereditary Nonpolyposis Colorectal Cancer, 2193
Salvati F, *see* Gatzemeier U
Salwen HR, *see* Cohn SL
Salzberger B, *see* Josting A
Samantas E, *see* Briasoulis E
Sambrook RJ, *see* Thatcher N
Sampson J, *see* Friedman HS
Sanchez-Rovira P, *see* von der Maase H
Sandberg EA, *see* Earle CC
Sandercock J, *see* Torri V
Sanders J, *see* Socié G
Sanders T, *see* Richardson MA
Sandler A. In Reply (correspondence), 2788
Sandler AB, Nemunaitis J, Denham C, Von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH. Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer, 122
Sandlund JT, Murphy SB, Santana VM, Behm F, Jones D, Berard CW, Furman WL, Ribeiro R, Crist WM, Greenwald C, Chen G, Walter A, Pui C-H. CNS Involvement in Children With Newly Diagnosed Non-Hodgkin's Lymphoma, 3018
Sandlund JT, *see* Leung W
—*see* Woo MH
Santana VM, *see* Sandlund JT
Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V. Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study, 2615
Santos VR, *see* DiPersio JF
Sardi A, *see* McMasters KM
Sartore-Bianchi A, *see* Siena S
Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized Trial of Omeprazole or Ranitidine Versus Placebo in the Prevention of Chemotherapy-Induced Gastroduodenal Injury, 463
Sartorius SE, *see* Baker SD
Sasaki CT, *see* Smith BD
Sastre A, *see* Marco F
Sather HN, *see* Heerema NA
—*see* Mattano LA Jr
Sato T, *see* Toyoda Y
Sattler D, *see* Schelling M
Sauer R, *see* Brizel DM
Sauerbrei W, *see* Schmoor C
Sauerbrei W, Bastert G, Bojar H, Beyerle C, Neumann RLA, Schmoor C, Schumacher M for the German Breast Cancer Study Group. Randomized 2 X 2 Trial Evaluating Hormonal Treatment and the Duration of Chemotherapy in Node-Positive Breast Cancer Patients: An Update Based on 10 Years' Follow-Up, 94
Savarese D, Al-Zoubi A, Boucher J. Glutamine for Irinotecan Diarrhea (correspondence), 445
Sawka C, *see* Boon H
Saxton J, *see* Adelstein DJ
Scadden DT, *see* Tulpule A
Scadden DT. Epstein-Barr Virus, the CNS, and AIDS-Related Lymphomas: As Close as Flame to Smoke (editorial), 3323
Scambia G, *see* Lavarino C
Scardino PT, *see* Kattan MW
Scarfone G, *see* Lavarino C
Scarpi E, *see* Amadori D
Schaapveld M, *see* van Leeuwen FE
Schachter J, *see* Paridaens R
Schadendorf D, *see* Middleton MR
Schaefer K-L, *see* Poremba C
Schaefer PL, *see* Sparano JA
Schaison G, *see* Landman-Parker J
—*see* Michel G
Schapira L, Eisenberg PD, MacDonald N, Mumber MP, Loprinzi C. A Revisitation of 'Doc, How Much Time Do I Have?', 2640
Schattenberg A, *see* Lokhorst HM
Scheel C, *see* Poremba C
Scheib R, *see* Burstein HJ
Scheinberg DA, *see* Camacho LH
Scheithauer BW, *see* Smith JS
Scheithauer W, *see* Raderer M
Schell MJ, *see* Stark A
Schellens JHM, *see* Malingré MM
Schelling M, *see* Avril N
Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Jänicke F, Graeff H, Schwaiger M. Positron Emission Tomography Using [^{18}F]fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer, 1689
Scheper RJ, *see* Plaat BEC
Scher HI, *see* Zelefsky MJ
Schiavo R, *see* Siena S
Schiavone EM, *see* Ferrara F
Schiffer CA, *see* Hensley ML
—*see* Ozer H
Schildberg FW, *see* Allgayer H
Schiller G, *see* Davies SM
Schilsky RL, *see* Mani S
Schlom J, *see* Marshall JL

Schlosser NJJ, *see* Van Zandwijk N
Schmidt M, Hochhaus A, König-Merediz SA, Brendel C, Proba J, Hoppe GJ, Wittig B, Ehninger G, Hehlmann R, Neubauer A. Expression of Interferon Regulatory Factor 4 in Chronic Myeloid Leukemia: Correlation With Response to Interferon Alfa Therapy, 3331
Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK. Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children's Cancer Group Study, 1260
Schmoll H-J, *see* Vanhoefer U
Schmoor C, *see* Sauerbrei W
Schmoor C, Sauerbrei W, Bastert G, Schumacher M for the German Breast Cancer Study Group. Role of Isolated Locoregional Recurrence of Breast Cancer: Results of Four Prospective Studies, 1696
Schneider DT, Calaminus G, Reinhard H, Gutjahr P, Kremens B, Harms D, Göbel U. Primary Mediastinal Germ Cell Tumors in Children and Adolescents: Results of the German Cooperative Protocols MAKEI 83/86, 89, and 96, 832
Schneider KA, *see* Dorval M
Schneider P, *see* Michel G
Schnieden V, *see* Meiser B
Schnitt SJ, *see* Park CC
Schölmerich J, *see* Van Cutsem E
Schornagel JH, *see* Detmar SB
—*see* van Groeningen CJ
Schrag D, *see* Lu KH
Schramel F, *see* Van Zandwijk N
Schubiger PA, *see* Hughes ODM
Schuchter LM, *see* Hensley ML
Schuermann M, *see* Kersting M
Schuessler M, *see* Briasoulis E
Schuller M-P, *see* Blaise D
Schulman KA, *see* Cheng JD
—*see* Weaver CH
Schultz D, *see* D'Amico AV
Schultze W, *see* Sezer O
Schumacher M, *see* Sauerbrei W
—*see* Schmoor C
Schuster M, *see* Cagnoni PJ
Schuster MW, *see* DiPersio JF
Schwab G, *see* Johnston E
Schwaiger M, *see* Avril N; Schelling M
Schwandt P, *see* Empen K
Schwartz G, *see* Rowinsky EK
Schwartz L, *see* Zelefsky MJ
Schwartz LH, *see* Motzer RJ
Schwartz LH, Ginsberg MS, DeCorato D, Rothenberg LN, Einstein S, Kijewski P, Panicek DM. Evaluation of Tumor Measurements in Oncology: Use of Film-Based and Electronic Techniques, 2179
Scorilas A, *see* Nam RK
Scott C, *see* Del Rowe J
—*see* Glisson B
Seamans DP, Wong GY, Wilson JL. Interventional Pain Therapy for Intractable Abdominal Cancer Pain, 1598
Sebban C, *see* Haioun C
—*see* Tilly H
Seckl MJ, *see* Newlands ES
Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative Tumor Cell Content of Bone Marrow and Blood as a Predictor of Outcome in Stage IV Neuroblastoma: A Children's Cancer Group Study, 4067
Seeger RC, *see* Maris JM
—*see* Nickerson HJ
—*see* Ozkaynak MF
—*see* Perez CA
—*see* Schmidt ML
Sehested M, *see* Langer SW
Seibel N, *see* Cagnoni PJ
Seidman A, *see* Baselga J
Seiter S, *see* Middleton MR
Seitz J-F, *see* Van Cutsem E
Sekar K, *see* Nemunaitis J
Sekeres M, Vasconcelles MJ, Mcmenamin M, Rosenfeld-Darling M, Bueno R. Synovial Cell Sarcoma of the Lung, 2341
Sekine I, *see* Yamamoto N
Selch M, *see* Nickerson HJ
Senn H-J, *see* Colleoni M; Crivellari D
Sensel MG, *see* Heerema NA
—*see* Ortega JA
Seong C-M, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall P, Siciliano MJ, Champlin RE. Early Detection of Relapse by Hypermetaphase Fluorescence in Situ Hybridization After Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia, 1831
Sepucha KR, Belkora JK, Tripathy D, Esserman LJ. Building Bridges Between Physicians and Patients: Results of a Pilot Study Examining New Tools for Collaborative Decision Making in Breast Cancer, 1230
Seshadri R, *see* Bhatia S
—*see* Pauletti G
Sessa C, *see* Neijt JP
Sexton DJ, *see* Gopal AK
Seymour M, *see* de Gramont A
Seynaeve C, *see* Verhoog LC
—*see* Verweij J
Sezer O, Possinger K, Metzner B, Illiger H-J, Wattad M, Heit W, Fuss H, Schultze W. Optimal CD34+ Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation (correspondence), 3319
Sfikakis P, *see* Dimopoulos MA
Sgro C, *see* Chaplain G
Shafford E, *see* Pritchard J
Shafman TD, *see* Cokgor I
Shah M, *see* Gopal AK
Shahidi M, *see* Cornes PGS
Shalev M, *see* Lotan Y
—*see* Thaller C
Shamash J, *see* Steele JPC
Shamberger R, *see* Grupp SA
Shanahan TG, *see* Martenson JA
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal Predictors of Prostate Cancer: A Meta-Analysis, 847
Shani J, *see* Presant CA
Shapiro J, *see* Grem JL
Shapiro JD, *see* Takimoto CH
Shappell H, *see* Matloff ET
Sharma M, *see* Porcu P

Sharp PF, *see* Smith IC
Sharpington T, *see* Gordon AN
Shea K, *see* Tulpule A
Shearer P, *see* Leung W
Sheinfeld J, *see* Motzer RJ
—*see* Motzer RJ
Shek TW, *see* Au WY; Chim CS
Shen Q, *see* Siminoff LA
Shepherd FA. Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Modest Progress, Many Choices, 35s
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy, 2095
Shepherd FA, Hammershaimb L, Kim YS. In Reply (correspondence), 3738
Sherman JW, *see* DiPersio JF
Sherry RM, *see* Lindsey KR
Shibamoto Y, *see* Jeremic B
Shields CL, *see* Friedman DL
Shields CL, Shields JA, Meadows AT. Chemoreduction for Retinoblastoma May Prevent Trilateral Retinoblastoma (correspondence), 235
Shields JA, *see* Friedman DL
—*see* Shields CL
Shields PG, Harris CC. Cancer Risk and Low-Penetrance Susceptibility Genes in Gene-Environment Interactions, 2309
Shimada H, *see* Nickerson HJ
—*see* Perez CA
—*see* Schmidt ML
Shimada Y, *see* Kurata T
Shimizu A, *see* Akasaka T
Shin DM, *see* Nemunaitis J
Shina D, *see* Levitan N
Shinohara K, *see* Small EJ
Shitara T, *see* Toyoda Y
Shoemaker D, *see* Johnston E
Shpall EJ, *see* Nieto Y
Shulman LN, *see* Burstein HJ
Shumaker SA, *see* Moinpour CM
Shuster JJ, *see* Mahoney DH Jr
—*see* Pollock BH
Siamopoulos K, *see* Briasoulis E
Siciliano MJ, *see* Seong C-M
Siegel RS, *see* Pandolfino TL
Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts, 2908
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic Relevance of CD34+ Cell Dose in Blood Cell Transplantation for Cancer Therapy, 1360
Siena S, Schiavo R, Sartore-Bianchi A, Pedrazzoli P. In Reply (correspondence), 3320
Sigaux F, *see* Morschhauser F
Sikic BI, *see* Dahl GV
Silingardi V, *see* Federico M
—*see* Sabbatini R
Silver B, *see* Park CC
Silver G, *see* Spitler LE
Silver RT, *see* Hensley ML
Siminoff LA, Zhang A, Colabianchi N, Sturm CMS, Shen Q. Factors That Predict the Referral of Breast Cancer Patients Onto Clinical Trials by Their Surgeons and Medical Oncologists, 1203
Simmonds PD, *see* Gale J
Simon J, *see* Fandi A
Simoncini E, *see* Colleoni M; Crivellari D
Simoni R, *see* Zinzani PL
Simonitsch I, *see* Königsberg R
Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ. Prognostic Value of Histologic Grade and Proliferative Activity in Axillary Node-Positive Breast Cancer: Results From the Eastern Cooperative Oncology Group Companion Study, EST 4189, 2059
Singletary SE, *see* Breslin TM
—*see* Katz A
—*see* Richardson MA
Sinnett HD, *see* Smith BM
Sismondi P, *see* Boccardo F
Sittisomwong T, *see* Verschraegen CF
Siu L, *see* Eckhardt SG
Siu LL, *see* Patnaik A
Skarlos D, *see* Briasoulis E
Skibber J, *see* Hoff PM
Skillings J, *see* Norris B
Slade MJ, *see* Smith BM
Slamon DJ, *see* Pauletti G
Slaton J, *see* Pettaway CA
Slavin MB, *see* Crémieux P-Y
Sledge GW Jr, Hu P, Falkson G, Tormey D, Abeloff M for the Eastern Cooperative Oncology Group. Comparison of Chemotherapy With Chemohormonal Therapy as First-Line Therapy for Metastatic, Hormone-Sensitive Breast Cancer: An Eastern Cooperative Oncology Group Study, 262
Sleijfer DTh, *see* Meinardi MT
Slezak J, *see* Cheng L
Slichenmyer WJ, *see* Small EJ
Slingerland J, *see* Chappuis PO
Sloan JA, *see* Adjei AA
—*see* Jatoi A
—*see* Martenson JA
—*see* Quella SK
Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL. Sex Differences in Fluorouracil-Induced Stomatitis, 412
Sluiter WJ, *see* Meinardi MT
Small EJ, *see* Hussain M
—*see* Roach M III
Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells, 3894
Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer, 3595
Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED. Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional-Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point, 2537
Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB,

Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone, 1440
Small JM, *see* Muggia FM
Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia, 1758
Smart T, *see* Zelefsky MJ
Smetzer L, *see* Rowinsky EK
Smit EF, *see* Huisman C; Postmus PE; Van Zandwijk N
Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic Significance of Vascular Endothelial Growth Factor Protein Levels in Oral and Oropharyngeal Squamous Cell Carcinoma, 2046
Smith BM, Slade MJ, English J, Graham H, Lüchtenborg M, Sinnett HD, Cross NCP, Coombes RC. Response of Circulating Tumor Cells to Systemic Therapy in Patients With Metastatic Breast Cancer: Comparison of Quantitative Polymerase Chain Reaction and Immunocytochemical Techniques, 1432
Smith C, *see* Eckhardt SG
Smith CD, *see* Katz A
Smith GL, *see* Smith BD
Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF. Positron Emission Tomography Using [^{18}F]- Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy, 1676
Smith IE, Johnston SRD, O'Brien MER, Hickish TF, De Boer RH, Norton A, Cirkel DT, Barton CM. Low-Dose Oral Fluorouracil With Eniluracil as First-Line Chemotherapy Against Advanced Breast Cancer: A Phase II Study, 2378
Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas, 636
Smith L, *see* Rowinsky EK
Smith LG, *see* Pollack A
Smith M, *see* Fizazi K
Smith SL, *see* Eckhardt SG
Smith T, *see* Loprinzi CL
Smith TJ, *see* Desch CE
—*see* Hayes D
—*see* Hillner BE
—*see* Kirkwood JM
—*see* Ozer H
Smith TJ, Hillner BE. In Reply (correspondence), 1800
Smith TJ, Hillner BE. Tamoxifen Should Be Cost-Effective in Reducing Breast Cancer Risk in High-Risk Women, 284
Smith TJ. Tell It Like It Is, 3441
Smith TL, *see* Kantarjian HM
Snijdewint FGM, *see* von Mensdorff-Pouilly S
Sobocinski KA, *see* Socié G
Socie G, *see* Guermazi A
Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, Sullivan KM, Rowlings PA, Kingma DW, Banks PM, Travis WD, Witherspoon RP, Sanders J, Jaffe ES, Horowitz MM. New Malignant Diseases After Allogeneic Marrow Transplantation for Childhood Acute Leukemia, 348
Socié G, *see* Davies SM
—*see* Girinsky T
—*see* Morschhauser F
Soignet SL, *see* Camacho LH
Sokal M, *see* Mann JR
Solá C, *see* Gomez-Martin C
Solal-Celigny P, *see* Foran JM
—*see* Guermazi A
Solary E, *see* Harousseau JL
Solin LJ, *see* Pierce LJ
Somerfield MR, *see* Desch CE
—*see* Ozer H
Somers R, *see* van Leeuwen FE
Somlo G, *see* Ozer H
Sommer H, *see* Braun S
Sondak VK, *see* Kirkwood JM
Sondel PM, *see* Ozkaynak MF
Sood N, Bandarenko N, Paradowski LJ. Acute Respiratory Failure Secondary to Lymphangitic Carcinomatosis, 227
Soong SJ, *see* Spitler LE
Soong Y-K, *see* Chang T-C
Sorensen JM, *see* Rowinsky EK
Sørensen PG, *see* Neijt JP
Soria J-C, *see* Fizazi K
Sosman J, *see* Stadler WM
Souhami L, *see* Peters WA III
Souleau B, *see* Foran JM
Soussi T, *see* Cabelguenne A
Southern Italy Cooperative Oncology Group and Interregional Association for the Study of Lung Carcinoma–Italy, *see* Frasci G
Spanish Oncology Genitourinary Group, *see* Bellmunt J
Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colongy-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196, 2369
Sparreboom A, *see* de Jonge MJA
Späth H-M, *see* Mille D
Specchia G, *see* Ferrara F
Spector T, *see* Baker SD
Spencer SA, *see* Bonner JA
Sperone P, *see* Berruti A
Spertus I, *see* Green BL
Spiegelman D, *see* Holmes MD
Spielman M, *see* Alexandre J
Spielmann M, *see* Delozier T
Spillane A, Thomas JM. Misconceptions With Staging of Soft Tissue Sarcoma (correspondence), 1800
Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial Sarcoma: A Clinicopathologic, Staging, and Prognostic Assessment, 3794
Spinelli S, *see* Faulkner LB
Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ. Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor, 1614
Spitz MR, *see* Hong WK
Sposto R, *see* Gururangan S; Lones MA
Spunt SL, Pappo AS. Cyclophosphamide and Etoposide for Pediatric Solid Tumors (correspondence), 3741
Srivastava DK, *see* Leung W
—*see* Phipps S

Stack BC Jr, *see* Lowe VJ
Stackhouse MA, *see* Bonner JA
Stadler W, *see* Kaufman D
Stadler WM, *see* Rini BI
Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE. Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study, 371
Stagg RJ, *see* Vose JM
Stahel RA, *see* Pichert G
Stanley P, *see* Malogolowkin MH
—*see* Thomas PRM
Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ III, Liu ET, Conway K. HER-2/*neu* Amplification in Benign Breast Disease and the Risk of Subsequent Breast Cancer, 267
Stark D, *see* Lewis IJ
Starkschall G, *see* Pollack A
Statkevich P, *see* Middleton MR
Steele DA, *see* Malogolowkin MH
Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma, 3912
Steele M, *see* Kirkwood JM
Steensma DP. Submitting to Autonomy, 3736
Steer G, *see* Loprinzi CL
Stefoni V, *see* Zinzani PL
Steger M, *see* Verschraegen CF
Stehbens JA, *see* Thomas PRM
Steinberg M, *see* Bonneterre J
—*see* Nabholtz JM
Steinberg SM, *see* Gutierrez M
—*see* Little RF
Steinherz PG, *see* Heerema NA
Stenke L, *see* Tidefelt U
Stenson K, *see* Vokes EE
Stephan JL, *see* Frappaz D
Stephens RJ, *see* Hopwood P
—*see* Thatcher N
Stern DF, *see* Thor AD
Stern JW, *see* Grupp SA
Stern N, *see* Green BL
Stetler-Stevenson M, *see* Kreitman RJ
Steuber CP, *see* Mahoney DH Jr
Stevens M, *see* Thomas H
Stewart ES, *see* Friedman HS
Stewart K, *see* Patnaik A
Stewart M, *see* Boon H
St Guily JL, *see* Temam S
Stiegelis WF, *see* Bontenbal M
Stinson TJ, *see* Bennett CL
Stitt L, *see* Tai PTH
Stock RJ, *see* Peters WA III
Stockton P, *see* Green BL
Stone PW, *see* Earle CC
Stopfer J, *see* Dorval M
Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelénat H, Pouillart P, Vincent-Salomon A, Fourquet A for the Institut Curie Breast Cancer Group and Bernard Asselain. Familial Invasive Breast Cancers: Worse Outcome Related to *BRCA1* Mutations, 4053
Storm H, *see* Metayer C
Storm MC, *see* Woo MH
St Peter M, *see* Morse MA
Stracks J, *see* List MA
Straetmans N, *see* Morschhauser F
Stram DO, *see* Maris JM
—*see* Nickerson HJ
—*see* Perez CA
—*see* Schmidt ML
—*see* Seeger RC
Straneo M, *see* Venturini M
Strang G, *see* Small EJ
Strawderman M, *see* Pierce LJ
Strickland DK, *see* Leung W
Stringer SP, *see* Mendenhall WM
Strnad V, *see* Brizel DM
Strom EA, *see* Katz A
Stromberg JS, *see* Kestin LL
Stroobants S, *see* Flamen P
Stuart G, *see* Hoskins P
Stuart RK, *see* Harris JE
Stuber M, *see* Hobbie WL
Study Section on Infections of Mulitnational Association for Supportive Care in Cancer, *see* Klastersky J
Stump E, *see* Swanson G
Sturm CMS, *see* Siminoff LA
Su L-K, *see* Frazier ML
Sugarbaker D, *see* Partridge A
Sugarman S, *see* Madajewicz S
—*see* Saleh MN
Sugiura T, *see* Masuda N
Suh CO, *see* Kim GE
Sullivan KM, *see* Socié G
Sullivan P, *see* List MA
Sulman EP, *see* Maris JM
Sulzen L, *see* Vokes EE
Summers KE, *see* Apostolidis J
Sun A, *see* Kirkbride P
Sundman-Engberg B, *see* Tidefelt U
Sutherland W, *see* Alexandre J
Suthers G, *see* Meiser B
Sutton G, *see* Muggia FM
Sutton L, *see* Blaise D
—*see* Yakoub-Agha I
Sutton LN, *see* Grotzer MA
Sutton T, *see* Bennett CL
Swan D, *see* Quella SK
Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET. Growth Factor Usage Patterns and Outcomes in the Community Setting: Collection Through a Practice-Based Computerized Clinical Information System, 1764
Swanson G, Stump E. In Reply (correspondence), 3321
Swantkowski J, *see* Seong C-M
Swart M, *see* Malingré MM
Swart MS, *see* van Groeningen CJ
Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, Einhorn LH. Results and Outcome of Retroperitoneal Lymph Node Dissection for Clinical Stage I Embryonal Carcinoma-Predominant Testis Cancer, 358
Sweetenham JW, *see* Gale J

Sweitzer NK, *see* Oh WK
Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC. Risk of Second Malignancy After Hodgkin's Disease in a Collaborative British Cohort: The Relation to Age at Treatment, 498
Swisher SG, *see* Nemunaitis J
Swiss Institute for Applied Cancer Research Network for Cancer Predisposition Testing and Counseling, *see* Pichert G
Sylvester R, *see* Paridaens R
Syngal S. Hereditary Nonpolyposis Colorectal Cancer: A Call for Attention (editorial), 2189
Szatrowski TP, *see* Hensley ML
Szekely EM, *see* Koç ON

Taamma A, *see* Fandi A
Taber D, *see* Stadler WM
Taber DA, *see* Rini BI
Tadic L, *see* Jeremic B
Tai PTH, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, Gilchrist J. Chemotherapy in Neuroendocrine/merkel Cell Carcinoma of the Skin: Case Series and Review of 204 Cases, 2493
Tainer N, *see* Koç ON
Tait NS, *see* Zamboni WC
Takada M, *see* Masuda N
Takashima S, *see* Kurata T
Takeuchi M, *see* Nishihira H
Takimoto CH, *see* Grem JL
Takimoto CH, Morrison G, Harold N, Quinn M, Monahan BP, Band RA, Cottrell J, Guemei A, Llorens V, Hehman H, Ismail AS, Flemming D, Gosky DM, Hirota H, Berger SJ, Berger NA, Chen AP, Shapiro JD, Arbuck SG, Wright J, Hamilton JM, Allegra CJ, Grem JL. Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients, 659
Talamini MA, *see* Heath EI
Talamini R, *see* Nasti G
Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB III. Eastern Cooperative Oncology Group Phase I Trial of Protracted Venous Infusion Fluorouracil Plus Weekly Gemcitabine With Concurrent Radiation Therapy in Patients With Locally Advanced Pancreas Cancer: A Regimen With Unexpected Early Toxicity, 3384
Talbot D, *see* von Pawel J
Talcott J, *see* Klastersky J
Talmant P, *see* Le Gouill S
Talpaz M, *see* Kantarjian HM
Tamburini A, *see* Faulkner LB
Tammara BK, *see* Patnaik A
Tampellini M, *see* Berruti A
Tamura T, *see* Kurata T
—*see* Yamamoto N
Tan T-D, *see* Cheng SH
Tanaka Y, *see* Nishihira H
Tang SG-J, *see* Chang T-C
Tanguy ML, *see* Yakoub-Agha I
Tannock IF, *see* Brezden CB
Tannock IF. Commentary on 'Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949,' 39s
Tarabichi A, *see* Allgayer H
Tarantolo SR, *see* Bishop MR
Tassinari D, *see* Sartori S
Tate PS, *see* McMasters KM
Tavelin B, *see* Linderholm B
TAX 320 Non–Small-Cell Lung Cancer Study Group, *see* Fossella F
Tedeschi L, *see* Carella AM
Tefft M, *see* Baidas SM
Teitelbaum A, *see* Foon KA
Temam S, Flahault A, Périé S, Monceaux G, Coulet F, Callard P, Bernaudin J-F, St Guily JL, Fouret P. *p53* Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck, 385
Tendi E, *see* Trippoli S
ten Velde GPM, *see* Gatzemeier U
Tepper J. Refluxtions on Esophageal Cancer: Can We Swallow the Changes? (editorial), 453
Termeer A, *see* Van Zandwijk N
Terragna C, *see* Martinelli G
Terrier-Lacombe MJ, *see* Landman-Parker J
ter Steeg J, *see* de Jonge MJA
Terwogt JMM, *see* Malingré MM
Tesch H, *see* Santoro A
Testoni N, *see* Martinelli G
Thall P, *see* Seong C-M
Thaller C, Shalev M, Frolov A, Eichele G, Thompson TC, Williams RH, Dillioglugil O, Kadmon D. Fenretinide Therapy in Prostate Cancer: Effects on Tissue and Serum Retinoid Concentration, 3804
Thames HD, *see* Katz A
Thatcher N, *see* Middleton MR
Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ for the Medical Research Council Lung Cancer Working Party. Improving Survival Without Reducing Quality of Life in Small-Cell Lung Cancer Patients by Increasing the Dose-Intensity of Chemotherapy With Granulocyte Colony-Stimulating Factor Support: Results of a British Medical Research Council Multicenter Randomized Trial, 395
Theriault R, *see* Katz A
Thieblemont C, *see* Voog E
This P, Magdelanat H. Phytoestrogens and Adjuvant Endocrine Treatment of Breast Cancer (correspondence), 2788
Thomas H, Boddy AV, English MW, Hobson R, Imeson J, Lewis I, Morland B, Pearson ADJ, Pinkerton R, Price L, Stevens M, Newell DR. Prospective Validation of Renal Function–Based Carboplatin Dosing in Children With Cancer: A United Kingdom Children's Cancer Study Group Trial, 3614
Thomas JM, *see* Spillane AJ
Thomas PRM, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P, Albright L, Allen JC, Packer RJ, Linggood R, Mulhern R, Stehbens JA, Langston J, Stanley P, Duffner P, Rorke L, Cherlow J, Friedman HS, Finlay JL, Vietti TJ, Kun LE. Low-Stage Medulloblastoma: Final Analysis of Trial Comparing Standard-Dose With Reduced-Dose Neuraxis Irradiation, 3004
Thompson IM Jr, *see* Moinpour CM
Thompson J, *see* Nemunaitis J
Thompson PM, *see* Maris JM
Thompson S, *see* Fouladi M
Thompson TC, *see* Lotan Y
—*see* Thaller C
Thor AD, *see* Berry DA

—*see* Stark A
Thor AD, Liu S, Edgerton S, Moore D II, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/*neu*): A Study of Incidence and Correlation With Outcome in Breast Cancer, 3230
Thuret I, *see* Landman-Parker J
Thürlimann B, *see* Bonneterre J
—*see* Colleoni M
—*see* Crivellari D
Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, Stenke L, Elmhorn-Rosenborg A, Möllgård L, Lehman S, Xu D, Covelli A, Gustavsson B, Paul C. P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin in Vivo in Patients With P-Glycoprotein-Positive Acute Myeloid Leukemia, 1837
Tidmarsh GF, *see* Vose JM
Tieman M, *see* Koch P
Tienghi A, *see* Amadori D
Tijssen JGP, *see* Hutten BA
Tilgen W, *see* Middleton MR
Tilly H, *see* Haioun C
Tilly H, Mounier N, Lederlin P, Brière J, Dupriez B, Sebban C, Bosly A, Biron P, Nouvel C, Herbrecht R, Bordessoule D, Coiffier B for the Groupe D'Etudes Des Lymphomes De L'Adulte. Randomized Comparison of ACVBP and M-BACOD in the Treatment of Patients With Low-Risk Aggressive Lymphoma: The LNH87-1 Study, 1309
Timmons T, *see* Nemunaitis J
Tinaz A, *see* Fossati R
Tinaz A. In Reply (correspondence), 1392
Tintori V, *see* Faulkner LB
Tirelli U, *see* Nasti G
Tischkowitz MD, *see* Steele JPC
Tkaczuk K, *see* Nemunaitis J
Tkaczuk KH, *see* Zamboni WC
Todd A, *see* Zujewski J
Toi A, *see* Nam RK
Tolcher A, *see* Gelmon KA
—*see* Rowinsky EK
Tolcher AW. BR96-Doxorubicin: Been There, Done That! (correspondence), 4000
Tolino G, *see* Venturini M
Tomasic G, *see* Coradini D
Tomaszewski JE, *see* D'Amico AV
Tomlin I, *see* von der Maase H
Tondo A, *see* Faulkner LB
Tonelli D, *see* Verweij J
Tong KB, *see* Cagnoni PJ
Tong WP, *see* Motzer RJ
Tonita J, *see* Tai PTH
Toomey MA, *see* Marshall JL
Topazian M, *see* Heath EI
Torelli G, *see* Federico M
—*see* Sabbatini R
Tormey D, *see* Sledge GW Jr
Torn Broers GH, *see* Plaat BEC
Torre T, *see* Potters L
Torri V, Harper PG, Colombo N, Sandercock J, Parmar MKB. Paclitaxel and Cisplatin in Ovarian Cancer (correspondence), 2349
Tosato G, *see* Little RF
Tosi P, *see* Martinelli G
Tournilhac O, *see* Harousseau JL
Tourt-Uhlig S, *see* Friedman HS
Tovo PA, *see* Caselli D
Toyoda Y, *see* Nishihira H
Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, Ohara A, Ohkawa Y, Mori T, Ishimoto K, Sato T, Kaneko T, Maeda M, Koike K-I, Shitara T, Hoshi Y, Hosoya R, Tsunematsu Y, Bessho F, Nakazawa S, Saito T for the Acute Lymphoblastic Leukemia Committee of the Tokyo Children's Cancer Study Group. Six Months of Maintenance Chemotherapy After Intensified Treatment for Actue Lymphoblastic Leukemia of Childhood, 1508
Trachtenberg J, *see* Nam RK
Trask PC, Esper P, Riba M, Redman B. Psychiatric Side Effects of Interferon Therapy: Prevalence, Proposed Mechanisms, and Future Directions, 2316
Travis LB, *see* Metayer C
—*see* Socié G
Travis WD, *see* Socié G
Treat J, *see* von Pawel J
Trevisani L, *see* Sartori S
Trigg ME, *see* Mattano LA Jr
Tripathy D, *see* Sepucha KR
Trippoli S, Vaiani M, Messori A, Tendi E. Survival Gain in Cost-Effectiveness Studies (correspondence), 3318
Trojanowski JQ, *see* Grotzer MA
Troncoso P, *see* Pettaway CA
Tropé CG, *see* Baekelandt M
Trotter G, *see* O'Brien P
Trudeau M, *see* Norris B
Trummell HQ, *see* Bonner JA
Trunet PF, *see* Chaudri HA
Tsai C-S, *see* Chang T-C
Tsai SYC, *see* Cheng SH
Tsang KY, *see* Marshall JL
Tseng C-J, *see* Chang T-C
Tsokos M, *see* Wexler LH
Tsuchida M, *see* Toyoda Y
Tsunematsu Y, *see* Toyoda Y
Tubiana-Hulin M, *see* Lønning PE
Tucker K, *see* Meiser B
Tulikoura J, *see* Salovaara R
Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, Gill PS. Results of a Randomized Study of IM862 Nasal Solution in the Treatment of AIDS-Related Kaposi's Sarcoma, 716
Tura S, *see* Martinelli G
—*see* Zinzani PL
Turk PS, *see* McMasters KM
Turner RR, *see* Giuliano AE
Turner SL, *see* van Groeningen CJ
Tursz T, *see* Le Cesne A
Tuttle TM, *see* McMasters KM
Tuxen MK, *see* Neijt JP
Twaddell T, *see* Nemunaitis J
Twelves C, *see* Van Cutsem E
Twijnstra A, *see* van Oostenbrugge RJ
Tzamakou E, *see* Briasoulis E

Uchiyama T, *see* Akasaka T
Uckun FM, *see* Heerema NA
Uckun FM. In Reply (correspondence), 1392
Ueda C, *see* Akasaka T
Underhill C, *see* Basser RL
Unger JM, *see* Fisher RI
Unnithian J, Macklis R. Breast Cancer Radiotherapy: Safe for All? (correspondence), 4000
Uppsala Örebro Breast Cancer Study Group, *see* Liljegren G
Urias RE, *see* Martenson JA
Urtasun RC, *see* Del Rowe J

Vaccher E, *see* Nasti G
Vaiani M, *see* Trippoli S
Valavaara R, *see* Holli K
Valbonesi M, *see* Carella AM
Valentí V, *see* Gomez-Martin C
Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials, 2740
Valkamo E, *see* Salovaara R
Valone FH, *see* Small EJ
van Alphen RJ, *see* de Jonge MJA
van Besien K, Khouri I, Champlin R, McCarthy P. Allogeneic Transplantation for Low-Grade Lymphoma: Long-Term Follow-Up (correspondence), 702
van Beurden V, *see* de Jonge MJA
Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz J-F, Schölmerich J, Burger HU, Verweij J. Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study, 1337
Van Cutsem E, *see* Flamen P
—*see* Vanhoefer U
—*see* Wilke H
van den Berg E, *see* Plaat BEC
van den Berg MP, *see* Meinardi MT
Vandenberg T, *see* Norris B
van den Broek LCJM, *see* Elkhuizen PHM
van der Burg MEL, *see* de Jonge MJA
van der Graaf WTA, *see* Meinardi MT
—*see* Plaat BEC
van der Linden GHM, *see* Bontenbal M
van der Velden J, *see* Ong LML
van der Velden PC, *see* Bontenbal M
van der Zee AG, *see* Mourits MJ
van der Zee AGJ, *see* de Hullu JA
van de Velde CJH, *see* Elkhuizen PHM
—*see* Nagtegaal ID
van de Vijver MJ, *see* Elkhuizen PHM
Van Diest PJ, *see* von Mensdorff-Pouilly S
van Diest PJ, *see* de Hullu JA
Van Echo DA, *see* Zamboni WC
van Geel AN, *see* Bontenbal M
van Glabbeke M, *see* Verweij J
Van Glabbeke M, *see* Le Cesne A
—*see* Piccart MJ
van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G. Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid Tumors, 2772
van Heerde P, *see* van Leeuwen FE
Vanhoefer U, *see* Wilke H
Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll H-J, Bleiberg H, Nordlinger B, Couvreur M-L, Baron B, Wils JA. Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, 2648
Van Hoesel Q, *see* Le Cesne A
van Hoessel R, *see* Verweij J
van Houwelingen HC, *see* Neijt JP
Van Kamp GJ, *see* von Mensdorff-Pouilly S
van Krieken JHJM, *see* Nagtegaal ID
van Leeuwen FE, *see* Metayer C
van Leeuwen FE, Klokman WJ, Aleman BMP. In Reply (correspondence), 2185
van Leeuwen FE, Klokman WJ, Van't Veer MB, Hagenbeek A, Krol ADG, Vetter UAO, Schaapveld M, Van Heerde P, Burgers JMV, Somers R, Aleman BMP. Long-Term Risk of Second Malignancy in Survivors of Hodgkin's Disease Treated During Adolescence or Young Adulthood, 487
van Meerbeeck J, *see* Postmus PE
Vannozzi MO, *see* Venturini M
van Oers MHJ, *see* Lokhorst HM
van Oostenbrugge RJ, Hopman AHN, Arends JW, Ramaekers FCS, Twijnstra A. Treatment of Leptomeningeal Metastases Evaluated by Interphase Cytogenetics, 2053
Van Oosterom A, *see* Le Cesne A
van Putten WLJ, *see* Bontenbal M
Van Raemdonck D, *see* Flamen P
van Slooten H-J, *see* Elkhuizen PHM
van Tellingen O, *see* Malingré MM
van't Veer MB, *see* Metayer C
—*see* van Leeuwen FE
van Veldhuisen DJ, *see* Meinardi MT
Van Vreckem A, *see* Paridaens R
Van Zandwijk N, Smit EF, Kramer GWP, Schramel F, Gans S, Festen J, Termeer A, Schlosser NJJ, Debruyne C, Curran D, Giaccone G. Gemcitabine and Cisplatin as Induction Regimen for Patients With Biopsy-Proven Stage IIIA N2 Non–Small-Cell Lung Cancer: A Phase II Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955), 2658
Vargo JJ, *see* Adelstein DJ
Vasconcelles MJ, *see* Sekeres M
Vasen HFA. Clinical Diagnosis and Management of Hereditary Colorectal Cancer Syndromes, 81s
Vaskovic Z, *see* Jeremic B
Vaughn DJ, *see* Talamonti MS
vd Donk NWCJ, *see* Lokhorst HM
Vecchione F, *see* Lavarino C
Veerman G, *see* Briasoulis E
Veltman JA, Bot FJ, Huynen FC, Ramaekers FCS, Manni JJ, Hopman AHN. Chromosome Instability as an Indicator of Malignant Progression in Laryngeal Mucosa, 1644

Veltroni M, *see* Faulkner LB
Venkatraman E, *see* Barakat RR
Vennekotter DJ, *see* McMasters KM
Vennin P, *see* Delozier T
Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565, 2780
Venturini M, Lunardi G, Del Mastro L, Vannozzi MO, Tolino G, Numico G, Viale M, Pastrone I, Angiolini C, Bertelli G, Straneo M, Rosso R, Esposito M. Sequence Effect of Epirubicin and Paclitaxel Treatment on Pharmacokinetics and Toxicity, 2116
Venzon D, *see* Conley B
Verdaguer A, *see* Marco F
Verdiani S, *see* Carella AM
Verdonck LF, *see* Lokhorst HM
Vergote I, *see* Bonneterre J
—*see* Hoskins P
—*see* Piccart MJ
Verheijen RHM, *see* de Hullu JA
Verhoef G, *see* Wijermans P
Verhoog LC, Berns EMJJ, Brekelmans CTM, Seynaeve C, Meijers-Heijboer EJ, Klijn JGM. Prognostic Significance of Germline *BRCA2* Mutations in Hereditary Breast Cancer Patients, 119s
Vermorken J, *see* Hoskins P
Vernillet L, *see* de Jonge MJA; Gelmon KA
Veronesi A, *see* Colleoni M
—*see* Crivellari D
Versari M, *see* Bacci G
Verschraegen CF, Sittisomwong T, Kudelka AP, de Paula Guedes E, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ. Docetaxel for Patients With Paclitaxel-Resistant Müllerian Carcinoma, 2733
Verstraeten AA, *see* von Mensdorff-Pouilly S
Verweij J, *see* de Jonge MJA
—*see* Le Cesne A
—*see* Van Cutsem E
Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, Van Hoessel R, Seynaeve C, Di Paola ED, Van Glabbeke M, Tonelli D, Judson IR. Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 2081
Vescio R, *see* von Pawel J
Vetter UAO, *see* van Leeuwen FE
Viale M, *see* Venturini M
Viallet J, *see* von Pawel J
Vianelli N, *see* Martinelli G
Vicini FA, *see* Kestin LL
Vicini FA, Kestin LL, Goldstein NS, Chen PY, Penninga J, Frazier RC, Martinez AA. Impact of Young Age on Outcome in Patients With Ductal Carcinoma-In-Situ Treated With Breast-Conserving Therapy, 296
Vickers A, Christos P. Bezwoda: Evidence of Fabrication in Original Article (correspondence), 2933
Vickers A, Christos P. Re: 'Bezwoda: Evidence of Fabrication in Original Article' (correspondence), 3875
Viens P, *see* Alexandre J
—*see* Macquart-Moulin G
—*see* Négrier S
Vierhapper H, *see* Raderer M
Vietti TJ, *see* Thomas PRM
Villalona-Calero MA, *see* Eckhardt SG
—*see* Hidalgo M
Villaret DB, *see* Mendenhall WM
Vilque JP, *see* Harousseau JL
Vincent M, *see* Shepherd FA
—*see* Verschraegen CF
Vincent-Salomon A, *see* Stoppa-Lyonnet D
Vinci M, *see* Carella AM
Viola M, *see* Madajewicz S
Virgolini I, *see* Raderer M
Viscardi E, *see* Faulkner LB
Visser MRM, *see* Ong LML
Visseren-Grul CM, *see* von der Maase H
Viviani S, *see* Santoro A
Vogel V, *see* Bennett CL
Vogelzang NJ, *see* Rini BI
—*see* Stadler WM
Vokes E, *see* Fossella F
—*see* Gandara DR
Vokes EE, *see* List MA
—*see* Stadler WM
Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R, Dolan ME, Pelzer H, Sulzen L, Witt ME, Hsieh Y-C, Mittal BB, Weichselbaum RR. Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer, 1652
Volpi A, *see* Amadori D
von Borstel R, *see* Hidalgo M
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez-Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study, 3068
von Eschenbach AC, *see* Pollack A
von Euler M, *see* Bonneterre J; Nabholtz JM
Von Hoff DD, *see* Eckhardt SG
—*see* Hidalgo M
—*see* Monsky WL
—*see* Patnaik A
—*see* Rowinsky EK
von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FGM, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin, 574
von Pawel J, *see* Gatzemeier U
—*see* Sandler AB
von Pawel J, Von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group,

1351
von Roemeling R, *see* von Pawel J
Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski M-C, Coiffier B, Salles G. Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System, 325
Vorbeck F, *see* Penz M
—*see* Raderer M
Vos A, *see* Pritchard J
Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS. Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas, 1316
Voûte PA, *see* Cotterill SJ
Vowels M, *see* Davies SM

Wade JC, *see* Ozer H
Wade JL III, *see* Ozer H
—*see* Rini BI
Waggoner S, *see* Rose PG
Wagner H, *see* Glisson B
Wagner HM, *see* Blank C
Wahl RL, *see* Vose JM
Waikar S, *see* Smith IC
Wait J, *see* Nemunaitis J
Wakasugi H, *see* Kurata T
Waksal H, *see* Baselga J
Waksal HW, *see* Bonner JA
Waldmann TA, *see* Kreitman RJ
Walker R, *see* Briasoulis E
Walker S, *see* Dawson LA
Walsh GL, *see* Khuri FR
—*see* Nemunaitis J
Walsh TJ, *see* Cagnoni PJ
Walter A, *see* Fouladi M
—*see* Sandlund JT
Walter S, *see* Giacchetti S
Waluch V, *see* Presant CA
Wanders J, *see* Briasoulis E
Wang B, *see* Woo MH
Ware JE Jr, *see* Moinpour CM
Warner E, *see* Patnaik A
Warrell RP Jr, *see* Camacho LH
Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM. Proton Magnetic Resonance Spectroscopic Imaging in Children With Recurrent Primary Brain Tumors, 1020
Warzocha K, *see* Voog E
Wasserman TH, *see* Brizel DM
Wastie ML, *see* Hughes ODM
Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, Di Stefano F, Cotter FE. Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma, 1812
Wattad M, *see* Sezer O
Wattel E, *see* Yakoub-Agha I
Watterson J, *see* Hilden JM
Weaver CH, *see* Mani S
Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized Trial of Filgrastim, Sargramostim, or Sequential Sargramostim and Filgrastim After Myelosuppressive Chemotherapy for the Harvesting of Peripheral-Blood Stem Cells, 43
Weaver RL, *see* Davis TA
Webb A, *see* Waters JS
Weber B, *see* Delozier T
Weber BL, *see* Dorval M
—*see* Eisen A
—*see* Pierce LJ
Weber W, *see* Avril N
Webster A, *see* Bonneterre J
—*see* Nabholtz JM
Webster K, *see* Markman M
Weeden S, *see* Lewis IJ
Weeks JC, *see* Hayman JA
—*see* Hillner BE
—*see* Lee SJ
—*see* Ng AK
Weeks JC. In Reply (correspondence), 942
Weichselbaum RR, *see* Vokes EE
Weijl NI, Rutten MFJ, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, Cleton FJ, Osanto S. Thromboembolic Events During Chemotherapy for Germ Cell Cancer: A Cohort Study and Review of the Literature, 2169
Weill D, *see* Nemunaitis J
Wein A, *see* D'Amico AV
Weinberg V, *see* Roach M III
Weiner RS, *see* Bennett CL
Weinstein HJ, *see* Dahl GV
—*see* Grupp SA
Weisdorf DJ, *see* Davies SM
Weiss G, *see* Hidalgo M
Weiss J, *see* Middleton MR
Weiss MJ, *see* Maris JM
Weissman C, *see* Gordon AN
Weitman S, *see* Eckhardt SG
Weitz I, *see* Presant CA
Weitzman S, *see* Barr RD
Welch AE, *see* Smith IC
Welch WR, *see* Lu KH
Welles L, *see* Little RF
Wen PY, *see* Fine HA
Werner M, *see* Schelling M
Werner-Wasik M, *see* Del Rowe J
Wersall P, *see* von der Maase H
West W, *see* Weaver CH
Westeel V, *see* Andre F
Westervelt P, *see* Fracasso PM
Wetzler M, Lincoff N. Unusual Manifestations of Acute Leukemia; Case 3: Unilateral Leukemic Hypopyon, 3439
Wever LDV, *see* Detmar SB
Wexler LH, Meyer WH, Parham DM, Tsokos M. Neural Differentiation and Prognosis in Peripheral Primitive Neuroectodermal Tumor (correspondence), 2185
Wheeler TM, *see* Lotan Y
Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? a Meta-Analysis, 1220
Whitaker T, *see* Smith IC

Whitby D, *see* Little RF
White CA, *see* Davis TA
White JD, *see* Kreitman RJ
White PS, *see* Maris JM
White R, *see* Mani S
Whittington R, *see* D'Amico AV
—*see* Talamonti MS
WHO Myeloid Disease Writing Committees, WHO Clinical Advisor Committee. In Reply (correspondence), 3447
Wibault P, *see* Fandi A
Wicha MS, *see* Bennett CL
Wieand S. In Reply (correspondence), 942
Wieczorek TJ, *see* Krop IE
Wiener ES, *see* Baker KS
Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A. Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients, 956
Wiklund T, *see* Metayer C
Wikstrand CJ, *see* Cokgor I
Wildiers J, *see* Paridaens R
Wilding G, *see* Dreicer R
—*see* Motzer RJ
Wiley J, *see* Davies SM
Wilke H, *see* Vanhoefer U
Wilke H, Vanhoefer U, Rougier P, Nordlinger B, Van Cutsem E, Wils JA, Baron B. In Reply (correspondence), 4001
Wilking N, *see* Linderholm B
Willemse PBH, *see* Meinardi MT
Willemse PH, *see* Mourits MJ
Willett CG, *see* Coia LR
Willett WC, *see* Holmes MD
Willgeroth F, *see* Braun S
Williams J, *see* Horning SJ
Williams N, *see* Mokbel K
Williams R, *see* Lotan Y
—*see* Morse MA
Williams RH, *see* Thaller C
Willich N, *see* Koch P
Wils JA, *see* Vanhoefer U
—*see* Wilke H
Wilson C, *see* de Gramont A
Wilson JF, *see* Lones MA
Wilson JL, *see* Seamans DP
Wilson-Relyea B, *see* Weaver CH
Wilson WH, *see* Gutierrez M
—*see* Kreitman RJ
Winer EP, *see* Baidas SM
—*see* Burstein HJ
—*see* Hensley ML
Winick NJ, *see* Mantadakis E
Winick NJ. In Reply (correspondence), 3742
Winn RJ, *see* Ozer H
Winquist E, *see* Tai PTH
Winter JN, *see* DiPersio JF
—*see* Hochster HS
Wiseman CL, *see* Presant CA
Wissler K, *see* Hobbie WL
Witherspoon RP, *see* Socié G
Witt ME, *see* Vokes EE
Wittig B, *see* Schmidt M
Witz B, *see* Harousseau JL
Woestenborghs R, *see* Zujewski J
Wold LE, *see* Stark A
Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. Management of Breast Cancer After Hodgkin's Disease, 765
Wolf L, *see* Briasoulis E
Wolf W, *see* Presant CA
Wolff AC, Davidson NE. Primary Systemic Therapy in Operable Breast Cancer, 1558
Wolff RA, *see* Pisters PWT
Wolmark N, *see* Wieand S
Wolmark N. In Reply (correspondence), 942
Wong ET, Joseph JT. Meningeal Carcinomatosis in Lung Cancer; Case 1: Carcinomatous Leptomeningeal Metastases, 2926
Wong GY, *see* Seamans DP
Wong J, *see* Poon RT-P
Wong KK, *see* Chim CS
Wong N, *see* Chappuis PO
Wong R, *see* Kirkbride P
Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Rubnitz JE, Harrison PL, Wang B, Evans WE, Pui C-H, Relling MV. Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia, 1525
Wood DP, *see* Hussain M
Wood WC, *see* Eisen A
—*see* Sparano JA
Woodruff JM, *see* Lewis JJ
Woods WG, *see* Gamis AS
Workman SB, *see* Jacobson JS
Wozniak AJ, *see* Ozer H
Wright DH, *see* Gale J
Wright J, *see* Takimoto CH
—*see* Whelan TJ
Wu H, *see* Khuri FR
Wu S, *see* Conley B
Wu T-T, *see* Heath EI
Wu YH, *see* D'Amico AV
Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ, Bell RS, Andrulis IL. *MDR1* Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study, 2685
Wyvill KM, *see* Little RF

Xiong X, *see* Fouladi M
Xiros N, *see* Briasoulis E
Xu D, *see* Tidefelt U
Xu J, *see* Seong C-M
Xu XC, *see* Lotan Y
Xu X-C, *see* Khuri FR

Yahalom J, *see* Abrey LE
Yakoub-Agha I, De La Salmonière P, Ribaud P, Sutton L, Wattel E, Kuentz M, Jouet JP, Marit G, Milpied N, Deconinck E, Gratecos N, Leporrier M, Chabbert I, Caillot D, Damaj G, Dauriac C, Dreyfus F, François S, Molina L, Tanguy ML, Chevret S, Gluckman E. Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70

Patients–Report of the French Society of Bone Marrow Transplantation, 963
Yamabe H, *see* Akasaka T
Yamamoto N, *see* Kurata T
Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol, 2301
Yamauchi H, *see* Baidas SM
Yang B-B, *see* Johnston E
Yang J, *see* Fouladi M
Yang SC, *see* Heath EI
Yang WI, *see* Kim GE
Yannelli JR, *see* Foon KA
Yarchoan R, *see* Little RF
Yarnitsky D, *see* Israel O
Yates A, *see* Smith JS
Ye W, *see* Giuliano AE
Yeager A, *see* Davies SM
Yee G, *see* Hillner BE
Yeldandi V, *see* Cagnoni PJ
Yen KL, *see* Cheng SH
Yerushalmi R, *see* Nieto Y
Yonetani N, *see* Akasaka T
Young SD. *Horizon of Hope* (poem), 1808
Young JW, *see* Baggers J
Younger J, *see* Burstein HJ
Yu CM, *see* Liang R
Yu E, *see* Tai PTH
Yung WKA, *see* Fine HA
—*see* Meyers CA
—*see* Osoba D

Zaccaria A, *see* Zinzani PL
Zacharias D, *see* Bishop MR
Zagars GK, *see* Pollack A
Zalcberg J, *see* Basser RL
Zalutsky MR, *see* Cokgor I
Zamagni E, *see* Martinelli G
Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH. Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors, 3288
Zampa G, Magnolfi E, Borgomastro A. Premedication for Irinotecan (correspondence), 235
Zapf J, *see* Empen K
Zee B, *see* Geels P
—*see* Kirkbride P
Zelefsky MJ, *see* Kattan MW
Zelefsky MJ, Kelly WK, Scher HI, Lee H, Smart T, Metz E, Schwartz L, Fuks Z, Leibel SA. Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer, 1936
Zelenetz AD, *see* Vose JM
Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM. Prognostic Value of P53 for Local Failure in Mastectomy-Treated Breast Cancer Patients, 1906
Zentko S, *see* Grem JL
Zeroli C, *see* Nasti G
Zevon MA, *see* Green DM
Zhang A, *see* Siminoff LA
Zhang J, *see* Brizel DM
Zhang T, *see* Heerema NA
Zhao H, *see* Grotzer MA
—*see* Osborne CK
Zhao X-G, *see* Cokgor I
Zidani R, *see* Giacchetti S
Ziegler S, *see* Avril N
Zilembo N, *see* Kaufmann M
Zincke H, *see* Cheng L
Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S. Efficacy of Tituximab in Hairy Cell Leukemia Treatment (correspondence), 3875
Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S. Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients, 2603
Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardigni L, Mazza P, Marra R, Ronconi F, Lauta VM, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S. Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma, 773
Zojer N, *see* Königsberg R
Zuccaro G, *see* Adelstein DJ
Zucker JM, *see* Frappaz D
Zucker S. Plasma MMPs as Surrogates of BAY 12-9566 (correspondence), 1800
Zuhowski EG, *see* Fracasso PM
Zujewski J, *see* Conley B
Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH. Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer, 927
Zunino F, *see* Lavarino C
Zwinderman AH, *see* Weijl NI

SUBJECT INDEX

Abscess, splenic, primary malignant lymphoma mimicking, 3731–3733
Academic functioning, in survivors of pediatric BMT, 1004–1011
Acquired immunodeficiency syndrome
  CNS lymphomas in (editorial), 3323–3324
  Kaposi's sarcoma in. *See* Kaposi's sarcoma, AIDS-related
Acute lymphoblastic leukemia
  adult, hyper-CVAD therapy for, 547–561
  childhood
    abnormalities of chromosome bands 13q12–14 in, 3837–3844
    asparaginase hypersensitivity and outcome in, 1525–1532
    high hyperdiploidy in, 1876–1887
    Ikaros gene abnormalities in (correspondence), 1395–1397
    intensified chemotherapy for, maintenance chemotherapy after, 1508–1516
    isolated CNS relapse in, improved survival of, 703 (errata)
    maintenance chemotherapy after intensified chemotherapy for, 1508–1516
    methotrexate dose intensification in, 1285–1294
    MTX dose intensification in, 1285–1294
    osteonecrosis in, 3262–3272
    pre-transplant regimens in, 340–347
    recombinant G-CSF in, 1517–1524
    survival, racial differences in, 813–823
      Mexican *vs.* American-Mexican children (correspondence), 2349–2350
Acute myelogenous leukemia, after high-dose therapy for non-Hodgkin's lymphoma, 947–955
Acute myeloid leukemia
  allogeneic BMT for, 963–971
  alpha hemolytic streptococcal infection in children with, 1845–1855
  GCSF after consolidation chemotherapy in, 780–787
  late effects of treatment in survivors of, 3273–3279
  minimal residual disease evaluation in, 788–794
Acute promyelocytic leukemia
  CD56 expression in, 1295–1300
  CNS extramedullary relapse after arsenic trioxide-induced remission in, 3435–3437
  leukocytosis and retinoic acid syndrome in, 2620–2625
Acute respiratory failure, secondary to lymphangitic carcinomatosis, 229–232, 944 (erratum)
ACVBP chemotherapy, in aggressive lymphoma, 1309–1315
Adaptation, to BMT-associated stress, 1539–1549
Adenocarcinoma
  in breast, gemcitabine/cisplatin for, 2245–2249
  esophageal, preoperative chemoradiation and adjuvant chemotherapy for (phase II trial), 868–876
  poorly differentiated, Her-2 overexpression, 632–635
Adenomatous polyposis coli tumor suppressor, biology of, 1967–1979
Adenovirus, *p53* gene transfer in non–small-cell lung cancer mediated by, 609–622
Adjuvant chemoradiation therapy, postoperative, for gastric cancer, 32s–34s
Adjuvant chemotherapy. *See also* Neoadjuvant chemotherapy
  for breast cancer
    acute leukemia after, 2836–2842
    cognitive function in patients receiving, 2695–2701
    disease-free survival and, 3125–3134
    early start of, 584–590
    in high-risk patients, therapy-resistant tumor cells in bone marrow and, 80–86
  for colon cancer, Dukes' B *versus* Dukes' C (correspondence), 235–236, 942
  for Ewing's sarcoma of bone, prognostic factors in, 4–11
  for gastric cancer (correspondence), 3061–3062
  and preoperative chemoradiation, for esophageal cancer (phase II trial), 868–876
Adjuvant therapy. *See also* Adjuvant chemotherapy
  dendritic cells. *See* Dendritic cells
  GM-CSF in melanoma (editorial), 1603–1605 stage III and IV, 1614–1621
  patient selection for trials, PSA failure and, 3240–3246
  threshold in older breast cancer patients, 1709–1717
Adolescents
  Hodgkin's disease in, second malignancy after treatment for, 1492–1499
  mediastinal germ cell tumors in, 832–839
  mediastinal large-cell lymphoma in, 3845–3853
Adrenocortical carcinoma, metastatic, right atrial thrombus in, 2638–2639
Advanced cancers
  CEA vaccines for (phase I trial), 3964–3973
  DX-8951F infusion in (phase I trial), 3986–3992
  farnesyl protein transferase inhibitor R115777 for (phase I trial), 927–941
  gemcitabine/vesnarinone in (phase I trial), 3974–3985
  paclitaxel/oxaliplatin in (phase I trial), 2293–2300
  of urothelial tract (phase II trial), 1058–1061
AIDS
  CNS lymphomas in, 3323–3324 (editorial), 3325–3330
  Kaposi's sarcoma in. *See* Kaposi's sarcoma, AIDS-related
ALL. *See* Acute lymphoblastic leukemia
Allogeneic bone marrow transplantation. *See* Bone marrow transplantation, allogeneic
Allogeneic stem-cell transplantation. *See* Stem-cell transplantation, allogeneic
Allopurinol, intravenous, for prevention and treatment of hyperuricemia, 1758–1763, 2188 (erratum)
Alternative medicine. *See* Complementary/alternative medicine
American Cancer Society Award Lecture (ASCO 2000), 19s–31s
American Society of Clinical Oncology
  annual meeting
    editorial overview, 1s
    presidential address, 2s–8s
  guidelines from
    antiemetics use (errata), 2933, 3064
    bisphosphonates role in breast cancer, 1378–1391
    colorectal cancer surveillance, 2000 update on, 3586–3588
    for use of chemotherapy and radiotherapy protectants (correspondence), 2004–2006, 3064
  recommendations for use of CSFs, 2000 update on, 3558–3585
Amifostine
  as radioprotector in head and neck cancer (phase III trial), 3339–3345
  subcutaneous, during fractionated radiotherapy (phase II trial), 2226–2233
AML. *See* Acute myelogenous leukemia; Acute myeloid leukemia
Amphotericin B, liposomal, pharmacoeconomics of, 2476–2483, 3064 (erratum)
Amyloidosis, mediastinal lymphadenopathy due to, lung cancer with, 2636–2637
Anastrazole, *vs.* tamoxifen, in advanced breast cancer, 3748–3757, 3758–3767

Androgen blockade, bicalutamide *vs.*, in prostate cancer (correspondence), 448–450
Androgen deprivation
in metastatic prostate cancer, 1043–1049
neoadjuvant, prostate brachytherapy and, 1187–1192
Angiocentric lymphoma, of head and neck, 54–63
Angiogenesis, in neuroblastoma, 27–34, 2789–2791 (correspondence)
Anthracycline
chemotherapy with and without (correspondence), 1392
extravasation, dexrazoxane in (correspondence), 3064
pretreatment in breast cancer, vinorelbine/5-FU for (phase II trial), 3370–3377
Anti-CD20 monoclonal antibody therapy, in non-Hodgkin's lymphoma retreatment, 3135–3143
Anti-epidermal growth factor receptor mAb C225 (phase I trial), 904–914
Anti-idiotype vaccine, for advanced melanoma, 376–384
Anti-Tac(Fv)-PE38, antitumor activity of (phase I trial), 1622–1636
Antiangiogenic therapy
for high-grade gliomas (phase II trial), 708–715, 3453 (correspondence)
vascular endothelial growth factor and, 45s–46s
Antibiotic therapy
for febrile neutropenia, outcome and cost of, 3699–3706
flush solution, for prevention of catheter-related infections, 1269–1278
prophylaxis, in neutropenic patients, 2126–2134
Antiemetics, ASCO guidelines (errata), 2933, 3064
APL. *See* Acute promyelocytic leukemia
Apoptosis, enhanced, with C225/radiation treatment, 47s–53s
Apoptosis-related proteins, and patient prognosis in advanced ovarian cancer, 3745–3747, 3775–3781
Appetite loss, in cancer patients, 2930–2932
9-β-D-Arabinofuranosyl guanine, pharmacokinetics of (phase I trial), 995–1003
Arsenic-induced leukocytosis, and retinoic acid syndrome in APL patients, 2620–2625
Arsenic trioxide-induced remission, in acute PML, CNS extramedullary relapse of, 3435–3437
ASCO. *See* American Society of Clinical Oncology
Asparaginase hypersensitivity, in childhood ALL, 1525–1532
Astrocytomas, survival predictors in, 636–645
Ataxia telangiectasia locus, 11q chromosome deletion at, in non-Hodgkin's lymphoma, 2607–2614
Autografting, for refractory lymphomas, 3918–3924
Autologous bone marrow transplantation. *See* Bone marrow transplantation, autologous
Autologous stem-cell transplantation. *See* Stem-cell transplantation, autologous
Autologous tumor cell vaccine, for colon cancer (phase II and III trials), 148–157
Avipoz virus, and CEA vaccines for advanced cancer (phase I trial), 3964–3973
Axillary lymph node, in breast cancer
dissection *vs.* sentinel node biopsy in, 2560–2566
histologic grade and prognosis in, 2059–2069
plasma D-dimer levels correlated with node status in, 600–608

B-cell lymphoma
CNS involvement in pediatric patients, 2017–2025
non-Hodgkin's
iodine-131 tositumomab for (phase II trial), 1316–1323
11q deletion at *ATM* locus in, 2607–2614
primary cutaneous, 2152–2168
rituximab for (phase II trial), 317–324, 2006 (erratum)
BAC expression, prognosis and, 3745–3747
m-BACOD chemotherapy, in aggressive lymphoma, 1309–1315
Bacteremia, *Staphylococcus aureus,* in nonneutropenic cancer patients, 1110–1115
Base-base mismatch DNA repair system, 75s–80s
BAY 12–9566 for, for solid malignancies (phase I trial), 178–186, 1805–1806 (correspondence)
Bcl-2 antisense therapy, for non-Hodgkin's lymphoma (phase I trial), 1812–1823
BCL-2 proteins, prognosis and, 3745–3747
BCT. *See* Blood cell transplantation
Beckwith-Wiedemann syndrome, in children, 2026–2031
Best supportive care, in non–small-cell lung cancer, docetaxel *vs.*, 2095–2103, 3738–3739 (correspondence)
Bicalutamide, *vs.* maximal androgen blockade in prostate cancer (correspondence), 448–450
Biliary stents, preoperative chemoradiation in pancreatic cancer and, 860–867
Biologic predictors, of breast cancer outcome (correspondence), 1601–1602
Biopsy
endometrial, in office setting, 3459–3463
of prostate gland. *See* Prostate biopsy
Bisphosphonates, role in breast cancer, ASCO guidelines on, 1378–1391
Bladder cancer. *See also* Urothelial tract cancer
copper-67–labeled C595 for, 363–370
gemcitabine/cisplatin *vs.* MVAC for (phase III trial), 3068–3077
hepatocyte growth factor in, 2963–2971
Bleeding complications, of venous thromboembolism, in malignancy, 3078–3083
Bleomycin
in neoadjuvant therapy for bulky stage IB and IIA cervical cancer, 1740–1747
in response-adapted chemotherapy of localized childhood Hodgkin's disease, 1500–1507
Blood, tumor cell counts predicting neuroblastoma outcome, 4067–4076
Blood cell transplantation
$CD34^+$ cell dose in, 1360–1377, 3319–3320 (correspondence)
lenograstim-primed, BMT *vs.*, 537–546
Blood transfusion, in outpatient setting, cost of, 2755–2761
BMT. *See* Bone marrow transplantation
Bone
and complications in metastatic breast cancer, pamidronate for prevention of, 72–79
Ewing's sarcoma of, prognostic factors in, 4–11, 3108–3114
metastases to, after breast cancer, 3925–3935
PNET of, neoadjuvant chemotherapy for, 885–892, 2187–2188 (correspondence)
Bone disease, metastatic, SPECT predicting response to rhenium-186 etidronate in, 2747–2754
Bone marrow
therapy-resistant tumor cells in, 80–86
tumor cell counts predicting neuroblastoma outcome, 4067–4076
Bone marrow transplantation
adaptation to, 1539–1549

allogeneic
for chronic myeloid leukemia, relapse detection after, 1831–1836
for low-grade lymphoma (correspondence), 702–703
for myelodysplastic syndrome and AML, 963–971
autologous
high-dose therapy with, for follicular lymphoma, 527–536
myelodysplasia and acute leukemia after (editorial), 945–946
for non-Hodgkin's lymphoma, myelodysplastic syndrome after (correspondence), 3446–3447
child survivors of, cognitive and academic functioning in, 1004–1011
for childhood acute leukemia
in infants, 3256–3261
lymphoblastic, pre-transplant regimens in, 340–347
new malignant disease after, 348–357
for early stage leukemia, lenograstim-primed BCT *vs.*, 537–546
partially mismatched related-donor, for pediatric acute leukemia, 1856–1866
in pediatric neuroblastoma, 2567–2575
predicting costs of, 64–71
BR96-doxorubicin, in Lewis Y-expressing epithelial tumors (phase I trial), 2282–2292, 4000 (correspondence)
Brachytherapy, high–dose-rate, for prostate cancer, 2869–2880, 4003–4005 (correspondence)
Brain metastases, of small-cell lung cancer, treatment of (phase III trial), 3400–3408
Brain tumors, pediatric
lacunar lesions after irradiation in, 824–831
nuclear MRS in, 1020–1026
Brainstem gliomas, diffuse, radiation therapy with tamoxifen for, 1246–1253
BRCA1 and *BRCA2* genes
cancer susceptibility testing programs and, 2135–2142
mutation carriers cancer chemoprevention options in, 93s–99s locally recurrent breast cancer in (correspondence), 1159–1160
prophylactic oophorectomy in, 100s–103s, 2728–2732 radiotherapy effects after breast-conserving treatment in, 3360–3369
predicting outcome, 4045–4052
prognosis with, 4053–4059
BRCA1-associated breast cancer, 104s–106s
vs. BRCA2 breast cancer, immunophenotypic and pathologic differences between, 107s–112s
prognosis in, 113s–118s
BRCA2-associated breast cancer, 104s–106s
vs. BRCA1 breast cancer, immunophenotypic and pathologic differences between, 107s–112s
prognostic significance of germline mutations in, 119s–124s
Breast
benign disease of, *HER-2/neu* amplification in, 267–274
granulocytic sarcoma (chloroma) of, 3993–3996
Breast cancer
adjuvant therapy/chemotherapy in
cognitive function in patients receiving, 2695–2701
early start of, 584–590
in older patients, 1412–1422, 1709–1717
treatment duration with tamoxifen, 3507–3512
advanced
anastrazole *vs.* tamoxifen in, 3748–3757, 3758–3767
autologous-blood and mesenchymal stem cell transplantation in, 307–316
efficacy and safety of docetaxel for, 562–573
gemcitabine/doxorubicin pharmacokinetics in (phase II trial), 2545–2552
megestrol acetate for, letrozole *vs.*, in postmenopausal women (correspondence), 1802–1803
oral 5-FU with eniluracil in (phase II trial), 2378–2384
in postmenopausal women, exemestane *vs.* megestrol acetate for (phase III trial), 1399–1411, 4109 (correspondence)
after Hodgkin's disease, management of, 765–772
anthracycline-pretreated, vinorelbine/5-FU for (phase II trial), 3370–3377
axillary node-positive, grade and prognosis in, 2059–2069
biologic predictors of outcome for (correspondence), 1601–1602
bisphosphonates role in, ASCO guidelines on, 1378–1391
BRCA-1/2 and $p27^{Kip1}$ predicting survival in, 4045–4052
chemotherapy for
vs. chemohormonal therapy in, 262–266
duration of, hormonal treatment and, 94–101
vs. endocrine therapy in, 2718–2727
estrogenic recruitment prior to, 734–742
MLH1 expression in tumors after, 87–93, 944 (erratum)
PET and
monitoring, 1689–195
predicting pathologic response to, 1678–1688
questionable data (correspondence), 2933, 3875
collaborative decision making in, 1230–1238
complementary/alternative medicine for, 668–683
early-stage
breast-conserving therapy for, 43s–44s
invasive, tumor location and relapse risk in, 2828–2835
MUC1 and survival in, 574–583
second malignancies after, 2406–2412, 4000–4001 (correspondence)
trauma history and, 1084–1093
in elderly, adjuvant combined chemotherapy for, 1412–1422
endometrial ultrasound screening for, 3464–3470
estrogenic recruitment in, 734–742
familial invasive, prognosis in *BRCA-1* carriers, 4053–4059
HER-2/*neu* in
activation of, 3230–3239
detection by FISH, 3651–3664
tamoxifen resistance and, 3471–3479
hereditary. *See also BRCA1*-associated breast cancer; *BRCA2*-associated breast cancer
prophylactic bilateral mastectomy in, 2250–2257
high-risk patients
bone metastases in, 3925–3935
cost-effectiveness of tamoxifen in, 284–286, 1807 (correspondence)
Her-2/*neu* and *p53* in, predictive value of, 2070–2080
prophylactic surgery in, 1980–1995, 3454–3455 (correspondence)
bilateral mastectomy, 2250–2257
tamoxifen and 4-HPR in, 275–283
therapy-resistant tumor cells in bone marrow in, 80–86
inflammatory, high-dose sequential chemotherapy in, 754–764
localized recurrent, *BRCA1* and *BRC2* germline mutations in (correspondence), 1159–1160
locoregional radiation therapy in, 1220–1229
locoregional recurrence of, 1696–1708
in males, 2948–2956

malignant behavior in, clinical progression of, 591–599
margin status affecting outcome in, 1668–1675
maspin RT-PCR for tumor cell detection in, 1914–1920, 3196–3197 (correspondence)
mastectomy for. *See* Mastectomy
metastatic
doxorubicin/docetaxel plus GCSF in (phase II trial), 2369–2377
epirubicin-based chemotherapy in, 3115–3124
exemestane after failed nonsteroidal aromatase inhibitors in (phase II trial), 2234–2244
high-dose chemotherapy for
phase I/II trial, 2363–2368
questionable date on (correspondence), 2933, 3875
pamidronate for prevention of bone complications in, 72–79
quality-of life scores predicting outcome in, 3768–3774
response of circulating tumor cells to therapy for, 1432–1439
symptom change/tumor response in, 2395–2405
thalidomide in treatment of (phase II trial), 2710–2717
vinorelbine/doxorubicin *vs.* doxorubicin alone for (phase III study), 2385–2394
weekly docetaxel for, 1212–1219
operable
and breast conservation. *See* Breast-conserving therapy
primary systemic therapy for, 1558–1569
paclitaxel *vs.* doxorubicin for, 724–733
pathologic response in, PET for prediction of, 1676–1688
peripheral-blood stem cell mobilization in, 2762–2771
plasma D-dimer levels in, 600–608
in postmenopausal women
adjuvant toremifene or tamoxifen therapy for, 3487–3494
megestrol acetate *vs.* letrozole for (correspondence), 1802–1803
tamoxifen-treated, endometrial ultrasound screening for, 3464–3470
primary node-positive, VEGF in, 1423–1431
referral of patients to clinical trials, 1203–1211
relapsed, gemcitabine/cisplatin for, 2245–2249
sentinel lymphadenectomy in, 2553–2559, 3873 (correspondence)
sentinel node biopsy in, 2560–2566
accuracy after neoadjuvant chemotherapy for, 3480–3486
stage I, sector resection in (correspondence), 942–943
stages I and II, chest roentgenography and, 3503–3506
steroid receptors in, time-dependent relevance of, 2702–2709
survivors of. *See* Breast cancer survivors
tamoxifen for. *See* Tamoxifen
Breast cancer survivors
complementary/alternative medicine use by, 2515–2521
fatigue in, 743–753
hot flashes in, soy phytoestrogens for, 1068–1074, 2792–2793 (correspondence)
Breast-conserving therapy
for ductal carcinoma-in-situ in young women, 296–306
for early-stage breast cancer, 43s–44s
local recurrence risk reduction after, 1075–1083
outcome in, 1668–1675
radiotherapy effects after, in *BRCA1/2* mutations, 3360–3369
Burkitt's lymphoma, molecular biology of, 3707–3721

c-erbB-2
in gastric cancer, tumor-associated protease systems and, 2201–2209
in male breast cancer, 2948–2956
C225 monoclonal antibody
anti-epidermal growth factor receptor (phase I trial), 363–370
radiation treatment and, enhanced apoptosis with, 47s–53s
C595 monoclonal antibody, copper-67–labeled, for bladder cancer, 363–370
C-*MYC*/IGh fusion, in diffuse large B-cell lymphoma, 510–518
CA-125, response rates in ovarian cancer (phase I trials), 1733–1739
Caliper measurement, of tumors, 437–444
CAM. *See* Complementary/alternative medicine
Cancer chemoprevention
in *BRCA1* and *BRCA2* mutation carriers, 93s–99s
Lynch syndrome and, 19s–31s
in 21st. century, 9s–18s
Cancer diagnosis, in children, 3193–3195
Cancer drug development, phase I clinical trial design in, 684–692
Cancer genetics program, Swiss model, 65s–69s
Cancer patients
depressive symptoms in, 2143–2151
nonneutropenic, *Staphylococcus aureus* bacteremia in, 1110–1115
Cancer rates, in 1990s, 2258–2268
Cancer risk
in benign breast disease, 267–274
in gene-environment interactions, 2309–2315
HER-2/neu amplification in benign breast disease and, 267–274
tamoxifen and 4-HPR in high-risk women, 275–283
Capecitabine, in colorectal cancer (phase II trial), 1337–1345
Carboplatin therapy
in chemotherapy combination for ovarian cancer (phase I trial), 2957–2962
in dose-intensive salvage therapy for germ cell tumor patients, 1173–1180
with paclitaxel
for advanced transitional-cell carcinoma, 2537–2544
for ovarian cancer (phase III trial), 3084–3092
for unknown primary carcinoma (phase II trial), 3101–3107
renal function-based dosing in children, 3614–3621
for solid malignancies (phase I trial), 3677–3689
Carcinoembryonic antigen vaccines, for advanced cancer (phase I trial), 3964–3973
Carcinogen exposure, environmental, 2309–2315
Carcinoid tumors
myocardial metastases from, 1596–1597
peptide receptor scintigraphy for, 1331–1336
Carcinoma. *See also* Cancer *entries; individual conditions and tumors*
advanced. *See* Advanced cancers
poorly differentiated, Her-2 overexpression, 632–635
of unknown primary site, carboplatin/paclitaxel for (phase II trial), 3101–3107
Carcinomatosis, lymphangitic, acute respiratory failure secondary to, 229–232, 944 (erratum)
Carcinomatous leptomeningeal metastases, 2926–2927
Carcinomatous meningitis, 2927–2929
Cardiac lymphoma
primary transmural, 1996–1997
secondary, 1998–1999
Cardiovascular morbidity, in metastatic testicular cancer survivors, 1725–1732
Carmustine, plus O^6-benzylguanine, for malignant glioma (phase I trial), 3522–3528
Catheters
central venous, warfarin prophylaxis in patients with, 3665–3667
infections associated with, antibiotic flush solution for prevention of,

1269–1278
thrombus and, in metastatic adrenocortical carcinoma, 2638–2639
CD34$^+$ cell dose, in blood cell transplantation, 1360–1377, 3319–3320 (correspondence)
CD56 expression, in acute promyelocytic leukemia, 1295–1300
CEA (carcinoembryonic antigen) vaccines, for advanced cancer (phase I trial), 3964–3973
Ceftazidime, metropenem *vs.*, for febrile neutropenia, 3690–3698
Cell sorting, and leukopheresis timing in high-risk neuroblastoma patients, 3829–3836
Central nervous system
AIDS-related lymphomas of, 3323–3324 (editorial), 3325–3330
extramedullary relapse of PML after arsenic trioxide-induced remission, 3435–3437
isolated relapse in childhood ALL, survival and, 703 (errata)
pediatric lymphoma of
B-cell, 2017–2025
non-Hodgkin's, 3018–3024
primary lymphoma of
combined modality therapy for (phase II trial), 519–526
treatment of, 3144–3150
Cerebrospinal fluid, trastuzumab in (correspondence), 2350–2351
Cervical cancer
bulky stage IB and IIA, neoadjuvant therapy for, 1740–1747
concurrent chemotherapy and pelvic radiation therapy for, 1606–1613
Chemoembolization, for pediatric liver tumors, 1279–1284
Chemohormonal therapy, chemotherapy *vs.*, for breast cancer, 262–266
Chemoradiation therapy
with paclitaxel, in esophageal cancer (phase II trial), 2032–2039
preoperative
in pancreatic cancer, 860–867
and postoperative chemotherapy, for esophageal cancer (phase II trial), 868–876
for small-cell lung cancer, 2990–2995
Chemoreduction, for intraocular retinoblastoma, 12–17
Chemotherapy. *See also* Adjuvant chemotherapy; Neoadjuvant chemotherapy; *specific regimes and agents*
ASCO guidelines for use of (correspondence), 2004–2006, 3064
for breast cancer. *See* Breast cancer, chemotherapy for
for cervical cancer, concurrent with pelvic radiation therapy, 1606–1613
consolidation. *See* Consolidation chemotherapy
dose-intensity of, in small-cell lung cancer, 395–404
dosing paradigm for, 2935–2937
gastroduodenal injury induced by, prevention of, 463–467
with gemcitabine, side effects of, 693–694
for germ cell cancer, thrombolic events during, 2169–2178
for gestational and placental site trophoblastic tumors, 854–859, 2187 (correspondence)
hepatic arterial, for colorectal cancer (editorial), 239–242, 1806–1807 (correspondence)
high-dose. *See* High-dose chemotherapy
intensified, for childhood ALL, maintenance chemotherapy after, 1508–1516
for intraocular retinoblastoma, 2881–2887
JEB, for germ cell tumors in children, 3809–3818
in Merkel cell carcinoma of skin, 2493–2499
myelosuppressive. *See* Myelosuppressive chemotherapy
for nonmetastatic extremity osteosarcoma
long-term outcome in, 4016–4027
received dose-intensity in, 4028–4037
nonmyeloablative immunosuppressive, for refractory lymphomas, 3918–3924
for non–small-cell lung cancer. *See* Non–small-cell lung cancer
perioperative, reducing local recurrence risk after breast-conserving therapy, 1075–1083
for posttransplant lymphoproliferative disease, remission after, 3622–3632
priming, GM-CSF treatment prior to, in breast cancer patients (erratum), 237
with radiation therapy
for early-stage nasopharyngeal carcinoma, 2040–2045
for pancreatic cancer (phase I trial), 3384–3389
up-front accelerated thoracic, in limited small-cell lung cancer (phase II trial), 1662–1667
with and without anthracycline (correspondence), 1392
Chest roentgenography, stage I and II breast cancer and, 3503–3506
Child survivors, of BMT, cognitive and academic functioning in, 1004–1011
Childhood cancer survivors, PTSD symptoms in, 4060–4066
Children
acute leukemias in
lymphoblastic. *See* Acute lymphoblastic leukemia
myeloid, alpha hemolytic streptococcal infection in, 1845–1855
new malignant disease after BMT for, 348–357
PMRD-BMT for, 1856–1866
Beckwith-Wiedemann syndrome in, 2026–2031
brain tumors in
lacunar lesions and, 824–831
nuclear MRS in, 1020–1026
cancer in
HIV-related, 3854–3861
PTSD in survivors of, 4060–4066
revealing diagnosis to, 3193–3195
with febrile neutropenia, low-risk prediction rule in, 1012–1019
germ cell tumors in, JEB chemotherapy for, 3809–3818
with hematologic malignancies, pharmacokinetics of nelarabine and ara-G in (phase I trial), 995–1003
hepatoblastoma in
cisplatin/doxorubicin and delayed surgery for, 3819–3828
treatment outcome for, 2665–2675
HIV-related cancer in, 3854–3861
Hodgkin's disease in
localized, chemotherapy and radiotherapy for, 1500–1507
second malignancy after treatment for, 1492–1499
immunocompromised, preventing catheter-related infections in, 1269–1278
with liver tumors, chemoembolization for, 1279–1284
mediastinal germ cell tumors in, 832–839
mediastinal large-cell lymphoma in, 3845–3853
neuroblastoma in
ch14–18 therapy in (phase I trial), 4077–4085
LMCE3 treatment strategy for, 468–476
stage I and II, outcomes after surgery, 18–26
stage IV, prognosis in infants, 1260–1268
stage IV-S, 477–486
tandem stem-cell transplantation in, 2567–2575
non-Hodgkin's lymphoma in, CNS involvement in, 3018–3024
in phase I clinical trials, pediatricians' perspectives of (United Kingdom), 1900–1905
renal function-based carboplatin dosing in, 3614–3621

small noncleaved-cell lymphoma and B-cell leukemia in, CNS involvement and, 2017–2025
solid tumors in, cyclophosphamide and etoposide for (phase II trial), 2576–2581, 3741–3743 (correspondence)
Wilms' tumor in, 2026–2031
Chloroma, in leukemia, 3993–3997
Chromosomes
changes in premalignant laryngeal lesions, 1644–1651
in childhood ALL
13q12–14 band abnormalities, 3837–3844
trisomies 10, 17 and 5, prognostic impact of, 1876–1887
1p and 19p deletions as predictors of survival, 636–645
11q deletion at *ATM* locus in non-Hodgkin's lymphoma, 2607–2614
Chronic myelogenous leukemia
homoharringtonine and cytarabine for, 3513–3521
neuropsychiatric toxicity in, 1301–1308
Chronic myeloid leukemia
INF4 expression in, 3331–3338
interphase FISH in, 1533–1538
Cirrhosis, HBV-related, hepatocellular carcinoma prognosis and, 1094–1101
Cisplatin
in combination chemotherapy
for advanced gastric cancer (phase III trial), 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
for non–small-cell cancer (phase III trial), 1451–1457
for urothelial TCC (phase I/II trial), 3247–3255
with doxorubicin and delayed surgery for childhood hepatoblastoma, 3819–3828
etoposide with, for advanced lung cancer, 623–631
gemcitabine with
for metastatic urothelial cancer (phase II trial), 1921–1927, 2644 (erratum)
for relapsed breast cancer, 2245–2249
with ifosfamide/paclitaxel, for transitional-cell carcinoma of urothelial tract (phase I trial), 840–846
with irinotecan
3-week schedule for solid tumors (phase I trial), 187–194
in dose-escalating study, pharmacokinetics of, 195–203
low-dose daily, for squamous cell carcinoma of head and neck, 1458–1464, 3320–3321 (correspondence)
in MVAC regimen for urothelial TCC (phase III trial), 3068–3077
in neoadjuvant therapy for bulky stage IB and IIA cervical cancer, 1740–1747
for non–small-cell lung cancer
and adenovirus-mediated *p53* gene transfer in, 609–622
advanced form, 1351–1359
alone or with gemcitabine (phase III trial), 122–130, 2791–2792 (correspondence)
alone *vs.* combination therapy for (phase III trial), 3390–3399
in combination chemotherapy (phase III trial), 1451–1457
for ovarian cancer (stage III or IV), *vs.* paclitaxel (phase III trial), 102–105
vs. paclitaxel, for advanced ovarian cancer (phase III trial), 102–105
with paclitaxel
for advanced lung cancer, 623–631
for advanced urothelial cancer (phase II trial), 1058–1061
for ovarian cancer (phase III trial), 3084–3092
in PIEo chemoradiation for small-cell lung cancer, 2990–2995
in salvage therapy for testicular germ cell cancer, 2413–2418
in sequential couplet therapy for ovarian cancer (phase II trial), 4038–4044
for small-cell lung cancer, with concurrent radiation (phase I/II trial), 1102–1109, 3453–3454 (correspondence)
before surgery or radiotherapy in non–small-cell cancer (phase II trial), 2658–2664
and topotecan interactions, in humans (phase I trial), 2104–2115
for urothelial TCC (phase III trial), 3068–3077
Clinical practice guidelines, economic impact of, 1718–1724
Clinical trials. *See also specific* Phase *entries*
children in, pediatricians' perspectives of (United Kingdom), 1900–1905
financial impact of, 2805–2810
interim analysis of (editorial), 4007–4008
multicenter, reliability of date from, 1771–1779
policing of (editorial), 2353
referral of breast cancer patients to, 1203–1211
standards of reporting quality of life in (correspondence), 1801–1802
CML. *See* Chronic myelogenous leukemia; Chronic myeloid leukemia
CNS. *See* Central nervous system
Cognitive function
in breast cancer patients receiving adjuvant chemotherapy, 2695–2701
as predictor of survival in recurrent malignant glioma, 646–650
in survivors of pediatric BMT, 1004–1011
Collaborative decision making, in breast cancer, 1230–1238
Colon cancer. *See also* Colorectal cancer
active specific immunotherapy for (phase II and III trials), 148–157
Dukes' B *vs.* Dukes' C, adjuvant chemotherapy for (correspondence), 235–236, 942
Flt3-ligand immunotherapy of, 3883–3893
hereditary and sporadic, induction of, 75s–80s
metastatic ovarian cancer simulating, 3189–3192, 4005 (erratum)
oxaliplatin-chronomodulated 5-FU/leucovorin treatment in (phase III trial), 136–147
Colony-stimulating factors. *See also individual factors*
ASCO recommendations for use of, 2000 update on, 3558–3585
usage patterns and outcomes in community setting, 1764–1770, 3321–3322 (correspondence)
Colorectal cancer
5-FU uptake enhancement in, 255–261
ASCO surveillance guidelines, 2000 update on, 3586–3588
capecitabine in (phase II trial), 1337–1345
hepatic arterial chemotherapy for (editorial), 239–242, 1806–1807 (correspondence)
5-FU/leucovorin *vs.* fluorodeoxyuridine in, 243–254
hereditary nonpolyposis (editorial), 2189–2192
hereditary syndromes, diagnosis and management of, 81s–92s
leucovorin/fluorouracil with or without oxaliplatin for, 2938–2947
Lynch syndrome, 19s–31s
metastatic, oral 5-FU/eniluracil in (phase II study), 2894–2901
Communication, physician-patient, 3441–3445
Complementary/alternative medicine (editorial), 2501–2504
for breast cancer, 668–683
in comprehensive cancer center, 2505–2514, 3455–3456 (correspondence)
use by breast cancer survivors, 2515–2521
Computed tomography, in tumor measurement, evaluation of, 2179–2184
Computerized clinical information system, for CSF usage data collection, 1764–1770, 3321–3322 (correspondence)
Concomitant chemoradiotherapy

for locoregionally advanced head and neck cancer, 1652–1661
for nasopharyngeal carcinoma, 2040–2045
Congestive heart failure, with mediastinal lymphadenopathy, 2635–2636
Consolidation chemotherapy
in aggressive lymphoma, 1309–1315
in AML, GCSF after, 780–787
Consolidation interferon therapy, for non-Hodgkin's lymphoma (phase III trial), 2010–2016, 3322 (correspondence)
Consolidative radiotherapy, for Hodgkin's disease, 972–980
Consultation, patient-physician (correspondence), 3739–3741
Copper-67–labeled C595, for superficial bladder cancer, 363–370
Cost
of antibiotic therapy in febrile neutropenia, 3699–3706
of bone marrow transplantation, predictors for, 64–71
and financial impact of clinical trials, 2805–2810
of outpatient blood transfusion, 2755–2761
Cost-effectiveness
of electron-beam boost in early-stage breast cancer, 287–295
survival and (correspondence), 3318
of tamoxifen in women at high risk for breast cancer, 284–286, 1807 (correspondence)
temozolomide *vs.* dacarbazine, for metastatic melanoma, 1474–1480
Cost-utility assessments, in oncology, 3302–3317
Counseling. *See* Genetic counseling
Cranial irradiation, prophylactic, in limited small-cell lung cancer (phase II trial), 1662–1667
CSF (cerebrospinal fluid), trastuzumab in (correspondence), 2350–2351
CSFs. *See* Colony-stimulating factors
Cyclophosphamide
in adjuvant chemotherapy for breast cancer, disease-free survival and, 3125–3134
in combination therapy for breast cancer, 2718–2727
in elderly patients, 1412–1422
fludarabine with, for low-grade lymphoma, 987–994
with G-CSF, progenitor-cell mobilization and, 1824–1830, 3063 (correspondence)
for pediatric solid tumors (phase II trial), 2576–2581, 3741–3743 (correspondence)
Cyclosporine, in combination therapy for pediatric AML, 1867–1875
CYP34A activity, docetaxel clearance and, 2301–2308
Cystic neck mass, presenting as Hodgkin's disease, 1150–1152
Cytarabine
low-dose, for chronic myelogenous leukemia, 3513–3521
for lymphomatous meningitis, slow-release *vs.* standard formulation (correspondence), 2003–2004, 3064
and neuropsychiatric toxicity in CML, 1301–1308
Cytochrome P450 activity, docetaxel clearance and, 2301–2308
Cytogenetic response, in chronic myeloid leukemia, interphase FISH and, 1533–1538
Cytogenetics, interphase. *See* Interphase cytogenetics
Cytokine gene polymorphisms, in myeloma, 2843–2851
Cytokine therapy. *See also* Interferon/Interferon alfa-2b; Interleukin/Interleukin-2
in advanced renal cell carcinoma, effect on survival, 1928–1935
in melanoma (editorial), 1603–1605
Cytoreduction
and leukopheresis timing in high-risk neuroblastoma patients, 3829–3836
and nephrectomy in metastatic renal cancer, 39s–42s
Dacarbazine
for metastatic melanoma, cost-effectiveness of, 1474–1480
temozolomide *vs.*, for metastatic melanoma (phase III trial), 158–166, 2185 (correspondence), 2351–2352 (errata)
Daniplestim, with G-CSF, for peripheral-blood stem cell mobilization, 2762–2771
Data
on CSF usage, computerized collection of, 1764–1770, 3321–3322 (correspondence)
fabricated, metastatic breast cancer treatment and (correspondence), 2933, 3875
from multicenter trials, reliability of, 1771–1779
Daunorubicin, in acute myeloid leukemia, cellular pharmacokinetics of, 1837–1844
David A Karnofsky Memorial Award Lecture (ASCO 2000), 9s–18s
DCIS. *See* Ductal carcinoma-in-situ
Death, denial of, 3998–3999
Decision making
collaborative, in breast cancer, 1230–1238
early-stage Hodgkin's disease treatment alternatives (correspondence), 943–944
patient autonomy and, 3736–3737
prioritizing treatment outcomes in head and neck cancer, 877–884
Decitabine therapy, for high-risk myelodysplasia patients (phase II trial), 956–962
Dendritic cells, as immunologic adjuvants
editorial overview, 3879–3882
in hormone-refractory prostate cancer, 3894–3903
in metastatic colon cancer, 3883–3893
Denial, of terminal illness, 3998–3999
Depression
in lung cancer patients, 893–903
in patients receiving interleukin 2 and/or interferon alfa-2b therapy, 2143–2151
Dermatitis, from gemcitabine therapy, 693–694
Dexamethasone
for emesis protection, 3409–3422
for radiation-induced emesis (phase III trial), 1960–1966
Dexrazoxane, ASCO guidelines for use of (correspondence), 2004–2006, 3064
Diarrhea
irinotecan causing, glutamine for (correspondence), 450–451
sucralfate for prevention of, in pelvic radiation therapy (phase III trial), 1239–1245
Dietary fat intake, and sex steroid hormone levels in postmenopausal women, 3668–3676
Dihydropyrimidine dehydrogenase expression, in epithelial ovarian cancer, 3946–3951
Disialoganglioside GD2, anti-idiotype vaccine mimicking, for advanced melanoma, 376–384
DNA repair defects, tumor suppressor genes inactivated by, 75s–80s
Docetaxel
for breast cancer
advanced, efficacy and safety of, 562–573
metastatic, weekly administration of, 1212–1219
cisplatin/fluorouracil/leucovorin chemotherapy, for squamous cell carcinoma of head and neck, phase II trial (correspondence), 1393–1395
clearance of, and estimated CYP34A activity, 2301–2308
doxorubicin and, plus GCSF in metastatic breast cancer (phase II trial), 2369–2377

vs. doxorubicin for soft tissue sarcomas (phase II trial), 2081–2086
and G-CSF for pancreatic cancer, phase II trial (correspondence), 445–451
with irinotecan, for solid tumors (phase I trials), 3545–3552
advanced, pharmacokinetics of, 1116–1123
for non–small-cell lung cancer (phase II trial), 1346–1350
for paclitaxel-resistant Müllerian carcinoma, 2733–2739
for platinum-treated non–small-cell lung cancer
activity in (phase II trial), 131–135
vs. best supportive care, 2095–2103, 3738–3739 (correspondence)
and topotecan interaction in solid tumors, 3288–3294
vs. vinorelbine/ifosfamide for non–small-cell lung cancer (phase II trial), 2354–2362
Donor leukocyte infusion, for treatment of relapse after allogeneic stem-cell transplantation, 2269–2272
Donor lymphocyte infusions, for relapsed multiple myeloma, 3031–3037
Dose-escalating study
70 Gy and 78 Gy compared, 3904–3911
of irinotecan and cisplatin, pharmacokinetics of, 195–203
Dose-intensity, of chemotherapy, in small-cell lung cancer, 395–404
Double-blind trials
advanced breast cancer in postmenopausal women, exemestane *vs.* megestrol acetate for (phase III trial), 1399–1411, 4109 (correspondence)
effect of audiotaped initial consultation on patient satisfaction and quality of life, 3052–3060
febrile neutropenia, metropenem *vs.* ceftazidime for, 3690–3698
preventing catheter-related infections in immunocompromised children, 3690–3698
Doxorubicin therapy. *See also* EPOCH chemotherapy
with cisplatin and delayed surgery for childhood hepatoblastoma, 3819–3828
in combination therapy for advanced gastric cancer (phase III trial), 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
with docetaxel plus GCSF in metastatic breast cancer (phase II trial), 2369–2377
docetaxel *vs.*, for soft tissue sarcomas (phase II trial), 2081–2086
with gemcitabine
in advanced breast cancer (phase II trial), 2545–2552
for transitional-cell carcinoma of urothelial tract (phase I trial), 840–846
high-dose *vs.* standard-dose for, advanced soft tissue sarcomas (phase III trial), 2676–2684
locoregional patterns of recurrence after mastectomy, 2817–2827
for metastatic breast cancer, in combination or alone (phase III study), 2385–2394
in MVAC regimen for urothelial TCC (phase III trial), 3068–3077
paclitaxel *vs.*, for breast cancer, 724–733
DPD (dihydropyrimidine dehydrogenase) expression, in epithelial ovarian cancer, 3946–3951
Drug development, phase I clinical trial design in, 684–692
Drug-induced rash, in leukemia, 3437–3439
Drug interactions
in palliative care, 1780–1799
topotecan/cisplatin, in humans (phase I trial), 2104–2115
Drug selection, and CA-125 response rates in ovarian cancer (phase I trials), 1733–1739
Ductal carcinoma-in-situ, in young women, breast-conserving therapy for, 296–306
Dukes' B colon cancer, adjuvant chemotherapy in (correspondence), 235–236, 942
Dukes' C colon cancer, adjuvant chemotherapy in (correspondence), 235–236, 942
DX-8951F
infusion in advanced cancer (phase I trial), 3986–3992
pharmacokinetics in solid tumors (phase I trial), 3151–3163
Dying patient. *See* End-of-life care

EBV. *See* Epstein-Barr virus
ECF combination therapy, in gastric cancer (correspondence), 3874, 4001–4003
Economic impact, of clinical practice guidelines and harmonizing medical practices, 1718–1724
EGF (epidermal growth factor) receptor, therapeutic agents targeting, 54s–59s
Elderly patients
breast cancer in, adjuvant combined chemotherapy for, 1412–1422
myelodysplastic syndrome in, decitabine therapy for (phase II trial), 956–962
non–small-cell lung cancer in, chemotherapy evaluation in, 2529–2536
Electron-beam boost, in early-stage breast cancer, cost-effectiveness of, 287–295
Electronic techniques, in tumor measurement evaluation, 2179–2184
Embryonal carcinoma-predominant testicular cancer, lymph node dissection for, 358–362
Emesis
chemotherapy-induced, dexamethasone to control, 3409–3422
radiation-induced, dexamethasone for (phase III trial), 1960–1966
Emitefur, pharmacokinetics in solid tumors (phase I trial), 3423–3434
Emotional reactions, to genetic testing, 2135–2142
End-of-life care, 233–234
death denial and, 3998–3999
editorial overview, 3
hydration and, 1156–1158
patient autonomy and, 3736–3737
for pediatric patients, 3193–3195
spirituality and, 2000–2002
time-frame in, 699–701, 2640–2643
Endocrine therapy, in breast cancer, chemotherapy *vs.*, 2718–2727
Endometrial biopsy, in office setting, 3459–3463
Endometrial cancer, screening for (correspondence), 446–448
Endometrium, in tamoxifen-treated women, 3459–3463
Eniluracil
5-FU with, in advanced breast cancer (phase II trial), 2378–2384
chronic oral 5-FU plus (phase I trial), 915–926
for solid tumors, weekly oral administration of (phase I trial), 3952–3963
Enteropathy-type intestinal T-cell lymphoma, 795–803
Environmental carcinogen exposure, cancer risk and, 2309–2315
EP/EMA chemotherapy, in gestational and placental site trophoblastic tumors, 854–859, 2187 (correspondence)
Epidermal growth factor receptor, therapeutic agents targeting, 54s–59s
Epirubicin
for metastatic breast cancer, 3115–3124
paclitaxel with, sequence effect on pharmacokinetics and toxicity, 2116–2125
Epithelial ovarian cancer, DPD and TP expression in, 3946–3951
Epithelial tumors, Lewis Y-expressing, BR96-doxorubicin in (phase I trial), 2282–2292, 4000 (correspondence)

EPOCH chemotherapy, in relapsed and resistant lymphomas, 3633–3642
Epstein-Barr virus, AIDS-related lymphomas and, 3323–3324 (editorial), 3325–3330
ErbB-2. *See* HER-2/*neu*
Errata
  acute respiratory failure secondary to lymphangitic carcinomatosis, 944
  allopurinol for prevention and treatment of hyperuricemia, 2188
  androgen-independent prostate cancer, eligibility and response guidelines for, 2644
  ASCO antiemetics guidelines, 2933, 3064
  CNS relapse in childhood ALL, survival and, 703
  filgrastim for peripheral-blood stem cell mobilization, 3589
  gemcitabine/cisplatin for metastatic urothelial cancer, phase II trial (erratum), 2644
  GM-CSF treatment prior to chemotherapy in breast cancer patients, 237
  hereditary nonpolyposis colorectal cancer detection, 3456
  impact of quality of life and patient expectations regarding clinical trials, 1807
  liposomal amphotericin B pharmacokinetics in febrile neutropenia, 3064
  metastatic ovarian cancer simulating colon cancer, 4005
  MLH1 expression in breast tumors after chemotherapy, 944
  preoperative prediction of prostatectomy surgical margins, 3589
  rituximab for mantle-cell lymphoma, 2006
  sentinel nodes in breast cancer, 3873
  standardization of response criteria for non-Hodgkin's lymphoma, 2351
  valspodar and paclitaxel in refractory tumors (phase I trial), 2793
Esophageal cancer
  changing patterns in (editorial), 453–454
  paclitaxel chemoradiotherapy in (phase II trial), 2032–2039
  preoperative chemoradiation and adjuvant chemotherapy for (phase II trial), 868–876
  radiation outcomes in, 455–462
  staging of
    FDG-PET for, 3202–3210
    PET for, 3199–3201 (editorial), 3202–3210
Essential thrombocytopenia, meningeal granulocytic sarcoma (chloroma) of, 3996–3997
Estramustine, and 3-D conformal radiotherapy for prostate cancer (phase II trial), 1936–1941
Estrogen receptor modulators, characteristics and use of, 3172–3186
Estrogenic recruitment, before chemotherapy for breast cancer, 734–742
Etidronate, for metastatic bone disease, SPECT predicting response to, 2747–2754
Etoposide therapy
  with cisplatin, for advanced lung cancer, 623–631
  in combination therapy
    for advanced gastric cancer (phase III trial), 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
    for ovarian cancer (phase I trial), 2957–2962
    for pediatric AML, 1867–1875
  in dose-intensive salvage therapy for germ cell tumor patients, 1173–1180
  for pediatric solid tumors (phase II trial), 2576–2581, 3741–3743 (correspondence)
  in PIEo chemoradiation for small-cell lung cancer, 2990–2995
  in response-adapted chemotherapy of localized childhood Hodgkin's disease, 1500–1507
  for small-cell lung cancer, with concurrent radiation (phase I/II trial), 1102–1109, 3453–3454 (correspondence)
Ewing's sarcoma
  of bone, prognostic factors in, 4–11, 3108–3114
  molecular biology of, 204–213
Exemestane therapy
  after failed nonsteroidal aromatase inhibitors in metastatic breast cancer (phase II trial), 2234–2244
  vs. megestrol acetate for advanced breast cancer in postmenopausal women (phase III trial), 1399–1411, 4109 (correspondence)
External-beam radiation
  intraocular retinoblastoma and, 2881–2887
  for prostate cancer, 2869–2880, 4003–4005 (correspondence)
Extravasation, anthracycline, dexrazoxane in (correspondence), 3064
Extremity, nonmetastatic osteosarcoma of, chemotherapy for
  outcome in, 4016–4027
  received dose-intensity in, 4028–4037

Familial invasive breast cancers, prognosis in, 4053–4059
Farnesyl protein transferase inhibitor R115777, for advanced cancer (phase I trial), 927–941
Fatigue, in breast cancer survivors, 743–753
FDG–PET. *See* Fluorine-18 fluorodeoxyglucose–PET
Febrile neutropenia
  liposomal amphotericin B for, pharmacokinetics for, 2476–2483, 3064 (erratum)
  MASCC risk index for, 3038–3051
  metropenem *vs.* ceftazidime for, 3690–3698
  outcome and cost of antibiotic therapy in, 3699–3706
  pediatric, low-risk prediction rule for, 1012–1019
Fenretinide therapy, in prostate cancer, 3804–3808
Filgrastim. *See* Granulocyte colony-stimulating factor
Film-based techniques, in tumor measurement evaluation, 2179–2184
Financial impact, of clinical trials, 2805–2810
FISH. *See* Fluorescence in situ hybridization
FIt3-ligand, mobilizing dendritic cells in metastatic colon cancer, 3883–3893
Flavopiridol, for metastatic renal cancer (phase II trial), 371–375
Fludarabine
  with cyclophosphamide, for low-grade lymphoma, 987–994
Fluorescence in situ hybridization
  evaluating leptomeningeal metastases treatment, 2053–2058
  HER-2/*neu* detection in breast cancer by, 3651–3664
  hypermetaphase, in chronic myeloid leukemia, relapse detection by, 1831–1836
  interphase, in chronic myeloid leukemia, 1533–1538
  for prognosis in multiple myeloma, 804–812
Fluorine-18 fluorodeoxyglucose–PET
  of breast, 3495–3502
  for esophageal cancer staging, 3202–3210
[^{18}F]-Fluorodeoxy-D-glucose, in PET
  monitoring primary chemotherapy in breast cancer, 1689–1695
  to predict pathologic breast cancer response, 1678–1688
Fluorodeoxyuridine
  hepatic artery, and liver radiation therapy for unresectable intrahepatic cancer, 2210–2218
  for nonresectable liver metastases, 243–254
Fluorouracil
  in adjuvant chemotherapy for breast cancer, disease-free survival

and, 3125–3134
for advanced solid malignancies (phase I trial), 167–177
in chemotherapy and radiotherapy protocol for pancreatic cancer (phase I trial), 3384–3389
chronic oral, plus eniluracil (phase I trial), 915–926
in combination therapy
for advanced gastric cancer (phase III trial), 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
for breast cancer, 2718–2727
in elderly patients, 1412–1422
with eniluracil
in advanced breast cancer (phase II trial), 2378–2384
in metastatic colorectal cancer (phase II study), 2894–2901
gemcitabine and, for metastatic renal cell cancer (phase II trial), 2419–2426
IL-2/IFN with or without, for metastatic renal cancer, 4009–4015
with leucovorin
for nonresectable liver metastases, 243–254
with or without oxaliplatin for colorectal cancer, 2938–2947
oxaliplatin-chronomodulated, for colon cancer (phase III trial), 136–147
for solid tumors
gemcitabine modulating (phase I trial), 3553–3557
weekly oral administration of (phase I trial), 3952–3963
stomatitis induced by, sex differences in, 412–420
uptake enhancement in colorectal and gastric cancers, 255–261
with vinorelbine, for anthracycline-pretreated breast cancer (phase II trial), 3370–3377
Folinic acid, for solid tumors, gemcitabine modulating (phase I trial), 3553–3557
Follicular lymphoma, high-dose therapy for, 527–536
5-FU. *See* Fluorouracil
FUDR. *See* Fluorodeoxyuridine

Gastric cancer
5-FU uptake enhancement in, 255–261
adjuvant chemotherapy in (correspondence), 3061–3062
advanced, treatment of (editorial), 2645–2647
different chemotherapy regimens (phase III trial), 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
c-erbB-2 in, tumor-associated protease systems and, 2201–2209
postoperative adjuvant chemoradiation therapy for, 32s–34s
Gastroduodenal injury, chemotherapy-induced, prevention of, 463–467
Gastrointestinal stromal tumors, malignant, clinical outcome and multidrug resistance in, 3211–3220
GCSF. *See* Granulocyte colony-stimulating factor
Gemcitabine
and 5-FU for metastatic renal cell cancer (phase II trial), 2419–2426
in chemotherapy and radiotherapy protocol for pancreatic cancer (phase I trial), 3384–3389
with cisplatin
vs. cisplatin alone in non–small-cell lung cancer (phase III trial), 122–130, 2791–2792 (correspondence)
for metastatic urothelial cancer (phase II trial), 1921–1927, 2644 (erratum)
for relapsed breast cancer, 2245–2249
in combination chemotherapy
for non–small-cell cancer (phase III trial), 1451–1457
for urothelial TCC (phase I/II trial), 3247–3255
with doxorubicin
in advanced breast cancer (phase II trial), 2545–2552
for transitional-cell carcinoma of urothelial tract (phase I trial), 840–846
folinic acid and fluorouracil modulated by, in solid tumors (phase I trial), 3553–3557
for hepatic or renal dysfunction (phase I trial), 2780–2787
and MTA sequences in advanced solid tumors (phase I trial), 1748–1757
for non–small-cell lung cancer in elderly patients, 2529–2536
for pretreated cutaneous T-cell lymphoma, 2603–2606
radiation recall reaction from, 695–696
for refractory Hodgkin's disease (phase II trial), 2615–2619
side effects of, 693–694
before surgery or radiotherapy in non–small-cell cancer (phase II trial), 2658–2664
for urothelial TCC (phase III trial), 3068–3077
with vesnarinone, in advanced cancer (phase I trial), 3974–3985
with vinorelbine, for non–small-cell lung cancer (phase I/II trial), 405–411
Gene-directed therapy, oligonucleotides and (editorial), 1809–1811
Gene-environment interactions, cancer risk in, 2309–2315
Genetic counseling
in Lynch syndrome, 19s–31s
and testing process, 60s–64s
Genetic testing
counseling and. *See* Genetic counseling
emotional reactions to, 2135–2142
specialists' perspectives on, 2484–2492
Genetics
of cancer chemoprevention, 9s–18s
of Lynch syndrome, 19s–31s
Germ cell tumors
in children, JEB (carboplatin, etoposide, bleomycin) chemotherapy for, 3809–3818
dose-intensive salvage therapy for patients with, 1173–1180
mediastinal, in children and adolescents, 832–839
testicular, paclitaxel combination therapies for, 2413–2418
thrombolic events during chemotherapy for, 2169–2178
treatment after high-dose chemotherapy failure, 1181–1186
Germline mutations, in *BRCA2*-associated breast cancer, prognostic significance of, 119s–124s
Gestational trophoblastic tumors, EP/EMA chemotherapy in, 854–859, 2187 (correspondence)
Glioblastoma multiforme
recurrent, health-related quality of life in, 1481–1491
tirapazamine and radiation therapy for (phase II trial), 1254–1259
Glioma
diffuse brainstem, radiation therapy with tamoxifen for, 1246–1253
high-grade, thalidomide for (phase II trial), 708–715, 3453 (correspondence)
malignant
carmustine plus O^6-benzylguanine for (phase I trial), 3522–3528
^{131}I-81C6 in newly diagnosed (phase I trial), 3862–3872
recurrent, cognitive function as predictor of survival in, 646–650
Glomerular filtration rate, carboplatin dosing in children and, 3614–3621
Glufosfamide infusion, 6-hour (phase I trial), 3535–3544
Glutamine, for irinotecan diarrhea (correspondence), 450–451
GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
Granulocyte colony-stimulating factor
after consolidation chemotherapy in AML, 780–787
before chemotherapy priming for breast cancer (erratum), 237

chemotherapy with
and dose-intensity in small-cell lung cancer, 395–404
for inflammatory breast cancer, 754–764
with cyclophosphamide or GM-CSF, progenitor-cell mobilization and, 1824–1830, 3063 (correspondence)
with daniplestim, for peripheral-blood stem cell mobilization, 2762–2771
with doxorubicin/docetaxel, in metastatic breast cancer (phase II trial), 2369–2377
for pancreatic cancer, docetaxel with, phase II trial (correspondence), 445–451
for peripheral-blood stem cell mobilization, 43–53, 3589 (errata)
recombinant, in childhood ALL, 1517–1524
SD/01 *vs.*, for chemotherapy-induced neutropenia, 2522–2528
for treatment of relapse after allogeneic stem-cell transplantation, 2269–2272
Granulocyte-macrophage colony-stimulating factor
as adjuvant therapy in melanoma (editorial), 1603–1605
stage III and IV, 1614–1621
with G-CSF, progenitor-cell mobilization and, 1824–1830, 3063 (correspondence)
Granulocytic sarcoma (chloroma)
of breast, 3993–3996
meningeal, in essential thrombocytopenia, 3996–3997
Growth factors
EGF receptor, therapeutic agents targeting, 54s–59s
hepatocyte, in bladder cancer, 2963–2971
usage patterns and outcomes in community setting, 1764–1770, 3321–3322 (correspondence)
vascular endothelial, and antiangiogenic therapy, 45s–46s
Gynecologic surveillance, of women on tamoxifen (editorial), 3457–3458

Hairy cell leukemia, rituximab efficacy in (correspondence), 3875
Harmonizing medical practices, economic impact of, 1718–1724
Head and neck
angiocentric lymphoma of, 54–63
cystic mass in, presenting as Hodgkin's disease, 1150–1152
Head and neck cancer
amifostine as radioprotector in (phase III trial), 3339–3345
locoregionally advanced, concomitant chemoradiotherapy for, 1652–1661
oral and oropharyngeal squamous cell, VEGF levels, 2046–2052
prioritizing treatment outcomes in, 877–884
recurrent, PET surveillance of, 651–658
squamous cell
hyperfractionated radiation therapy for, 1458–1464, 3320–3321 (correspondence)
p53 gene status and tumor response in, 54–63, 1465–1473
Health behaviors, in prostate cancer prevention trial patients, 1942–1953
Health-related quality of life
after Wilms' tumor and neuroblastoma, 3280–3287
patients' and oncologists' preferences for discussing, 3295–3301
in prostate cancer prevention trial patients, 1942–1953
in recurrent glioblastoma multiforme, 1481–1491
Heart, in non-Hodgkin's lymphoma, 1996–1999
Hematologic malignancies
pediatric, pharmacokinetics of nelarabine and ara-G in (phase I trial), 995–1003
recombinant immunotoxin in (phase I trial), 1622–1636
total body irradiation in patients with, 981–986, 3062–3063 (correspondence)
WHO classification of (correspondence), 2788–2789, 3447–3452
Hematologic side-effects, with topotecan/cisplatin in humans (phase I trial), 2104–2115
Hepatic arterial chemotherapy, for colorectal cancer, 239–242 (editorial), 1806–1807 (correspondence)
5-FU/leucovorin *vs.* fluorodeoxyuridine, 243–254
Hepatic artery FUDR, and liver radiation therapy for unresectable intrahepatic cancer, 2210–2218
Hepatic dysfunction, gemcitabine in patients with (phase I trial), 2780–2787
Hepatoblastoma, childhood
cisplatin/doxorubicin and delayed surgery for, 3819–3828
treatment outcome for, 2665–2675
Hepatocellular carcinoma, associated with HBV-cirrhosis, long-term prognosis in, 1094–1101
Hepatocyte growth factor, in bladder cancer, 2963–2971
HER-2/*neu*
in benign breast disease, cancer risk and, 267–274
in breast cancer
activation of, 3230–3239
detection by FISH, 3651–3664
high-dose chemotherapy-treated high-risk, predictive value in, 2070–2080
tamoxifen resistance and, 3471–3479
in poorly differentiated carcinoma or adenocarcinoma, 632–635
Herbal supplements, PC-SPES for progressive prostate cancer, 3595–3603
Hereditary colorectal cancer
nonpolyposis (editorial), 2189–2192
population-based molecular detection of, 2193–2200, 3456 (erratum)
Hereditary colorectal cancer syndromes, diagnosis and management of, 81s–92s
Hereditary retinoblastoma, associated with primary ectopic intracranial retinoblastomas, 236–237 (correspondence)
Heterozygosity, loss at 1p36, pediatric neuroblastoma progression and, 1888–1899
High-dose chemotherapy
for adult soft tissue sarcomas, 3643–3650
for breast cancer
autologous-blood and mesenchymal stem cell coinfusion and, 307–316
Her-2/*neu* and *p53* predictive value in, 2070–2080
impact on quality of life, 754–764
metastatic (phase I/II trial), 2363–2368
questionable data on (correspondence), 2933, 3875
for follicular lymphoma, 527–536
for germ cell tumors, treatment options after failure of, 1181–1186
for infant acute leukemia, 3256–3261
for non-Hodgkin's lymphoma, survival benefit from, 3025–3030
for relapsed testicular cancer, 3346–3351
sequential, in inflammatory breast cancer, 754–764
High hyperdiploidy, in childhood ALL, 1876–1887
Histologic grade, in axillary node-positive breast cancer, prognostic value of, 2059–2069
HIV-related cancer, in children, 3854–3861
HMF. *See* Hypermetaphase FISH
Hodgkin's disease
breast cancer after, management of, 765–772
childhood

localized, chemotherapy and radiotherapy for, 1500–1507
second malignancy after treatment for, 1492–1499
cystic neck mass presenting as, 1150–1152
early-stage, treatment alternatives for (correspondence), 943–944
meningeal relapse in, 1153–1155
progressive, treatment of, 332–339
refractory, gemcitabine for (phase II trial), 2615–2619
resistant, treatment of, 3918–3924
second malignancy in, 498–509
in young survivors, 487–497, 2186–2187 (correspondence)
Stanford V regimen and radiotherapy for, 972–980
Homoharringtonine, for chronic myelogenous leukemia, 3513–3521
Horizon of Hope, by Scott D. Young (poem), 1808
Hormonal predictors, of prostate cancer, 847–853
Hormonal therapy
for breast cancer, and duration of chemotherapy, 94–101
before prostatectomy, 1050–1057
Hot flashes, in breast cancer survivors, soy phytoestrogens for, 1068–1074, 2792–2793 (correspondence)
4-HPR (*N*-(4-hydroxyphenyl) retinamide), and tamoxifen in high-risk breast cancer, 275–283
HRQL. *See* Health-related quality of life
Human glandular kallikrein-2 levels, in prostate cancer prediction, 1036–1042
Human immunodeficiency virus, and cancer in children, 3854–3861
Humoral immune response, to MUC1, breast cancer survival and, 574–583
Hydration, in terminally-ill patient, 1156–1158
Hydrocortisone, suramin and, for prostate cancer (phase III trial), 1440–1450
N-(4-hydroxyphenyl) retinamide, and tamoxifen in high-risk breast cancer, 275–283
Hyper-CVAD therapy, for adult acute lymphoblastic leukemia, 547–561
Hyperdiploidy, in childhood ALL, 1876–1887
Hypermetaphase FISH, in chronic myeloid leukemia, relapse detection by, 1831–1836
Hypersensitivity reactions, paclitaxel-associated, 102–105
Hyperuricemia, prevention and treatment of, 1758–1763, 2188 (erratum)
Hypoglycemic syncope, due to peripheral neuroectodermal tumor, 1594–1596
Hypopyon, unilateral leukemic, 3439–3440
Hysterectomy, radical, *vs.* radiation therapy for bulky stage IB and IIA cervical cancer, 1740–1747

Idarubicin, fludarabine with, for indolent or mantle-cell lymphoma, 773–779
IFN/IFN-α2b. *See* Interferon/Interferon alfa-2b
Ifosfamide
in dose-intensive salvage therapy for germ cell tumor patients, 1173–1180
with paclitaxel/cisplatin, for transitional-cell carcinoma of urothelial tract (phase I trial), 840–846
in PIEo chemoradiation for small-cell lung cancer, 2990–2995
in salvage therapy for testicular germ cell cancer, 2413–2418
vinorelbine with, for non–small-cell lung cancer (phase II trial), 2354–2362
IL/IL-2. *See* Interleukin/Interleukin-2
IM862 nasal solution, for AIDS-related Kaposi's sarcoma, 716–723
Immunocompromised children, preventing catheter-related infections in, 1269–1278
Immunocytochemistry, response of circulating breast cancer cells to therapy and, 1432–1439
Immunocytology, for prognosis in neuroblastoma, 4067–4076
Immunocytoma, rituximab for (phase II trial), 317–324, 2006 (erratum)
Immunohistochemistry
HER-2/*neu* detection in breast cancer by, 3651–3664
telomerase as prognostic marker in neuroblastoma, 2582–2592
Immunophenotyping, *BRCA1* and *BRCA2*-associated breast cancers, differences between, 107s–112s
Immunotherapy
active specific, for colon cancer (phase II and III trials), 148–157
dendritic cells as. *See* Dendritic cells
Immunotoxin, recombinant, in hematologic malignancies (phase I trial), 1622–1636
In memorium, Sydney E. Salmon, MD, 1–2
Indolent lymphoma, fludarabine alone *vs.* with idarubicin for, 773–779
Induction chemotherapy, *p53* gene status predicting tumor response to, 385–394
Inflammatory breast cancer, high-dose sequential chemotherapy in, 754–764
Insurance discrimination, specialists' perspectives on, 2484–2492
Interferon/Interferon alfa-2b. *See also* Cytokine therapy
5-FU uptake enhancement by, in colorectal and gastric cancers, 255–261
in CML
IRF4 expression and, 3331–3338
and neuropsychiatric toxicity, 1301–1308
depressive symptoms in patients receiving, 2143–2151
for high-risk melanoma, 2444–2458
IL-2 with, for metastatic renal cancer, 4009–4015
for melanoma (editorial), 1603–1605
and neuropsychiatric toxicity in CML, 1301–1308
for non-Hodgkin's lymphoma (editorial), 2007–2009
after intensive chemotherapy (phase III trial), 2010–2016, 3322 (correspondence)
psychiatric side effects of, 2316–2326
depressive symptoms, 2143–2151
in renal cell carcinoma (phase III trial), 2972–2980
Interferon regulatory factor 4, in chronic myeloid leukemia, 3331–3338
Interleukin/Interleukin-2. *See also* Cytokine therapy
depressive symptoms in patients receiving, 2143–2151
high-dose bolus, clinical response to, 1954–1959
with Interferon alfa for metastatic renal cancer, 4009–4015
for melanoma (editorial), 1603–1605
Interphase cytogenetics
HER-2/*neu* detection in breast cancer by, 3651–3664
leptomeningeal metastases treatment evaluation by, 2053–2058
for survival prediction in multiple myeloma, 804–812
Interphase FISH, in chronic myeloid leukemia, 1533–1538
Interstitial pneumonitis, acute, from gemcitabine therapy, 697–698
Intestinal lymphoma, enteropathy-type T-cell, 795–803
Intracavitary mass, secondary cardiac lymphoma manifesting as, 1998–1999
Intractable pain, in abdominal cancer, palliative therapy for, 1598–1600
Intrahepatic cancer, unresectable, treatment options for, 2210–2218
Intraocular retinoblastoma, external-beam irradiation and, 2881–2887
Intravenous allopurinol, for prevention and treatment of hyperuricemia, 1758–1763, 2188 (erratum)
Iodine-131 tositumomab, for B-cell non-Hodgkin's lymphoma (phase

II trial), 1316–1323
IRF4 (interferon regulatory factor 4) expression, in chronic myeloid leukemia, 3331–3338
Irinotecan
with cisplatin
3-week schedule for solid tumors (phase I trial), 187–194
in dose-escalating study, pharmacokinetics of, 195–203
diarrhea caused by, glutamine for (correspondence), 450–451
with docetaxel, for solid tumors (phase I trials), 3545–3552
advanced, pharmacokinetics of, 1116–1123
premedication for (correspondence), 237
for solid tumors
and cisplatin, 3-week schedule for (phase I trial), 187–194
96-hour weekly infusion for (phase I trial), 659–667
Irofulven pharmacokinetics, in solid tumors (phase I trial), 4086–4097
Irradiation. *See also* Radiotherapy
in combined modality therapy for primary CNS lymphoma (phase II trial), 519–526
neuraxial, in medulloblastoma, 3004–3011
postoperative, postmastectomy locoregional recurrence patterns and, 2817–2827
total body, in patients with hematologic malignancies, 981–986, 3062–3063 (correspondence)

JEB (carboplatin, etoposide, bleomycin) chemotherapy, for germ cell tumors in children, 3809–3818

hK2 (human glandular kallikrein-2) levels, in prostate cancer prediction, 1036–1042
K-*ras*, in lung cancer, 3221–3229
Kaposi's sarcoma, AIDS-related (editorial), 3323–3324
IM862 nasal solution for, 716–723
thalidomide activity in, 2593–2602
vinorelbine for (phase II trial), 1550–1557

Lacunar lesions, after irradiation of pediatric brain tumors, 824–831
Large-cell lymphoma, pediatric mediastinal, 3845–3853
Laryngeal mucosa, premalignant chromosomal changes in, 1644–1651
Leiomyosarcoma, soft tissue, clinical outcome and multidrug resistance in, 3211–3220
Lenograstim-primed BCT, for early stage leukemia, BMT *vs.*, 537–546
Leptomeningeal metastases, treatment evaluation by interphase cytogenetics, 2053–2058
Letrozole, for advanced breast cancer in postmenopausal women (correspondence), 1802–1803
Leucovorin
5-FU with, for nonresectable liver metastases, 243–254
for colon cancer (phase III trial), 136–147
in combination therapy for advanced gastric cancer (phase III trial), 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
and fluorouracil with or without oxaliplatin for colorectal cancer, 2938–2947
in preoperative combined-modality therapy for rectal cancer (phase I trial), 3529–3534
for solid tumors, weekly oral administration of (phase I trial), 3952–3963
Leukemia
acute
after autologous bone marrow transplantation (editorial), 945–946
after breast cancer treatment, 2836–2842
lymphoblastic. *See* Acute lymphoblastic leukemia
myelogenous. *See* Acute myelogenous leukemia
myeloid. *See* Acute myeloid leukemia
pediatric, PMRD-BMT for, 1856–1866
promyelocytic. *See* Acute promyelocytic leukemia
stem-cell transplantation in infant, 3256–3261
chronic forms. *See* Chronic myelogenous leukemia; Chronic myeloid leukemia
early stage, BMT *vs.* lenograstim-primed BCT for, 537–546
myeloblastoma (chloroma) in, 3993–3997
paraneoplastic *vs.* drug-induced rash in, 3437–3439
unilateral hypopyon in, 3439–3440
Leukemic hypopyon, unilateral, 3439–3440
Leukocyte infusion, for treatment of relapse after allogeneic stem-cell transplantation, 2269–2272
Leukocytosis, and retinoic acid syndrome in APL patients, 2620–2625
Leukopheresis, timing of, in high-risk neuroblastoma patients, 3829–3836
Lewis Y-expressing epithelial tumors, BR96-doxorubicin in (phase I trial), 2282–2292, 4000 (correspondence)
Liposarcoma
p27 protein expression in, 2888–2893
resected, prognostic factors in, 1637–1643
Liposomal doxorubicin, for platinum-sensitive ovarian cancer (phase II trial), 3093–3100
Liver
nonresectable metastases in, 5-FU/leuvocorin *vs.* fluorodeoxyuridine for, 243–254
pediatric tumors of, chemoembolization for, 1279–1284
radiation therapy and hepatic artery FUdR for unresectable intrahepatic cancer of, 2210–2218
LMB-2 (anti-Tac(Fv)-PE38), antitumor activity of (phase I trial), 1622–1636
LMCE3 treatment strategy, in pediatric neuroblastoma, 468–476
Loss of heterozygosity, at 1p36, pediatric neuroblastoma progression and, 1888–1899
Low-grade lymphoma
allogeneic BMT for (correspondence), 702–703
fludarabine/cyclophosphamide for, 987–994
Low-penetrance susceptibility genes, cancer risk and, 2309–2315
LTα (lymphotoxin alpha), in myeloma, 2843–2851
Lumpectomy
BRCA1 and *BRC2* germline mutations in locally recurrent breast cancer after (correspondence), 1159–1160
and radiation therapy, *vs.* mastectomy, 2406–2412, 4000–4001 (correspondence)
Lung
intravascular lymphomatosis in, 3733–3735
synovial cell sarcoma of, 2341–2342
Lung cancer
advanced, chemotherapy regimens for, 623–631
depression in patients with, 893–903
with mediastinal lymphadenopathy, 2636–2637
meningeal carcinomatosis in, 2926–2927
metastatic, small bowel obstruction due to, 227–228
non–small-cell. *See* Non–small-cell lung cancer
$p16^{INK4A}$, *p53*, and K-*ras* in, 3221–3229
small-cell. *See* Small-cell lung cancer
LV. *See* Leucovorin
Lymph node dissection, retroperitoneal, for embryonal carcinoma-predominant testicular cancer, 358–362

Lymphadenectomy, sentinel node. *See* Sentinel lymphadenectomy
Lymphadenopathy, mediastinal. *See* Mediastinal lymphadenopathy
Lymphangitic carcinomatosis, acute respiratory failure secondary to, 229–232, 944 (erratum)
Lymphocyte infusions, for relapsed multiple myeloma, 3031–3037
Lymphoma
  aggressive
    ACVBP and m-BACOD in, 1309–1315
    non-Hodgkin's, treatment of, 332–339
  AIDS-related, Epstein-Barr virus and, 3323–3324 (editorial), 3325–3330
  angiocentric, of head and neck, 54–63
  B-cell. *See* B-cell lymphoma
  Burkitt's, molecular biology of, 3707–3721
  diffuse large B-cell
    c-*MYC*/IGh fusion in, 510–518
    of spleen, 3731–3733
  follicular, high-dose therapy for, 527–536
  of heart
    primary transmural, 1996–1997
    secondary, 1998–1999
  large-cell, pediatric mediastinal, 3845–3853
  low-grade. *See* Low-grade lymphoma
  neutropenia in patients with, factors predicting, 325–331
  non-Hodgkin's. *See* Non-Hodgkin's lymphoma
  peripheral-blood stem cell mobilization in, 2762–2771
  primary CNS
    combined modality therapy in (phase II trial), 519–526
    treatment for, 3144–3150
  pulmonary intravascular, 3733–3735
  refractory, treatment of, 3918–3924
  relapsed and resistant, role of EPOCH chemotherapy in, 3633–3642
  small noncleaved-cell, pediatric CNS involvement and, 2017–2025
  T-cell. *See* T-cell lymphoma
Lymphomatosis, pulmonary intravascular, 3733–3735
Lymphomatous meningitis, slow-release *vs.* standard formulation of cytarabine for, 2003–2004 (correspondence), 3110–3116
Lymphotoxin alpha, in myeloma, 2843–2851
Lynch syndrome, 19s–31s

Macroglobulinemia, Waldenström's, 214–226
Magnetic resonance imaging, lacunar lesions detected by, in children with irradiated brain tumors, 824–831
Magnetic resonance spectroscopy
  in colorectal and gastric cancers, 5-FU uptake enhancement and, 255–261
  nuclear, in pediatric brain tumors, 1020–1026
Maintenance chemotherapy, after intensified chemotherapy, for childhood ALL, 1508–1516
Males, breast cancer in, 2948–2956
Malignancy
  and disease progression in breast cancer, 591–599
  new, after BMT in childhood acute leukemia, 348–357
  venous thromboembolism in (editorial), 3065–3067
Malignant gastrointestinal stromal tumors, clinical outcome and multidrug resistance in, 3211–3220
Managed care, quality of care and (editorial), 705–707
Mantle-cell lymphoma
  fludarabine alone or with idarubicin for, 773–779
  rituximab for (phase II trial), 317–324, 2006 (erratum)
Margins. *See* Surgical margins
MASCC risk index, for febrile neutropenia, 3038–3051
Maspin RT-PCR, for breast cancer cell detection, 1914–1920, 3196–3197 (correspondence)
Mass screening, neuroblastoma detection by, 3012–3017
Mastectomy
  locoregional recurrence patterns after, 2817–2827
  p53 protein predicting local failure in, 1906–1913
  radiation therapy and lumpectomy *vs.*, 2406–2412, 4000–4001 (correspondence)
Matrix metalloproteinases, biologic activity of, 1135–1149
MDR1 gene expression, in osteosarcoma, 2685–2694
Mediastinal germ cell tumors, in children and adolescents, 832–839
Mediastinal lymphadenopathy
  congestive heart failure with, 2635–2636
  lung cancer with, 2636–2637
Mediastinum, pediatric large-cell lymphoma of, 3845–3853
Medical practices, economic impact of, 1718–1724
Medulloblastoma, neuraxial irradiation in, 3004–3011
Megakarocyte growth and development factor, 2852–2861
Megestrol acetate, *vs.* exemestane for advanced breast cancer in postmenopausal women (phase III trial), 1399–1411, 4109 (correspondence)
Melanoma
  advanced, anti-idiotype vaccine for, 376–384
  GM-CSF as adjuvant therapy in (editorial), 1603–1605
    stage III and IV, 1614–1621
  high-risk, interferon alfa-2b for, 2444–2458
  metastatic
    prognostic factors in, 3782–3793
    temozolamide *vs.* dacarbazine for
      economic analysis of, 1474–1480
      phase III trial, 158–166, 2185 (correspondence), 2351–2352 (errata)
    to testis, 3187–3188
Meningeal carcinomatosis, in lung cancer, 2926–2927
Meningeal relapse, in Hodgkin's disease, 1153–1155
Meningitis
  carcinomatous, 2927–2929
  lymphomatous, slow-release *vs.* standard formulation cytarabine for, 2003–2004 (correspondence), 3110–3116
Merkel cell carcinoma, of skin, chemotherapy in, 2493–2499
Mesenchymal stem cell transplantation, in advanced breast cancer patients, 307–316
Mesothelioma, pleural, vinorelbine for (phase II trial), 3912–3917
Meta-analysis
  dexamethasone for emesis protection, 3409–3422
  hereditary retinoblastoma associated with primary ectopic intracranial retinoblastomas (correspondence), 236–237
  hormonal predictors of prostate cancer, 847–853
Metalloproteinases, biologic activity of, 1135–1149
Metastases
  adrenocortical carcinoma, thrombus in, 2638–2639
  of bone
    after breast cancer, 3925–3935
    SPECT predicting response to rhenium-186 etidronate in, 2747–2754
  brain, of small-cell lung cancer, treatment of (phase III trial), 3400–3408
  breast cancer. *See* Breast cancer, metastatic
  carcinomatous leptomeningeal, 2926–2927
  colon cancer, Flt3-ligand immunotherapy of, 3883–3893

colorectal cancer, oral 5-FU/eniluracil in (phase II study), 2894–2901
leptomeningeal, and treatment evaluation by interphase cytogenetics, 2053–2058
lung cancer, small bowel obstruction due to, 227–228
melanoma. *See* Melanoma, metastatic
myocardial, from carcinoid tumor, 1596–1597
nonresectable liver, hepatic arterial chemotherapy for, 243–254
ovarian, simulating colon cancer, 3189–3192, 4005 (erratum)
prostate cancer, androgen deprivation and suramin in, 1043–1049
renal cancer. *See* Renal cell cancer, metastatic
testicular
cardiovascular morbidity in survivors of, 1725–1732
melanoma and, 3187–3188
transitional-cell carcinoma of urothelial tract, two drug *vs.* three drug regimen for (phase I trial), 840–846
umbilical, non–small-cell lung cancer and, 3188–3189
undifferentiated carcinoma of nasopharyngeal type, long-term survivors in, 1324–1330
urothelial cancer, chemotherapy regimen for (phase II trial), 1921–1927, 2644 (erratum)
Methotrexate
5-FU uptake enhancement by, in colorectal and gastric cancers, 255–261
in adjuvant chemotherapy for breast cancer, disease-free survival and, 3125–3134
in combination therapy
for advanced gastric cancer (phase III trial), 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
for breast cancer, 2718–2727
in elderly patients, 1412–1422
for primary CNS lymphoma (phase II trial), 519–526
dose intensification in childhood ALL, 1285–1294
in MVAC regimen for urothelial TCC (phase III trial), 3068–3077
Metropenem, *vs.* ceftazidime, for febrile neutropenia, 3690–3698
MGDF (megakarocyte growth and development factor), 2852–2861
Microsatellite instability assays, technological applications in, 70s–74s
Minimal residual disease, evaluation in AML, 788–794
Mitomycin-ifosfamide-cisplatin chemotherapy, for unresectable non-small-cell lung cancer, effects on survival and quality of life (correspondence), 1802
Mitoxantrone, in combination therapy for pediatric AML, 1867–1875
MLH1 expression, in breast tumors after chemotherapy, 87–93, 944 (erratum)
Mobilization, of progenitor-cells, 1824–1830, 3063 (correspondence)
Molecular biology
of Burkitt's lymphoma, 3707–3721
of Ewing's sarcoma/primitive neuroectodermal tumor family, 204–213
Molecular remission, after allogeneic stem-cell transplantation for multiple myeloma, 2273–2281
Molecular studies
cancer chemoprevention and, 9s–18s
telomerase as prognostic marker in neuroblastoma, 2582–2592
Monoclonal antibodies
in newly diagnoses malignant gliomas (phase I trial), 3862–3872
in non-Hodgkin's lymphoma retreatment, 3135–3143
in pediatric neuroblastoma (phase I trial), 4077–4085
Morbidity/mortality
from cancer (1990s), 2258–2268
postoperative, after chemotherapy in soft tissue sarcoma, 3378–3383
MRS. *See* Magnetic resonance spectroscopy
MTA (multitargeted antifolate), and gemcitabine sequences in advanced solid tumors (phase I trial), 1748–1757
MTX. *See* Methotrexate
MUC1. *See* Polymorphic epithelial mucin
Müllerian carcinoma, paclitaxel-resistant, docetaxel for, 2733–2739
Multidrug resistance
in pediatric AML, 1867–1875
in soft tissue leiomyosarcoma and malignant gastrointestinal stromal tumors, 3211–3220
Multinational Association for Supportive Care in Cancer, risk index for febrile neutropenia, 3038–3051
Multiple myeloma
allogeneic stem-cell transplantation for, molecular remission after, 2273–2281
donor lymphocyte infusions for, 3031–3037
Multitargeted antifolate, and gemcitabine sequences in advanced solid tumors (phase I trial), 1748–1757
Mutations, *BRCA1* and *BRCA2* germline
cancer chemoprevention options in, 93s–99s
locally recurrent breast cancer in (correspondence), 1159–1160
prophylactic oophorectomy in, 100s–103s, 2728–2732
radiotherapy effects after breast-conserving treatment in, 3360–3369
MVAC chemotherapy, for urothelial TCC (phase III trial), 3068–3077
MYCN expression, in neuroblastoma, 3591–3594 (editorial), 3604–3613
Myeloblastoma, in leukemia, 3993–3997
Myelodysplasia
after autologous bone marrow transplantation (editorial), 945–946
after high-dose therapy for non-Hodgkin's lymphoma, 947–955
Myelodysplastic syndrome
after autologous BMT for non-Hodgkin's lymphoma (correspondence), 3446–3447
allogeneic BMT for, 963–971
decitabine therapy for high-risk patients (phase II trial), 956–962
Myeloid leukemia
acute, cellular pharmacokinetics of daunorubicin in, 1837–1844
acute pediatric
combination therapy in children, 1867–1875
streptococcal infection in, 1845–1855
chronic
interphase FISH in, 1533–1538
relapse detection by hypermetaphase FISH, 1831–1836
Myeloma
cytokine gene polymorphisms in, 2843–2851
interphase cytogenetics for prognosis in, 804–812
multiple
allogeneic stem-cell transplantation for, molecular remission after, 2273–2281
donor lymphocyte infusions for, 3031–3037
Myelosuppressive chemotherapy
filgrastim and sargramostim for PBSC mobilization after, 43–53, 3589 (errata)
in lymphoma patients, factors predicting, 325–331
platelet recovery after, 2852–2861
Myocardial metastases, from carcinoid tumor, 1596–1597
Myxoid liposarcoma, p27 protein expression in, 2888–2893

Nalarabine, pharmacokinetics of, in pediatric and adult patients (phase I trial), 995–1003
Nasopharyngeal carcinoma, early-stage, concomitant radiotherapy and

chemotherapy for, 2040–2045
National Surgical Adjuvant Breast and Bowel Project, adjuvant chemotherapy studies in Dukes' B *vs.* Dukes' C colon cancer (correspondence), 235–236, 942
Nausea, chemotherapy-induced, dexamethasone to control, 3409–3422
Neck. *See* Head and neck
Neoadjuvant androgen deprivation, prostate brachytherapy and, 1187–1192
Neoadjuvant chemotherapy
for breast cancer, sentinel node biopsy accuracy after, 3480–3486
for bulky stage IB and IIA cervical cancer, 1740–1747
for PNET of bone, 885–892, 2187–2188 (correspondence)
postoperative morbidity in soft tissue sarcoma after, 3378–3383
before prostatectomy, 1050–1057
Neuraxial irradiation, in medulloblastoma, 3004–3011
Neuroblastoma
advanced, health-related quality of life after, 3280–3287
angiogenesis in, 27–34, 2789–2791 (correspondence)
leukopheresis timing in, 3829–3836
mass screening detection of, 3012–3017
MYCN expression in, 3591–3594 (editorial), 3604–3613
pediatric
ch14–18 therapy in (phase I trial), 4077–4085
disease progression predictions in, 1888–1899
LMCE3 treatment strategy in, 468–476
stage I and II, surgery alone for, 18–26
stage IV, prognosis in infants, 1260–1268
stage IV-S, 477–486
tandem stem-cell transplantation in, 2567–2575
prognosis in
immunocytology for, 4067–4076
telomerase markers and, 2582–2592
Neurocognitive function, in survivors of pediatric BMT, 1004–1011
Neuropsychiatric toxicity, in chronic myelogenous leukemia, 1301–1308
Neutropenia
antibiotic prophylaxis in, 2126–2134
chemotherapy-induced, SD/01 *vs.* filgrastim for, 2522–2528
febrile. *See* Febrile neutropenia
in lymphoma patients, factors predicting, 325–331
Non-Hodgkin's lymphoma, 3918–3924
aggressive
survival in, 3025–3030
treatment of, 332–339
AIDS-related, EBV and CNS involvement in, 3325–3330
B-cell
iodine-131 tositumomab for (phase II trial), 1316–1323
11q deletion at *ATM* locus in, 2607–2614
Bcl-2 antisense therapy for (phase I trial), 1812–1823
heart involvement in, 1996–1999
high-dose therapy for
myelodysplasia and AML after, 947–955
survival benefit from, 3025–3030
interferon therapy after intensive chemotherapy (phase III trial), 2010–2016, 3322 (correspondence)
myelodysplastic syndrome after autologous BMT for (correspondence), 3446–3447
pediatric, CNS involvement in, 3018–3024
response criteria for, standardization of (erratum), 2351
rituximab retreatment in, 3135–3143
Non–small-cell lung cancer
adenovirus-mediated *p53* gene transfer in, 609–622
advanced, chemotherapy for, 35s–38s
docetaxel *vs.* vinorelbine/ifosfamide for (phase II trial), 2354–2362
tirapazamine/cisplatin, 1351–1359
docetaxel/irinotecan in (phase I trial), 2996–3003
docetaxel/vinorelbine for (phase II trial), 1346–1350
docetaxel *vs.* best supportive care in, 2095–2103, 3738–3739 (correspondence)
in elderly patients, chemotherapy evaluation in, 2529–2536
gemcitabine/cisplatin for
vs. cisplatin alone for (phase III trial), 122–130, 2791–2792 (correspondence)
before surgery or radiotherapy in (phase II trial), 2658–2664
gemcitabine/cisplatin/vinorelbine for (phase III trial), 1451–1457
gemcitabine/vinorelbine for (phase I/II trial), 405–411
high-dose cisplatin *vs.* paclitaxel/cisplatin for (phase III trial), 3390–3399
platinum-treated, docetaxel activity in, phase II trial, 131–135
relapsing or refractory, second-line chemotherapy, 3722–3730
resected N2, survival in, 2981–2989
second-line chemotherapy for, 3722–3730
stage 1, retinoic acid receptor-beta as prognostic factor in, 2798–2804
and umbilical metastasis, 3188–3189
unresectable, survival and quality of life in (correspondence), 1802
Nonsteroidal aromatase inhibitors, exemestane after, in metastatic breast cancer, 2234–2244
NSCLC. *See* Non–small-cell lung cancer
Nuclear magnetic resonance spectroscopy, in pediatric brain tumors, 1020–1026
Nuclear retinoid receptors, in normal and malignant prostates, 116–121

O^6-benzylguanine, carmustine plus, for malignant glioma (phase I trial), 3522–3528
Obstruction, small bowel, due to metastatic lung cancer, 227–228
Oligoastrocytomas, survival predictors in, 636–645
Oligodendrogliomas, survival predictors in, 636–645
Oligonucleotide therapeutics (editorial), 1809–1811
in non-Hodgkin's lymphoma (phase I trial), 1812–1823
Omeprazole, for gastroduodenal injury prevention, 463–467
Oncogenes, in male breast cancer, 2948–2956
Oncology, cost-utility assessments in, 3302–3317
Oophorectomy, prophylactic, in *BRCA1* and *BRCA2* mutation carriers, 100s–103s, 2728–2732
Oral/oropharyngeal squamous cell carcinoma, VEGF levels in, 2046–2052
Oral S-1, for solid tumors (phase I trial), 2772–2779
Osteonecrosis, in childhood ALL, 3262–3272
Osteoporosis, cancer treatment inducing, 1570–1593
Osteosarcoma
MDR1 gene expression in, 2685–2694
nonmetastatic extremity, chemotherapy for
long-term outcome in, 4016–4027
received dose-intensity in, 4028–4037
Outcome
of antibiotic therapy in febrile neutropenia, 3699–3706
and asparaginase hypersensitivity in childhood ALL, 1525–1532
in breast cancer
biologic predictors of (correspondence), 1601–1602
BRCA-1/2 and $p27^{Kip1}$ predicting, 4045–4052

effect of margin status on, 1668–1675
familial invasive, 4053–4059
HER-2/*neu* activation and, 3230–3239
metastatic, quality-of life scores predicting, 3768–3774
and CD56 expression in APL, 1295–1300
in children
with Beckwith-Wiedemann syndrome and Wilms' tumor, 2026–2031
low-risk prediction rule in febrile neutropenia, 1012–1019
with mediastinal large-cell lymphoma, 3845–3853
of donor lymphocyte infusions for relapsed multiple myeloma, 3031–3037
of growth factor use, 1764–1770, 3321–3322 (correspondence)
head and neck cancer patients' priorities for, 877–884
in locoregional rhabdomyosarcoma, 2427–2434
in nonmetastatic extremity osteosarcoma, 4016–4027
of pediatric stage I and II neuroblastoma treated with surgery alone, 18–26
physician specialization/volume impact on, 2327–2340
of radiation therapy in esophageal cancer, 455–462
in soft tissue sarcoma
leiomyosarcoma and malignant gastrointestinal stromal tumors, 3211–3220
misconceptions in (correspondence), 1800–1801
and TrkC expression in PNET, 1027–1035
Outpatient setting, cost of blood transfusion in, 2755–2761
Ovarian cancer
advanced, *p53* gene status in, 3936–3945
apoptosis-related proteins in, patient prognosis and, 3745, 3775–3781
CA-125 response rates (phase I trials), 1733–1739
cisplatin/topotecan/paclitaxel for (phase II trial), 4038–4044
cisplatin *vs.* paclitaxel for (phase III trial), 106–115, 1803–1805 (correspondence), 2349 (correspondence)
epithelial, DPD and TP expression in, 3946–3951
high-risk patients, prophylactic surgery in, 1980–1995, 3454–3455 (correspondence)
metastatic, simulating colon cancer, 3189–3192, 4005 (erratum)
oxaliplatin or paclitaxel in (phase II trial), 1193–1202
paclitaxel plus carboplatin/cisplatin for (phase III trial), 3084–3092
platinum-sensitive
liposomal doxorubicin for (phase II trial), 3093–3100
topotecan for, 1062–1067
Ovarian suppression, tamoxifen with, in breast cancer, 2718–2727
Ovarian tumors, in patients undergoing prophylactic oophorectomy, 2728–2732
Oxaliplatin
with or without leucovorin/fluorouracil, for colorectal cancer, 2938–2947
in ovarian cancer (phase II trial), 1193–1202
paclitaxel with. in advanced cancer (phase I trial), 2293–2300
Oxaliplatin-chronomodulated 5-FU, for colon cancer (phase III trial), 136–147

1p36, loss of heterozygosity at, pediatric neuroblastoma progression and, 1888–1899
p53 gene
alterations in, and tumor response to head and neck squamous cell carcinomas, 1465–1473
in breast cancer
high-dose chemotherapy-treated, predictive value of, 2070–2080
in males, 2948–2956
and tamoxifen resistance, 3471–3479
cancer susceptibility testing programs and, 2135–2142
in lung cancer, 3221–3229
non–small-cell, adenovirus-mediated transfer in, 609–622
tumor response predicted by status of, 385–394
in advanced ovarian carcinoma, 3936–3945
p27 protein, in liposarcoma, 2888–2893
p53 protein, prognostic value for local failure in mastectomy patients, 1906–1913
Paclitaxel
with carboplatin
for advanced transitional-cell carcinoma, 2537–2544
for unknown primary carcinoma (phase II trial), 3101–3107
with cisplatin
for advanced lung cancer, 623–631
for advanced urothelial cancer (phase II trial), 1058–1061
for non–small-cell lung cancer (phase III trial), 3390–3399
in combination chemotherapy
for ovarian cancer (phase I trial), 2957–2962
or urothelial TCC (phase I/II trial), 3247–3255
vs. doxorubicin for breast cancer, 724–733
with epirubicin, sequence effect on pharmacokinetics and toxicity, 2116–2125
for esophageal cancer (phase II trial), 2032–2039
hypersensitivity reactions associated with, 102–105
with ifosfamide/cisplatin, for transitional-cell carcinoma of urothelial tract (phase I trial), 840–846
oral, pharmacokinetics of (phase I trial), 2468–2475
for ovarian cancer (phase II trial), 1193–1202
cisplatin *vs.* (phase III trial), 102–105
plus carboplatin/cisplatin (phase III trial), 3084–3092
in sequential couplet therapy, 4038–4044
with oxaliplatin in advanced cancer (phase I trial), 2293–2300
in salvage therapy
dose-intensive, for germ cell tumor patients, 1173–1180
for testicular germ cell cancer, 2413–2418
for small-cell lung cancer, with concurrent radiation (phase I/II trial), 1102–1109, 3453–3454 (correspondence)
for solid malignancies (phase I trial), 3677–3689
and valspodar, in refractory tumors (phase I trial), 1124–1134, 2793 (erratum)
Paclitaxel-resistant Müllerian carcinoma, docetaxel for, 2733–2739
Pain management. *See* Palliative therapy
Palliative therapy
chemotherapy as, 2395–2405
drug interactions in, 1780–1799
for intractable abdominal cancer pain, 1598–1600
radiation as, physician communication regarding, 2902–2907
Pamidronate, in metastatic breast cancer, cost-effective analysis of, 72–79
Pancreatic cancer
chemotherapy and radiation therapy protocol in (phase I trial), 3384–3389
docetaxel and G-CSF for, phase II trial (correspondence), 445–451
preoperative chemoradiation for, 860–867
Paraneoplastic rash, in leukemia, 3437–3439
Partially mismatched related-donor BMT, for pediatric acute leukemia, 1856–1866
Patient autonomy, 3736–3737
Patient expectations, regarding phase I clinical trials, impact of quality

of life on, 421–428, 1807 (erratum)
Patient-physician communication, 3441–3445
Patient preferences, for discussing HRQL issues with physicians, 3295–3301
Patient satisfaction, audiotaped initial consultation and, 3052–3060
Patient selection, in adjuvant therapy trials, PSA failure, 3240–3246
PBSC. *See* Peripheral-blood stem cell mobilization
PC-SPES, for progressive prostate cancer, 3595–3603
Pediatricians, perspectives of phase I clinical trials (United Kingdom), 1900–1905
Pelvis, radiation therapy involving
with chemotherapy for cervical cancer, 1606–1613
sucralfate for diarrhea prevention in (phase III trial), 1239–1245
PEM. *See* Polymorphic epithelial mucin
Peptide receptor scintigraphy, for carcinoid tumors, 1331–1336
Perioperative chemotherapy, reducing local recurrence risk after breast-conserving therapy, 1075–1083
Peripheral-blood stem cell mobilization
with daniplestim/G-CSF, in breast cancer or lymphoma, 2762–2771
filgrastim and sargramostim for, 43–53, 3589 (errata)
Peripheral neuroectodermal tumor, hypoglycemic syncope due to, 1594–1596
Peripheral primary neuroectodermal tumor, of bone, neoadjuvant chemotherapy for, 885–892, 2187–2188 (correspondence)
PET. *See* Positron emission tomography
Pharmacodynamics
of docetaxel/topotecan, in solid tumors, 3288–3294
of paclitaxel/oxaliplatin, in advanced cancer (phase I trial), 2293–2300
Pharmacokinetics
of Bcl-2 antisense therapy in non-Hodgkin's lymphoma (phase I trial), 1812–1823
cellular, of daunorubicin in acute myeloid leukemia, 1837–1844
of docetaxel/irinotecan in solid tumors (phase I trial), 3545–3552
of docetaxel/topotecan in solid tumors, 3288–3294
of DX-8951F
infusion in advanced cancer (phase I trial), 3986–3992
in solid tumors (phase I trial), 3151–3163
of emitefur in solid tumors (phase I trial), 3423–3434
of gemcitabine
and doxorubicin in advanced breast cancer (phase II trial), 2545–2552
in patients with hepatic or renal dysfunction (phase I trial), 2780–2787
of irinotecan
and cisplatin in dose-escalating study, 195–203
and docetaxel in advanced solid tumors (phase I trial), 1116–1123
of irofulven in solid tumors (phase I trial), 4086–4097
of nelarabine and ara-G in pediatric hematologic malignancies (phase I trial), 995–1003
of oral paclitaxel (phase I trial), 2468–2475
of oral S-1 in solid tumors (phase I trial), 2772–2779
of RPR 109881A in solid tumors (phase I trial), 3164–3171
sequence effect of paclitaxel/epirubicin on, 2116–2125
of topotecan in a population model, 2459–2467
of vesnarinone with gemcitabine in advanced cancer (phase I trial), 3974–3985
of weekly oral 5-FU/eniluracil/leucovorin for solid tumors (phase I trial), 3952–3963
Phase I trials
of anti-epidermal growth factor receptor mAb C225, 904–914
BAY 12–9566 for solid tumors, 178–186, 1805–1806 (correspondence)
Bcl-2 antisense therapy for non-Hodgkin's lymphoma, 1812–1823
BR96-doxorubicin in Lewis Y-expressing epithelial tumors, 2282–2292, 4000 (correspondence)
CA-125 response rates in ovarian cancer, 1733–1739
carmustine plus O^6-benzylguanine for malignant glioma, 3522–3528
CEA vaccines for advanced cancer (phase I trial), 3964–3973
ch14–18 therapy in pediatric neuroblastoma, 4077–4085
chemotherapy and radiation therapy protocol in pancreatic cancer, 3384–3389
design in cancer drug development, 684–692
docetaxel/irinotecan
for non–small-cell lung cancer, 2996–3003
for solid tumors, 3545–3552
DX-8951F
in advanced cancer, 3986–3992
in solid tumors, 3151–3163
emitefur pharmacokinetics in solid tumors, 3423–3434
farnesyl protein transferase inhibitor R115777 for advanced cancer, 927–941
5-FU
chronic oral, plus eniluracil, 915–926
and PN401 for solid tumors, 167–177
gemcitabine
modifying treatments for solid tumors, 3553–3557
and MTA sequences in solid tumors, 1748–1757
in patients with hepatic or renal dysfunction, 2780–2787
^{131}I-81C6 in newly diagnosed malignant gliomas, 3862–3872
irinotecan
and cisplatin 3-week schedule for solid tumors, 187–194
and docetaxel pharmacokinetics in solid tumors, 1116–1123
96-hour weekly infusion for solid tumors, 659–667
irofulven pharmacokinetics in solid tumors, 4086–4097
nelarabine and ara-G pharmacokinetics in hematologic malignancies, 995–1003
oral S-1 in solid tumors, 2772–2779
paclitaxel
oral, pharmacokinetics of, 2468–2475
and valspodar for refractory tumors, 1124–1134, 2793 (erratum)
paclitaxel/carboplatin/etoposide combination for ovarian cancer, 2957–2962
paclitaxel/carboplatin/valspodar for solid tumors, 3677–3689
paclitaxel/oxaliplatin pharmacokinetics in advanced cancer, 2293–2300
pediatricians' perspectives of (United Kingdom), 1900–1905
preoperative combined-modality therapy for rectal cancer, 3529–3534
quality of life impact on patient expectations regarding, 421–428, 1807 (erratum)
recombinant immunotoxin for hematologic malignancies, 1622–1636
RPR 109881A for solid tumors
dose-finding study (phase I trial), 4098–4108
pharmacokinetics in, 3164–3171
6-hour glufosfamide infusion, 3535–3544
two drug *vs.* three drug regimen for urothelial tract TCC, 840–846
vesnarinone with gemcitabine for advanced cancer, 3974–3985
weekly oral 5-FU/eniluracil/leucovorin for solid tumors (phase I trial), 3952–3963
Phase I/II trials

chemotherapy with radiation for small-cell lung cancer, 1102–1109, 3453–3454 (correspondence)
combination chemotherapy for transitional cell carcinoma of urothelium, 3247–3255
gemcitabine/vinorelbine for non–small-cell lung cancer, 405–411
high-dose chemotherapy for metastatic breast cancer, 2363–2368
Phase II trials
capecitabine for colorectal cancer, 1337–1345
carboplatin with paclitaxel for carcinoma of unknown primary site, 3101–3107
chemotherapy and 3-D conformal radiotherapy for prostate cancer, 1936–1941
cisplatin/paclitaxel for urothelial cancer, 1058–1061
cisplatin/topotecan/paclitaxel for ovarian cancer, 4038–4044
combined modality therapy in primary CNS lymphoma, 519–526
content and quality of, 429–436
cyclophosphamide and etoposide for pediatric solid tumors, 2576–2581, 3741–3743 (correspondence)
decitabine therapy for myelodysplastic syndrome in elderly patients, 956–962
docetaxel
activity in platinum-treated non–small-cell lung cancer, 131–135
vs. doxorubicin for soft tissue sarcoma, 2081–2086
and G-CSF for pancreatic cancer (correspondence), 445–451
and vinorelbine for non–small-cell lung cancer, 1346–1350
vs. vinorelbine/ifosfamide for non–small-cell lung cancer, 2354–2362
doxorubicin
and docetaxel plus GCSF in metastatic breast cancer (phase II trial), 2369–2377
liposomal, for ovarian cancer, 3093–3100
exemestane after failed nonsteroidal aromatase inhibitors in metastatic breast cancer (phase II trial), 2234–2244
flavopiridol for metastatic renal cancer, 371–375
5-FU/eniluracil
for advanced breast cancer, 2378–2384
oral, for metastatic colorectal cancer, 2894–2901
gemcitabine
and cisplatin before surgery or radiotherapy in non–small-cell lung cancer, 2658–2664
and doxorubicin pharmacokinetics in advanced breast cancer, 2545–2552
for refractory Hodgkin's disease, 2615–2619
immunotherapy for colon cancer, 148–157
iodine-131 tositumomab for non-Hodgkin's lymphoma, 1316–1323
oxaliplatin or paclitaxel for ovarian cancer, 1193–1202
paclitaxel chemoradiotherapy for esophageal cancer, 2032–2039
preoperative chemoradiation and postoperative chemotherapy for esophageal cancer, 868–876
PSA in androgen independent prostate cancer (erratum), 2644
rituximab for B-cell lymphomas, 317–324, 2006 (erratum)
squamous cell carcinoma of head and neck (correspondence), 1393–1395
subcutaneous amifostine during fractionated radiotherapy, 2226–2233
thalidomide
for high-grade gliomas, 708–715, 3453 (correspondence)
for metastatic breast cancer, 2710–2717
tirapazamine and radiation therapy for glioblastoma multiforme, 1254–1259
up-front accelerated thoracic radiotherapy and chemotherapy in small-cell lung cancer, 1662–1667
vinorelbine
and 5-FU for anthracycline-pretreated breast cancer, 3370–3377
for AIDS-related Kaposi's sarcoma, 1550–1557
for pleural mesothelioma, 3912–3917
vinorelbine/doxorubicin *vs.* doxorubicin alone for metastatic breast cancer, 2385–2394
Phase III trials
amifostine as radioprotector in head and neck cancer, 3339–3345
in brain metastases of small-cell lung cancer, 3400–3408
chemotherapy regimens in advanced gastric cancer, 2648–2657, 3874 (correspondence), 4001–4003 (correspondence)
cisplatin
vs. paclitaxel/cisplatin, high-dose, for non–small-cell lung cancer, 3390–3399
vs. paclitaxel for stage III or IV ovarian cancer, 106–115, 1803–1805 (correspondence), 2349 (correspondence)
dexamethasone for radiation-induced emesis, 1960–1966
doxorubicin, high-dose *vs.* standard-dose, for advanced soft tissue sarcomas, 2676–2684
exemestane *vs.* megestrol acetate for advanced breast cancer in postmenopausal women, 1399–1411, 4109 (correspondence)
gemcitabine/cisplatin/vinorelbine for non–small-cell lung cancer, 1451–1457
gemcitabine/cisplatin *vs.* cisplatin alone in non–small-cell lung cancer, 122–130, 2791–2792 (correspondence)
immunotherapy for colon cancer, 148–157
interferon therapy after intensive chemotherapy in non-Hodgkin's lymphoma, 2010–2016, 3322 (correspondence)
oxaliplatin-chronomodulated 5-FU/leucovorin for colon cancer, 136–147
paclitaxel plus carboplatin/cisplatin for ovarian cancer, 3084–3092
sucralfate for diarrhea prevention in pelvic radiation therapy, 1239–1245
suramin for prostate cancer, 1440–1450
temozolomide *vs.* dacarbazine for metastatic melanoma, 158–166, 2185 (correspondence), 2351–2352 (errata)
Physicians
and collaborative decision making in breast cancer, 1230–1238
communication between, regarding palliative radiotherapy, 2902–2907
compliance with warfarin prophylaxis in patients with central venous catheters, 3665–3667
impact of specialization/volume on outcome, 2327–2340
and patient communication, 3441–3445
patient's end-of-life questions answered by, 699–701, 2640–2643
pediatricians' perspectives of phase I clinical trials (United Kingdom), 1900–1905
preferences for discussing HRQL issues with patients, 3295–3301
referral and consultation by, 2345–2348, 3739–3741 (correspondence)
and referral of breast cancer patients to clinical trials, 1203–1211
tumor measurement accuracy and reproducibility by, 437–444
Phytoestrogens, for hot flashes in breast cancer survivors, 1068–1074, 2792–2793 (correspondence)
PIEo chemoradiation, for small-cell lung cancer, 2990–2995
P16^{INK4A}, in lung cancer, 3221–3229
p27^{Kip1} protein, predicting survival in breast cancer, 4045–4052
Placental site trophoblastic tumors, EP/EMA chemotherapy in, 854–859, 2187 (correspondence)
Plasma D-dimer levels, in breast cancer, 600–608

Platelet recovery, after myelosuppressive chemotherapy, 2852–2861
Platinum/paclitaxel-based chemotherapy, p53 status in advanced ovarian carcinoma and, 3936–3945
Platinum-sensitive ovarian cancer
liposomal doxorubicin for (phase II trial), 3093–3100
topotecan for, 1062–1067
Platinum-treated non–small-cell lung cancer, docetaxel for activity in (phase II trial), 131–135
vs. best supportive care, 2095–2103, 3738–3739 (correspondence)
Pleural mesothelioma, vinorelbine for (phase II trial), 3912–3917
PML. *See* Acute promyelocytic leukemia
PMRD-BMT (partially mismatched related-donor BMT), for pediatric acute leukemia, 1856–1866
PN401, for advanced solid malignancies (phase I trial), 167–177
Pneumonitis, acute interstitial, from gemcitabine therapy, 697–698
Polymerase chain reaction
quantitative, and response of circulating breast cancer cells to therapy, 1432–1439
reverse transcriptase
of maspin, for breast cancer cell detection, 1914–1920, 3196–3197 (correspondence)
in t(8;21), for minimal residual disease evaluation in AML, 788–794
Polymorphic epithelial mucin, humoral immune response to, breast cancer survival and, 574–583
Population pharmacokinetic model, for topotecan, 2459–2467
Positron emission tomography
in breast cancer
monitoring primary chemotherapy, 1689–1695
predicting pathologic response to primary chemotherapy, 1678–1688
for esophageal cancer staging, 3199–3201(editorial), 3202–3210
with FDG, of breast, 3495–3502
for surveillance in recurrent cancer of head and neck, 651–658
Postmenopausal women
breast cancer in
adjuvant therapy toremifene or tamoxifen for, 3487–3494
advanced
anastrazole *vs.* tamoxifen in, 3748–3757, 3758–3767
exemestane *vs.* megestrol acetate for (phase III trial), 1399–1411, 4109 (correspondence)
letrozole *vs.* megestrol acetate for (correspondence), 1802–1803
fat intake and sex steroid hormone levels in, 3668–3676
tamoxifen-treated, effects on endometrium in, 3464–3470
Posttransplant lymphoproliferative disease, remission after chemotherapy for, 3622–3632
Posttraumatic stress disorder, in childhood cancer survivors, 4060–4066
Predisposition testing. *See also* Genetic testing
technological applications in, 70s–74s
Premalignant laryngeal lesions, chromosomal changes in, 1644–1651
Preoperative chemoradiation
in pancreatic cancer, 860–867
and postoperative chemotherapy, for esophageal cancer (phase II trial), 868–876
Primary cutaneous B-cell lymphoma, 2152–2168
Primary ectopic intracranial retinoblastomas, hereditary retinoblastoma associated with (correspondence), 236–237
Primary systemic therapy, for operable, breast cancer, 1558–1569
Primary transmural cardiac lymphoma, 1996–1997
Primitive neuroectodermal tumors
molecular biology of, 204–213
TrkC expression in, 1027–1035
Procarbazine, temozolomide *vs.*, for recurrent glioblastoma multiforme, 1481–1491
Progenitor-cell mobilization, 1824–1830, 3063 (correspondence)
Prognostic factors. *See also* Survival
and apoptosis-related proteins in advanced ovarian cancer, 3745–3747, 3775–3781
in breast cancer
axillary node-positive, 2059–2069
BRCA1-associated, 113s–118s
in *BRCA2*-associated, 119s–124s
familial invasive, 4053–4059
in Ewing's sarcoma of bone, 4–11, 3108–3114
and hepatocyte growth factor in bladder cancer, 2963–2971
in Hodgkin's disease (correspondence), 943–944
informing patient about, 699–701, 2640–2643
in metastatic melanoma, 3782–3793
in multiple myeloma, interphase cytogenetics for, 804–812
in neuroblastoma
angiogenesis and, 27–34, 2789–2791 (correspondence)
immunocytology for, 4067–4076
infant stage IV, 1260–1268
telomerase markers and, 2582–2592
p53 protein and local failure in mastectomy patients, 1906–1913
in pediatric ALL with high hyperdiploidy, 1876–1887
in resected liposarcoma, 1637–1643
retinoic acid receptor-beta in stage 1 non–small-cell lung cancer and, 2798–2804
in synovial sarcoma, 2087–2094, 3794–3803
VEGF levels in oral and oropharyngeal squamous cell carcinoma, 2046–2052
Prophylactic oophorectomy, in *BRCA1* and *BRCA2* mutation carriers, 100s–103s, 2728–2732
Prophylaxis
antibiotic, in neutropenic patients, 2126–2134
cranial irradiation, in limited small-cell lung cancer (phase II trial), 1662–1667
surgical
in high-risk breast and ovarian cancer patients, 1980–1995, 3454–3455 (correspondence)
oophorectomy. *See* Prophylactic oophorectomy
specialists' perspectives on, 2484–2492
warfarin in patients with central venous catheters, 3665–3667
Prospective trial
locoregional breast cancer recurrence, 1696–1708
p53 gene alterations and tumor response to head and neck squamous cell carcinomas, 1465–1473
PC-SPES for progressive prostate cancer, 3595–3603
squamous cell carcinoma of head and neck, hyperfractionated radiation therapy for, 1458–1464, 3320–3321 (correspondence)
Prostate biopsy (editorial), 1161–1163
positive, and PSA outcome after radical prostatectomy, 1164–1172
Prostate brachytherapy, and neoadjuvant androgen deprivation, 1187–1192
Prostate cancer
70 Gy and 78 Gy for, comparisons between, 3904–3911
androgen independent, prostate-specific antigen in, phase II trial (erratum), 2644
bicalutamide *vs.* maximal androgen patient blockade in (correspon-

dence), 448–450
biopsy in. *See* Prostate biopsy
chemotherapy and 3-D conformal radiotherapy for (phase II trial), 1936–1941
fenretinide therapy in, 3804–3808
high–dose-rate brachytherapy for, 2869–2880, 4003–4005 (correspondence)
higher-dose radiation therapy for, surgical advantage from, 2740–2746, 4003 (correspondence)
hormonal predictors of, 847–853
hormone-refractory, dendritic-cell immunotherapy for, 3894–3903
metastatic, androgen deprivation and suramin in, 1043–1049
nuclear retinoid receptors in, 116–121
pretreatment normogram predicting outcome in, 3352–3359
prevention trial, patient profiles in, 1942–1953
progressive, PC-SPES for, 3595–3603
serum hK2 levels predicting, 1036–1042
suramin for (phase III trial), 1440–1450
Prostate gland
biopsy of. *See* Prostate biopsy
cancer of. *See* Prostate cancer
nuclear retinoid receptors in, 116–121
Prostate-specific antigen
in androgen independent prostate cancer, phase II trial (erratum), 2644
and patient selection for adjuvant therapy trials, 3240–3246
and positive prostate biopsy outcome after radical prostatectomy, 1164–1172
Prostatectomy
neoadjuvant chemotherapy and hormonal therapy before, 1050–1057
positive biopsy and PSA outcome after, 1164–1172
preoperative prediction of surgical margins of, 2862–2868, 3589 (errata)
Protease systems, tumor-associated, and *c-erbB-2* in gastric cancer, 2201–2209
Psychiatric problems, in early-stage breast cancer patients, 1084–1093
Psychiatric side effects, of interferon therapy, 2316–2326
PTLD (posttransplant lymphoproliferative disease), remission after chemotherapy for, 3622–3632
PTSD (posttraumatic stress disorder), in childhood cancer survivors, 4060–4066
Pulmonary intravascular lymphomatosis, 3733–3735

Quality, of currently published phase II clinical trials, 429–436
Quality of care
antibiotic therapy in febrile neutropenia and, 3699–3706
impact of physician specialization/volume on outcome, 2327–2340
managed care and (editorial), 705–707
Quality of life
audiotaped initial consultation and, 3052–3060
in breast cancer survivors, 743–753
health-related
after Wilms' tumor and neuroblastoma, 3280–3287
patients' and oncologists' preferences for discussing issues in, 3295–3301
impact of high-dose sequential chemotherapy in inflammatory breast cancer, 754–764
impact on patient expectations regarding phase I clinical trials, 421–428, 1807 (erratum)
in lung cancer patients
with depression, 893–903
small-cell, and dose-intensity of chemotherapy, 395–404
unresectable non-small-cell (correspondence), 1802
reporting standards for (correspondence), 1801–1802
and symptom change/tumor response in metastatic breast cancer, 2395–2405
Quality-of-life scores, and outcome, metastatic *vs.* early breast cancer, 3768–3774

R115777 (farnesyl protein transferase inhibitor), for advanced cancer (phase I trial), 927–941
Racial differences, in survival of pediatric ALL, 813–823
Mexican *vs.* American-Mexican children (correspondence), 2349–2350
Radiation-induced emesis, dexamethasone for (phase II trial), 1960–1966
Radiation recall dermatitis, from gemcitabine therapy, 693–694
Radiation recall reaction, from gemcitabine therapy, 695–696
Radiation therapy. *See* Radiotherapy
Radical hysterectomy, *vs.* radiation therapy for bulky stage IB and IIA cervical cancer, 1740–1747
Radiotherapy. *See also* Irradiation
after breast-conserving treatment, effect of, 3360–3369
ASCO guidelines for use of (correspondence), 2004–2006, 3064
for base-of-tongue carcinoma, 35–42, 3452–3453 (correspondence)
BRCA1 and *BRC2* germline mutations in locally recurrent breast cancer after (correspondence), 1159–1160
for breast cancer, outcome in, 1668–1675
C225, enhanced apoptosis with, 47s–53s
with chemotherapy
for early-stage nasopharyngeal carcinoma, 2040–2045
for pancreatic cancer (phase I trial), 3384–3389
consolidative, for Hodgkin's disease, 972–980
electron-beam boost in early-stage breast cancer, cost-effectiveness of, 287–295
external-beam
intraocular retinoblastoma and, 2881–2887
for prostate cancer, 2869–2880, 4003–4005 (correspondence)
fractionated
for squamous cell carcinoma of head and neck, 1458–1464, 3320–3321 (correspondence)
subcutaneous amifostine during (phase II trial), 2226–2233
higher-dose, for prostate cancer, surgical advantage from, 2740–2746, 4003 (correspondence)
in liver, and hepatic artery FUDR for unresectable intrahepatic cancer, 2210–2218
locoregional, in breast cancer, 1220–1229
and lumpectomy, *vs.* mastectomy, 2406–2412, 4000–4001 (correspondence)
for non–small-cell lung cancer, gemcitabine/cisplatin before (phase II trial), 2658–2664
outcomes in esophageal cancer, 455–462
palliative, physician communication regarding, 2902–2907
in pediatric patients
for brain tumors, lacunar lesions after, 824–831
for localized Hodgkin's disease, response-adapted chemotherapy before, 1500–1507
pelvic
concurrent with chemotherapy for cervical cancer, 1606–1613
sucralfate for diarrhea prevention in (phase III trial), 1239–1245
in preoperative combined-modality therapy for rectal cancer (phase

I trial), 3529–3534
for prostate cancer, dose-escalation study in, 3904–3911
radical hysterectomy *vs.*, for bulky stage IB and IIA cervical cancer, 1740–1747
for small-cell lung cancer, chemotherapy with (phase I/II trial), 1102–1109, 3453–3454 (correspondence)
for squamous cell carcinoma of tonsillar region, 2219–2225
systemic failure patterns after, in angiocentric lymphoma of head and neck, 54–63
with tamoxifen, for diffuse brainstem gliomas, 1246–1253
3-D conformal
with chemotherapy for prostate cancer (phase II trial), 1936–1941
in prostate cancer, 3352–3359
tirapazamine and, for glioblastoma multiforme (phase II trial), 1254–1259
up-front accelerated thoracic, and chemotherapy in limited small-cell lung cancer (phase II trial), 1662–1667
whole-brain, in treatment of brain metastases of small-cell lung cancer (phase III trial), 3400–3408
Ranitidine, for gastroduodenal injury prevention, 463–467
Rash
from gemcitabine therapy
radiation recall dermatitis, 693–694
radiation recall reaction, 695–696
paraneoplastic *vs.* drug-induced, in leukemia, 3437–3439
Recombinant G-CSF, in childhood ALL, 1517–1524
Recombinant immunotoxin, in hematologic malignancies (phase I trial), 1622–1636
Recurrence
after mastectomy, locoregional patterns of, 2817–2827
of breast cancer
BRCA1 and *BRC2* germline mutations in (correspondence), 1159–1160
locoregional, 1696–1708
margin status and, 1668–1675
risk reduction after breast-conserving therapy, 1075–1083
and VEGF in primary node-positive breast cancer, 1423–1431
Referral, 2345–2348, 3739–3741 (correspondence)
of breast cancer patients to clinical trials, 1203–1211
Refractory Hodgkin's disease, gemcitabine for (phase II trial), 2615–2619
Refractory non–small-cell lung cancer, second-line chemotherapy in, 3722–3730
Refractory tumors
lymphomas, treatment of, 3918–3924
paclitaxel and valspodar in (phase I trial), 1124–1134, 2793 (erratum)
Relapse
after allogeneic stem-cell transplantation, donor leukocyte infusion for, 2269–2272
central nervous system
in childhood ALL, survival and, 703 (errata)
extramedullary, in acute APL, 3435–3437
in CML, detection by FISH, 1831–1836
meningeal, Hodgkin's disease, 1153–1155
and tumor location relationship in early invasive breast cancer, 2828–2835
and VEGF in primary node-positive breast cancer, 1423–1431
Relapsed breast cancer, gemcitabine with cisplatin for, 2245–2249
Relapsed lymphomas, EPOCH chemotherapy in, 3633–3642
Relapsed multiple myeloma, donor lymphocyte infusions for, 3031–3037
Relapsed testicular cancer, high-dose chemotherapy for, 3346–3351
Relapsing non–small-cell lung cancer, second-line chemotherapy in, 3722–3730
Reliability, of data from multicenter trials, 1771–1779
Remission
after chemotherapy for PTLD, 3622–3632
arsenic trioxide-induced, in acute PML, 3435–3437
molecular, after allogeneic stem-cell transplantation for multiple myeloma, 2273–2281
Renal cell cancer
advanced, effect of cytokine therapy on survival in, 1928–1935
INFα2a and 13-*cis*-retinoic acid in (phase III trial), 2972–2980
metastatic
cytoreduction nephrectomy in, 39s–42s
flavopiridol for (phase II trial), 371–375
gemcitabine and 5-FU for (phase II trial), 2419–2426
IL-2/IFN for, with or without 5-FU, 4009–4015
Renal function/dysfunction
carboplatin dosing in children and, 3614–3621
gemcitabine in patients with (phase I trial), 2780–2787
Reporting standards, for quality of life in clinical trials (correspondence), 1801–1802
Resection
for liposarcoma, prognosis for, 1637–1643
in stage I breast cancer (correspondence), 942–943
Respiratory failure, acute, secondary to lymphangitic carcinomatosis, 229–232, 944 (erratum)
Response criteria, for non-Hodgkin's lymphoma, standardization of (erratum), 2351
N-(4-hydroxyphenyl) Retinamide, and tamoxifen in high-risk breast cancer, 275–283
Retinoblastoma
chemoreduction and local ophthalmic therapy for, 12–17
intraocular, chemotherapy and radiotherapy in, 2881–2887
trilateral, meta-analysis of (correspondence), 236–237
13-*cis*-Retinoic acid, in renal cell carcinoma (phase III trial), 2972–2980
Retinoic acid receptor-beta, in stage 1 non–small-cell lung cancer, 2798–2804
Retinoic acid syndrome, leukocytosis and, in APL patients, 2620–2625
Retinoids, prostatic
fenretinide therapy effect on, 3804–3808
receptors for, 116–121
Reverse transcriptase-PCR
of maspin, for breast cancer cell detection, 1914–1920, 3196–3197 (correspondence)
in t(8;21), for minimal residual disease evaluation in AML, 788–794
Rhabdomyosarcoma, locoregional, improved outcome for, 2427–2434
Rhenium-186 etidronate, in metastatic bone disease, SPECT predicting response to, 2747–2754
Rifampin, and antibiotic prophylaxis in neutropenic patients, 2126–2134
Risk modeling, cancer chemoprevention and, 9s–18s
Rituximab
for B-cell lymphomas (phase II trial), 317–324, 2006 (erratum)
efficacy in hairy cell leukemia (correspondence), 3875
retreatment in non-Hodgkin's lymphoma, 3135–3143
Round-cell liposarcoma, p27 protein expression in, 2888–2893
RPR 109881A, in solid tumors
advanced, dose-finding study (phase I trial), 4098–4108

pharmacokinetics of (phase I trial), 3164–3171
RT. *See* Radiotherapy

Salmon, Sydney E., MD (in memorium), 1–2
Salvage therapy
dose-intensive, for germ cell tumor patients, 1173–1180
for platinum-sensitive ovarian cancer, 1062–1067
in relapsed testicular cancer, 3346–3351
for testicular germ cell cancer, 2413–2418
Sarcoma. *See also* Soft tissue sarcoma
Ewing's, molecular biology of, 204–213
granulocytic
of breast, 3993–3996
meningeal, in essential thrombocytopenia, 3996–3997
Kaposi's. *See* Kaposi's sarcoma
synovial
of lung, 2341–2342
prognostic factors in, 2087–2094
staging and prognostic assessment in, 3794–3803
uterine, 2343–2344
Sargramostim, for peripheral-blood stem cell mobilization, 43–53, 3589 (errata)
Screening
for endometrial cancer in patient receiving tamoxifen for breast cancer (correspondence), 446–448
for endometrial changes in breast cancer, 3459–3463
in postmenopausal women, 3464–3470
for neuroblastoma in general population, 3012–3017
SD/01, *vs.* filgrastim for chemotherapy-induced neutropenia, 2522–2528
Second-line chemotherapy, for non–small-cell lung cancer, 3722–3730
Second malignancy, in Hodgkin's disease, 498–509
in young survivors, 487–497, 2186–2187 (correspondence)
Sector resection, in stage I breast cancer (correspondence), 942–943
Sentinel lymphadenectomy
in breast cancer, 2553–2559, 3873 (correspondence) procedure in vulval squamous cell carcinoma, 2795–2797 (editorial), 2811–2816
Sentinel node biopsy
after neoadjuvant chemotherapy in breast cancer, 3480–3486
in breast cancer, 2560–2566
Sequence effect
of paclitaxel/epirubicin, 2116–2125
of topotecan/cisplatin, in humans (phase I trial), 2104–2115
Sex differences, in 5-FU-induced stomatitis, 412–420
Sex steroid hormones, levels in postmenopausal women, dietary fat intake and, 3668–3676
Sexual function, in prostate cancer prevention trial patients, 1942–1953
Side effects
from gemcitabine therapy, 693–694
hematologic, with topotecan/cisplatin in humans (phase I trial), 2104–2115
psychiatric, of interferon therapy, 2316–2326
Single-photon emission computed tomography, predicting response to rhenium-186 etidronate in metastatic bone disease, 2747–2754
6-hour glufosfamide infusion (phase I trial), 3535–3544
Skin
Merkel cell carcinoma of, chemotherapy in, 2493–2499
primary B-cell lymphoma of, 2152–2168
Small B-cell lymphocytic lymphoma, rituximab for (phase II trial), 317–324, 2006 (erratum)
Small bowel obstruction, due to metastatic lung cancer, 227–228
Small-cell lung cancer
chemotherapy with radiation for (phase I/II trial), 1102–1109, 3453–3454 (correspondence)
dose-intensity of chemotherapy in, 395–404
limited, up-front treatment and prophylaxis in (phase II trial), 1662–1667
PIEo chemoradiation for, 2990–2995
Small round-cell tumors, 1594–1597
Smokers, $p16^{INK4A}$, p53, and K-*ras* in, 3221–3229
Soft tissue sarcoma
advanced, high-dose *vs.* standard-dose doxorubicin for (phase III trial), 2676–2684
docetaxel *vs.* doxorubicin for (phase II trial), 2081–2086
high-dose chemotherapy in, 3643–3650
leiomyosarcoma, clinical outcome and multidrug resistance in, 3211–3220
long-term outcomes in, misconceptions in (correspondence), 1800–1801
postoperative morbidity after chemotherapy in, 3378–3383
Solid tumors
advanced, 5-FU and PN401 treatment in (phase I trial), 167–177
advanced, gemcitabine and MTA sequences in (phase I trial), 1748–1757
BAY 12–9566 for (phase I trial), 167–177
docetaxel/irinotecan for (phase I trial), 3545–3552
docetaxel/topotecan interaction in, 3288–3294
DX-8951F pharmacokinetics in (phase I trial), 3151–3163
emitefur pharmacokinetics in (phase I trial), 3423–3434
gemcitabine-modified treatments for (phase I trial), 3553–3557
irinotecan for
and cisplatin, 3-week schedule for (phase I trial), 187–194
with docetaxel, pharmacokinetics of (phase I trial), 1116–1123
96-hour weekly infusion for (phase I trial), 659–667
irofulven pharmacokinetics in (phase I trial), 4086–4097
oral S-1 in (phase I trial), 2772–2779
paclitaxel/carboplatin/valspodar in (phase I trial), 3677–3689
pediatric, cyclophosphamide and etoposide for (phase II trial), 2576–2581, 3741–3743 (correspondence)
pharmacokinetics of RPR 109881A in (phase I trial), 3164–3171
RPR 109881A for
dose-finding study (phase I trial), 4098–4108
pharmacokinetics of (phase I trial), 3164–3171
warfarin prophylaxis for central venous catheters in patients with, 3665–3667
weekly oral 5-FU/eniluracil/leucovorin for (phase I trial), 3952–3963
Soy phytoestrogens, for hot flashes in breast cancer survivors, 1068–1074, 2792–2793 (correspondence)
Spirituality, dying patient and, 2000–2002
Spleen, primary malignant (diffuse large B-cell) lymphoma of, 3731–3733
Squamous cell carcinoma
base-of-tongue, radiotherapy for, 35–42, 3452–3453 (correspondence)
esophageal, preoperative chemoradiation and adjuvant chemotherapy for (phase II trial), 868–876
of head and neck
combination chemotherapy for, phase II trial (correspondence), 1393–1395
hyperfractionated radiation therapy for, 1458–1464, 3320–3321

(correspondence)
p53 gene alterations and tumor response to, 1465–1473
oral and oropharyngeal, VEGF levels in, 2046–2052
p53 gene status predicting tumor response in, 385–394
of tonsillar region, radiation therapy for, 2219–2225
vulval, sentinel lymph node procedure in, 2795–2797 (editorial), 2811–2816
Staging
of soft tissue sarcoma, misconceptions in (correspondence), 1800–1801
in synovial sarcoma, prognostic assessment and, 3794–3803
Standardization, of response criteria for non-Hodgkin's lymphoma (erratum), 2351
Stanford V regimen, for Hodgkin's disease, 972–980
Staphylococcus aureus bacteremia, in nonneutropenic cancer patients, 1110–1115
Stem-cell transplantation. *See also* Bone marrow transplantation
allogeneic
for multiple myeloma, molecular remission after, 2273–2281
for refractory lymphomas, 3918–3924
relapse after, alternative therapies for treating, 2269–2272
autologous
in breast cancer patients
advanced, 307–316
high-risk, Her-2/*neu* and *p53* predictive value in, 2070–2080
for multiple myeloma, molecular remission after, 2273–2281
autologous hematopoietic
high-dose chemotherapy with, for soft tissue sarcomas, 3643–3650
for non-Hodgkin's lymphoma, myelodysplasia and AML after, 947–955
Steroid receptors, in breast cancer, time-dependent relevance of, 2702–2709
Stomatitis, 5-FU-induced, sex differences in, 412–420
Streptococcal infection, alpha hemolytic, in children with AML, 1845–1855
Stress, BMT-associated, adaptation to, 1539–1549
Stromal tumors, malignant gastrointestinal, clinical outcome and multidrug resistance in, 3211–3220
Sucralfate, for diarrhea prevention in pelvic radiation therapy (phase III trial), 1239–1245
Suramin, for prostate cancer
metastatic, 1043–1049
phase III trial, 1440–1450
Surgery
for base-of-tongue carcinoma, radiotherapy *vs.*, 35–42, 3452–3453 (correspondence)
cisplatin/doxorubicin with, for childhood hepatoblastoma, 3819–3828
for non–small-cell cancer, gemcitabine/cisplatin before (phase II trial), 2658–2664
for pediatric stage I and II neuroblastoma, outcomes in, 18–26
prophylactic
in high-risk breast and ovarian cancer patients, 1980–1995, 3454–3455 (correspondence)
oophorectomy. *See* Prophylactic oophorectomy
specialists' perspectives on, 2484–2492
Surgical margins
breast cancer outcome and, 1668–1675
in prostatectomy, preoperative prediction of, 2862–2868, 3589 (errata)
Surveillance, gynecologic, of women on tamoxifen (editorial), 3457–3458
Survival. *See also* Breast cancer survivors; Survivors
in advanced renal cell carcinoma, effect of cytokine therapy on, 1928–1935
angiogenesis in neuroblastoma and, 27–34, 2789–2791 (correspondence)
cognitive function as predictor of, 646–650
cost-effectiveness and (correspondence), 3318
disease-free, in breast cancer
with adjuvant chemotherapy, 3125–3134
BRCA-1/2 and $p27^{Kip1}$ predicting, 4045–4052
MLH1 expression predicting, 87–93, 944 (erratum)
and dose-intensity of chemotherapy in small-cell lung cancer, 395–404
in early breast cancer, MUC1 and, 574–583
in Hodgkin's disease, second malignancy risk and, 498–509
in young survivors, 487–497, 2186–2187 (correspondence), 2435–2443
in infant acute leukemia, 3256–3261
in male breast cancer, 2948–2956
in multiple myeloma, interphase cytogenetics predicting, 804–812
in non-Hodgkin's lymphoma, after high-dose chemotherapy, 3025–3030
in non-small-cell lung cancer, unresectable (correspondence), 1802
1p and 19p deletions as predictors of, 636–645
in resected N2 non–small-cell lung cancer, 2981–2989
and VEGF in primary node-positive breast cancer, 1423–1431
Survivors
of breast cancer, fatigue in, 743–753
of childhood ALL, racial differences in, 813–823
Mexican *vs.* American-Mexican children (correspondence), 2349–2350
of childhood AML, late effects of treatment in, 3273–3279
of childhood cancer, PTSD symptoms in, 4060–4066
long-term, in metastatic undifferentiated carcinoma of nasopharyngeal type, 1324–1330
of metastatic testicular cancer, cardiovascular morbidity in, 1725–1732
of pediatric BMT, cognitive and academic functioning in, 1004–1011
of pediatric Hodgkin's disease, second malignancy risk and, 487–497, 2186–2187 (correspondence), 2435–2443
of Wilms' tumor and advanced neuroblastoma, health-related quality of life in, 3280–3287
Susceptibility genes, low-penetrance, cancer risk and, 2309–2315
Syncope, hypoglycemic, due to peripheral neuroectodermal tumor, 1594–1596
Synovial sarcoma
of lung, 2341–2342
prognostic factors in, 2087–2094
staging and prognostic assessment in, 3794–3803
Systemic therapy
effect on breast cancer outcome, 1668–1675
for operable, breast cancer, 1558–1569

T-cell lymphoma
cutaneous pretreated, gemcitabine treatment in, 2603–2606
enteropathy-type intestinal, 795–803
primary cutaneous, 2908–2925
Tamoxifen

anastrazole *vs.*, in advanced breast cancer, 3748–3757, 3758–3767
for breast cancer
in combination therapy in elderly patients, 1412–1422
in high-risk patients
4-HPR and, 275–283
cost-effectiveness of, 284–286, 1807 (correspondence)
with ovarian suppression, 2718–2727
postmenopausal ultrasound screening of endometrium and, 3464–3470
screening for endometrial cancer in patient receiving (correspondence), 446–448
screening for endometrial changes in, 3459–3463
gynecologic surveillance of women on (editorial), 3457–3458
radiation therapy with, for diffuse brainstem gliomas, 1246–1253
toremifene *vs.*, as adjuvant therapy for breast cancer in postmenopausal women, 3487–3494
in women at high risk for breast cancer
4-HPR and, 275–283
cost-effectiveness of, 284–286, 1807 (correspondence)
Tamoxifen resistance, in breast cancer, HER-2/*new/p53* expression and, 3471–3479
Tandem stem-cell transplantation, in pediatric neuroblastoma, 2567–2575
TCC. *See* Transitional-cell carcinoma
Tegafur, in preoperative combined-modality therapy for rectal cancer (phase I trial), 3529–3534
Telomerase
in normal and cancer cells, 2626–2634
as prognostic marker in neuroblastoma, 2582–2592
Temozolomide
for metastatic melanoma
cost-effectiveness of, 1474–1480
vs. dacarbazine (phase III trial), 158–166, 2185 (correspondence), 2351–2352 (errata)
vs. procarbazine, for recurrent glioblastoma multiforme, 1481–1491
Tenoposide, in treatment of brain metastases of small-cell lung cancer (phase III trial), 3400–3408
Terminally-ill patient
care of. *See* End-of-life care
death denial in, 3998–3999
Testicular cancer
embryonal carcinoma-predominant, lymph node dissection for, 358–362
metastatic, cardiovascular morbidity in survivors of, 1725–1732
paclitaxel combination therapies for, 2413–2418
relapsed, high-dose chemotherapy for, 3346–3351
Testis
carcinoma of. *See* Testicular cancer
melanoma metastatic to, 3187–3188
Thalidomide
in AIDS-related Kaposi's sarcoma, 2593–2602
for high-grade gliomas (phase II trial), 708–715, 3453 (correspondence)
in treatment of metastatic breast cancer (phase II trial), 2710–2717
Thoracic radiotherapy, up-front accelerated, and chemotherapy in limited small-cell lung cancer (phase II trial), 1662–1667
3-D conformal radiotherapy, with chemotherapy, for prostate cancer (phase II trial), 1936–1941
Threshold, for adjuvant therapy in older breast cancer patients, 1709–1717
Thrombocytopenia, essential, meningeal granulocytic sarcoma (chloroma) of, 3996–3997
Thromboembolism, in malignancy (editorial), 3065–3067
Thrombolic events, during chemotherapy for germ cell cancer, 2169–2178
Thrombus, catheter-associated, in metastatic adrenocortical carcinoma, 2638–2639
Thymidine phosphorylase expression, in epithelial ovarian cancer, 3946–3951
Tirapazamine
for advanced non–small-cell lung cancer, 1351–1359
and radiation therapy for glioblastoma multiforme (phase II trial), 1254–1259
Tongue, squamous cell carcinoma at base of, radiotherapy for, 35–42, 3452–3453 (correspondence)
Tonsillar region, squamous cell carcinoma of, radiation therapy for, 2219–2225
Topotecan
and cisplatin interactions, in humans (phase I trial), 2104–2115
and docetaxel interaction in solid tumors, 3288–3294
for platinum-sensitive ovarian cancer, 1062–1067
population pharmacokinetic model for, 2459–2467
in sequential couplet therapy for ovarian cancer (phase II trial), 4038–4044
Toremifene, *vs.* tamoxifen as adjuvant therapy for breast cancer in postmenopausal women, 3487–3494
Total body irradiation, in patients with hematologic malignancies, 981–986, 3062–3063 (correspondence)
Toxicity
of biliary stents, preoperative chemoradiation in pancreatic cancer and, 860–867
of chemotherapy and radiotherapy protocol in pancreatic cancer (phase I trial), 3384–3389
neuropsychiatric, in CML, 1301–1308
sequence effect of paclitaxel/epirubicin on, 2116–2125
TP (thymidine phosphorylase) expression, in epithelial ovarian cancer, 3946–3951
Transitional-cell carcinoma
advanced, paclitaxel and carboplatin for, 2537–2544
of urothelial tract
combination chemotherapy for (phase I/II trial), 3247–3255
gemcitabine/cisplatin *vs.* MVAC in (phase III trial), 3068–3077
hepatocyte growth factor in, 2963–2971
two drug *vs.* three drug regimen for (phase I trial), 840–846
Transplantation. *See* Blood cell transplantation; Bone marrow transplantation; Stem-cell transplantation
Trastuzumab, in cerebrospinal fluid (correspondence), 2350–2351
Trauma, and early-stage breast cancer patients, 1084–1093
Trilateral retinoblastoma (correspondence), 236–237
TrkC expression, in PNET, 1027–1035
Trophoblastic tumors, gestational and placental site, EP/EMA chemotherapy in, 854–859, 2187 (correspondence)
Tumor cell vaccine, autologous, for colon cancer (phase II and III trials), 148–157
Tumor measurement
accuracy and reproducibility in, 437–444
evaluation techniques in, 2179–2184
Tumor necrosis factor alpha, in myeloma, 2843–2851
Tumor necrosis factor ligand-receptor system, and prediction of neutropenia in lymphoma patients, 325–331
Tumor response
in breast cancer, PET predicting, 1676–188

criteria for, standardization in non-Hodgkin's lymphoma (erratum), 2351
in head and neck squamous cell carcinomas, *p53* gene alterations and, 1465–1473
to 6-hour glufosfamide infusion (phase I trial), 3535–3544
in squamous cell carcinoma, *p53* gene status predicting, 385–394
Tumor suppressor genes, DNA repair defects inactivating, 75s–80s

Ultrasound screening, of endometrium in tamoxifen-treated postmenopausal women, 3464–3470
Umbilical metastasis, non–small-cell lung cancer and, 3188–3189
Undifferentiated carcinoma of nasopharyngeal type, metastatic, long-term survivors in, 1324–1330
Unilateral leukemic hypopyon, 3439–3440
Uracil, in preoperative combined-modality therapy for rectal cancer (phase I trial), 3529–3534
Urinary function, in prostate cancer prevention trial patients, 1942–1953
Urothelial tract cancer. *See also* Bladder cancer
advanced, cisplatin/paclitaxel for (phase II trial), 1058–1061
metastatic, chemotherapy regimen for (phase II trial), 1921–1927, 2644 (erratum)
transitional-cell
combination chemotherapy for (phase I/II trial), 3247–3255
gemcitabine/cisplatin *vs.* MVAC in (phase III trial), 3068–3077
hepatocyte growth factor in, 2963–2971
two drug *vs.* three drug regimen for (phase I trial), 840–846
Uterine sarcoma, 2343–2344

Vaccines
for advanced cancer (phase I trial), 3964–3973
for prostate cancer, 3894–3903
Vaccinia virus, and CEA vaccines for advanced cancer (phase I trial), 3964–3973
Valspodar
paclitaxel and, in refractory tumors (phase I trial), 1124–1134, 2793 (erratum)
for solid malignancies (phase I trial), 3677–3689
Vascular endothelial growth factor
and antiangiogenic therapy, 45s–46s
oral and oropharyngeal squamous cell carcinoma, 2046–2052
in primary node-positive breast cancer, 1423–1431
Venous thromboembolism, in malignancy
and bleeding complications, 3078–3083
editorial on, 3065–3067
Vesnarinone, with gemcitabine in advanced cancer (phase I trial), 3974–3985
Vinblastine
in MVAC regimen for urothelial TCC (phase III trial), 3068–3077
in response-adapted chemotherapy of localized childhood Hodgkin's disease, 1500–1507
and 3-D conformal radiotherapy for prostate cancer (phase II trial), 1936–1941
Vincristine, in neoadjuvant therapy for bulky stage IB and IIA cervical cancer, 1740–1747
Vinorelbine
for AIDS-related Kaposi's sarcoma (phase II trial), 1550–1557
for breast cancer
anthracycline-pretreated, with 5-FU (phase II trial), 3370–3377
metastatic, with doxorubicin (phase III study), 2385–2394
with ifosfamide, for non–small-cell lung cancer (phase II trial), 2354–2362
for non–small-cell lung cancer (phase II trial), 1346–1350
in combination chemotherapy (phase III trial), 1451–1457
in elderly patients, 2529–2536
gemcitabine with (phase I/II trial), 405–411
for pleural mesothelioma (phase II trial), 3912–3917
Vomiting, chemotherapy-induced, dexamethasone to control, 3409–3422
Vulva, squamous cell carcinoma of, sentinel lymph node procedure in, 2795–2797 (editorial), 2811–2816

Waldenström's macroglobulinemia, 214–226
Warfarin, in patients with central venous catheters, 3665–3667
WHO (World Health Organization), hematologic malignancies classification by (correspondence), 2788–2789, 3447–3452
Whole-brain radiotherapy, in treatment of brain metastases of small-cell lung cancer (phase III trial), 3400–3408
Wilms' tumor
in children, 2026–2031
health-related quality of life after, 3280–3287
World Health Organization, hematologic malignancies classification by (correspondence), 2788–2789, 3447–3452

Young, Scott D., *Horizon of Hope* (poem), 1808
Young women, ductal carcinoma-in-situ in, breast-conserving therapy for, 296–306